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                                  ABSTRACT 
 
AETIOLOGY AND OUTCOME OF NEONATAL SEPSIS AND MENINGITIS IN 
MALAWI. 
Introduction 
In Malawi there has been significant progress in reducing post-neonatal and under-
5 deaths over the past decade but very little progress in reducing neonatal deaths. 
The major causes of neonatal deaths in Malawi are prematurity, infections and birth 
asphyxia. Neonatal sepsis has been shown to have long term complications ranging 
from motor deficits to cognitive impairment, epilepsy and behavioural disorders in 
preterm very low birth weight infants in the developed setting. Contrary to the 
epidemiology in the developed setting where neonatal sepsis is predominantly seen 
in preterm low birth weight infants, in the developing setting neonatal sepsis is also 
common among term babies. However, very little is known on the long term 
outcome of neonatal sepsis in the resource restrained setting. In this thesis the 
aetiology and outcome of neonatal sepsis and meningitis is investigated. 
Methodology 
This was study had 2 components; a cross sectional arm and a prospective cohort 
arm. The cross sectional study was looking at the aetiology, resistance pattern and 
in hospital outcome of severe neonatal infection cases presenting at QECH in 
Blantyre. The prospective cohort arm involved participants who were recruited in 
the cross sectional arm at QECH and were residing within Blantyre urban and 
infants that never had an episode of severe neonatal infection were recruited from 
Zingwangwa health Centre. The infants from Zingwangwa acted as controls. The 
participants in the prospective cohort arm were followed up to the age of 1 year 
where neurodevelopmental outcomes were assessed using the Bayley’s assessment 
tool. These participants also had detailed neurologic examination during the follow 
viii 
 
up visits at 6 and 12 months of age. A comparison between the cases and controls 
was made to ascertain the impact of neonatal infection outcome. 
Results 
During the study a total of 412 cases were enrolled in the cross sectional arm. 75% 
of the cases had late onset disease. GBS was the commonest organism grown in 
blood culture 17/42(40%) and CSF culture 16/33(48%). 44% had abnormal serum 
sodium levels on admission and hypernatraemia was independently associated with 
an increased risk of dying in hospital (8.34[95% CI 1.95-35.7]). 51% of the gram 
negative organisms were multidrug resistant. In the long term outcome neonatal 
sepsis without overt meningitis was associated with an up to 6.6 –fold {95% CI 
(2.38-18.4} increased risk of developmental delay at 1 year of age. Meningitis was 
associated with a 17-fold {95% CI 4.89- 61.7} increased risk of developmental delay 
at 1 year of age. Positive blood or CSF culture and being HIV exposed were 
independent predictors of delay at I year of age. 
Conclusion 
GBS is a significant cause of neonatal infections in Malawi. The magnitude of 
developmental delay observed in infants who had neonatal sepsis without 
meningitis is worrying up to 35% of these infants were delayed. It is therefore 
important to employ measures that can prevent neonatal infections. Follow up is 
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                               INTRODUCTION 
 
1.1 Epidemiology of Neonatal Mortality 
1.1.1 Global picture 
Every year 130 million babies are born globally and 3.1 million die in the first 4 
weeks of life{Lawn J.E, H. Blencowe et al (2013)}. Most of the neonatal deaths (75%) 
occur in the first week of life, the highest risk of death is on the first day of 
life{Zupan J and E Aahman (2005)}. A similar number of babies are still born {Lawn 
J.E, H. Blencowe et al (2013}. Perinatal deaths are responsible for almost 7% of the 
total global burden of disease a proportion which exceeds that caused by vaccine 
preventable diseases and malaria together{WHO Global burden of disease report 
(2004)}. Worldwide mortality in children younger than 5 years has dropped from 
11·9 million deaths in 1990 to 7·7 million deaths in 2010, consisting of 3·1 million 
neonatal deaths, 2·3 million post neonatal deaths, and 2·3 million childhood deaths 
see Figure 1.1{RajaratnamJ, J.Marcus et al (2008)}. Neonatal deaths contribute 40% 
of all the deaths in children less than 5 years of age hence reducing neonatal deaths 
is an important target for the eventual reduction of childhood deaths 










The neonatal mortality rate is widely used as an indicator of public health, quality of 
health services, distribution of wealth and the general standard of living in a society 
{Lawn J.E, S.Cousens et al (2005)}. 
As many as 99% of the 3.1 million neonatal deaths that occur each year take place 
in the poorest countries of the world making newborn health as one of the most 
striking examples of health inequality { Lawn J.E, S.Cousens et al (2005)}. The largest 
number of neonatal deaths occurs in South East Asia but this region has seen a 
dramatic drop in neonatal deaths as a result of several initiatives aimed at 
improving newborn health  {WHO Global burden of disease report (2004)}.  On the 




Neonatal Deaths 3.1 million Postneonatal Deaths 2.3 million
Childhood Deaths 2.3 million
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the Sub-Saharan region accounting for almost 30% of  neonatal deaths  worldwide{ 
WHO Global burden of disease report (2004)}.  Most of the countries (80%) with the 
highest neonatal mortality rates are in Sub-Saharan Africa{ WHO Global burden of 
disease report (2004)}.The neonatal mortality rate for high income countries is 4 per 
1000 live births whereas in low-income and middle income countries it is estimated 
to be 33 per 1,000 live births {Zupan J, E. Aahman (2005)}. 
1.1.2 Trends in Neonatal Mortality 
Across 21 regions of the world, rates of neonatal, post neonatal, and childhood 
mortality are declining. 
Over the last 30 years, the reduction in neonatal mortality rates has been slower, 
compared to both the under-5 and post neonatal mortality rates{Rajaratnam J, J 
Marcus et al (2008)}. Even though the reduction in neonatal mortality rates has 
been slow globally there has been a significant decline in neonatal mortality rates in 












Figure  1.2 Worldwide neonatal postneonatal and childhood mortality from 1970 
to 2010{RajaratnamJ, J.Marcus et al (2008)} 
  
The United Kingdom and United States of America are some of the countries in the 
developed world that have shown success stories in the reduction of neonatal 
mortality. Early in the 20th century, neonatal mortality was 40-50 per 1,000 live 
birth for both the United Kingdom and the United States of America, and by 1997 it 
had been reduced to 4-5 per 1,000 live births{ Child health research project special 
report (1999),Seale A.C, H. Blencowe et al (2013), Lawn J.E, H. Blencowe et al 
(2013), Blencowe H, T.Vos et al (2013), Seale A.C, M Mwaniki et al (2009), Gordon 
A.L, M. English et al (2005), Osrin D, S. Vergnano et al (2004)Heath P.T, N.K Nik 
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Yusoff et al (2003)},  Bennet R, S.Berdahl et al (1989)}. The trends in England and 
Wales are shown in Figure 1.3{ Hill K, C. Yoonjoung et al (2005)}. 
Figure 1.3 : Early neonatal, late neonatal and postneonatal mortality rates for: 
England and Wales, 1905 to 1997{ Hill K, C. Yoonjoung et al (2005)} 
 
These improvements in neonatal mortality have been largely due to changes in 
obstetric care, maternal health, introduction of neonatology and better infant 
nutrition. Neonatology has evolved over the last century from being a simple, 
empirical care to modern, evidence-based medicine{Seale A.C, H. Blencowe et al 
(2013), Lawn J.E, H. Blencowe et al (2013), Blencowe H, T.Vos et al (2013), Seale A.C, 
M Mwaniki et al (2009), Heath P.T, N.K Nik Yusoff et al (2003)}.The pattern of 
decline in the early neonatal deaths( 0-7 days of age) was different from the late 
neonatal deaths(7-28 days of age).There was a very slow decline in the early 
neonatal deaths up to about 1950 but then there was faster decline to about 1975 
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and a sharply faster decline since 1975 {Hill K. C. Yoonjoung et al(2005)}.This has 
beeen attributed to changing patterns in reproductive health, socioeconiomic 
progress and improvements in the quality of obstetric and neonatal facilities in the 
UK {Seale A.C, M Mwaniki et al (2009), Hill K. C. Yoonjoung et al(2005) }. In the 
1950’s, the medical care of newborn infants was transferred from the obstetricians 
to the paediatricians and in the 1960’s, the speciality of neonatology was 
developed. There were also significant improvements in neonatal care from the 
1950’s with the introduction of surfactant replacement therapy for the 
management of respiratory distress syndrome, antenatal corticosteroids and 
respiratory support including oxygen therapy and mechanical ventilators 
{Milestones in neonatology (2005)}. The earlier decline in the late neonatal deaths 
could possibly be attributed  to the introduction of penicillin in 1944 which 
markedly reduced mortality from severe neonatal sepsis as infection is one of the 
major contributors of late neonatal deaths { Milestones in neonatology (2005}.This 
pattern has been noted throughout the developed world. 
On the other hand the decline in neonatal mortality in the developing world has 
varied widely between regions with Sub-Saharan Africa showing the least rate of 
decline (see figure 1.4 ) {A promise renewed-Progress report 2014, UNICEF, New 
York 2014 Seale A.C, H. Blencowe et al (2013), Lawn J.E, H. Blencowe et al (2013), 
Blencowe H, T.Vos et al (2013), Seale A.C, M Mwaniki et al (2009), Gordon A.L, M. 
English et al (2005), Hill K., Yoonjoung choi et al (2005), Osrin D, S. Vergnano et al 




Figure1. 4  Changes in neonatal mortality rates between 1990 and 2013 {A promise 
renewed-Progress report 2014, UNICEF, New York 2014} 
 
This trend in Africa especially in the Sub-Saharan region is worrying and needs 
exploring  the possible contributing factors. Much of the progress in neonatal 
survival in the developing countries in Africa and South Asia has been in the late 
neonatal period with little improvement in the first week of life where most of the 





1.1.3 Causes of neonatal deaths 
Global estimates for the direct causes of neonatal deaths are prematurity [26%], 
severe infections [36%], complications of asphyxia [23%] and deaths related to 
congenital abnormalities [7%]{Lawn J.E, S. Cousens et al (2005)}. However infection 
is one of the known risk factors for preterm labour and these preterm infants have 
reduced immunity rendering them prone to infections early on in life{Klinger G, L. 
Lerner-Geva et al (2009), Graham P. L,E. Larson et al(2006), Romero R, J.C Hobbins 
et al (1998), Minkoff H, W.M. McCormack et al (1984)}  . In most of the developing 
settings birth asphyxia is a clinical diagnosis and laboratory tests like umbilical cord 
gasses are not done but most of the clinical symptoms and signs of birth asphyxia 
are the same as of neonatal infections and as such there is a possibility of 
mislabelling neonatal infection cases as birth asphyxia{Neonatal handbook internet 
(cited July 2013)} . The distribution of the causes of neonatal deaths varies between 
countries with infections causing most of the neonatal deaths in very high mortality 










Figure 1.5. The distribution of the causes of neonatal deaths in relationship to 
NMR {Lawn J.E, A.Lee etal (2009)} 
The top 3 causes of neonatal deaths ; infections, asphyxia and prematurity are 
closely related to obstetric care and as such neonatal health cannot be separated 
from obstetric care{World health report (2005), Neonatal and Perinatal mortality 
(2006)}. In the case of neonatal infections there are known risk factors which 
include prolonged rupture of membranes in the mother, prematurity, low birth 
weight, maternal group B streptococcal carriage and maternal HIV status{Tausch 
W.H, R.A.Ballard et al (1998), Andreson-Berry A., L Bellig (2010)}. Haematogenous 
and transplacental dissemination of maternal infection occurs in the transmission of 
certain viral (e.g rubella, cytomegalovirus, HIV, parvovirus and varicella zoster), 
protozoal (e.gToxoplasma gondii) and treponemal (e.gTreponema pallidum) 
pathogens. A few bacterial pathogens (e.g Listeria monocytogenes, Mycobacterium 
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tuberculosis) may reach the fetus transplacentally, but most are acquired by the 
ascending route in utero or as the fetus passes through the colonized birth canal 
{Tausch W.H, R.A.Ballard et al (1998), Andreson-Berry A., L Bellig (2010)}. It 
therefore comes as no surprise to see that interventions that have been put in place 
to try and reduce neonatal deaths have put an emphasis on obstetric care 
{Neonatal and Perinatal mortality (2006}.These interventions include improvements 
in antenatal care, better management of hypertensive disorders of pregnancy, use 
of corticosteroids in preterm labour, better management of maternal carriage of 
Group B steptococci, use of antibiotics in prolonged premature rupture of 
membranes { Andreson-Berry A., L Bellig (2010}.   
The significance of good obstetric care can be seen in the association between 
skilled attendance at birth and the neonatal mortality rate. It has been shown that 
countries with low coverage of skilled attendants at birth have much higher 
neonatal mortality rates compared to countries with higher coverage see Table 1.1  









Table 1.1 Association between level of Skilled Attendance at Birth and Neonatal 
mortality Rate { Lawn J.E,A.Lee etal (2009)} 
Neonatal mortality rate(NMR) 
 
Level of skilled birth attendant 
Very low NMR (<5) 100% 
Low NMR (6-15) 99% 
Moderate NMR (16-30) 88% 
High NMR (31-45) 52% 
Very high NMR (>45) 45% 
 
 
In developing countries,  nearly 50% of the women still have unskilled attendants at 
birth signaling the need for community based interventions that would lead into a 
reduction in neonatal deaths{Count down to 2015, the 2008 report, Count down to 
2015 the decade report}. The lack of skilled attendants at birth could encourage the 
use of harmful practices like application of cow dung to the umbilical stump of the 
neonate {Ayaz S, S. Efe et al (2008), Girma T, H. Nida et al (2008)}. These practices 
could lead to introduction of infection like tetanus in the newborn. 
 Recently there have been several new interventions aimed at community 
participation in resource restrained settings that have led to a reduction in neonatal 
deaths. These interventions have included use of women groups, volunteer female 
health workers and community management of neonatal infections{ Bang A.T, R.A 
Bang et al (1999),   Bhutta Z.A, S. Ali  et al (2005), Bang A.T, R.A Bang et al (2005), 
Bhutta Z. A, G.L Darmstadt et al (2005)}. These interventions led to an improvement 
in the health seeking behaviour of the mothers/caregivers. The women who were 
12 
 
involved in the women groups were much more likely to seek medical attention in 
case of a sick neonate and attend antenatal clinics. The use of female health 
workers helped in identifying a sick neonate through home visits as early as possible 
and either referring them to the nearest facility for proper management or treating 
them at home with antibiotics if it was not possible to refer the neonate. This 
therefore ensured that the sick newborn was promptly identified and treated. 
These interventions have been tried in Asia and it would be interesting to see if 
these interventions would have the same impact in Sub-Saharan africa. The African 
WHO community management of severe neonatal sepsis study (AFRINEST) is 
currently underway {WHO (2013)}. 
1.1.4 Epidemiology of  Neonatal  Mortality in Malawi  
Malawi is a sub-Saharan African country of 16,777,547 people with annual births of 
599,000, and a neonatal mortality rate of 29 per thousand live births {Count down 
to 2015 decade report, Liu L, H.L Johnson et al (2012), Zimba E. M.V Kinney et al 
(2012)}. Malawi is one of the few countries which has achieved millenium 
development goal number 4 which aims to reduce the 1990 reported childhood 
deaths by two thirds by 2015{UNICEF Malawi report 2013}. Despite this progress, 
the neonatal mortality rate has not fallen –Fig 1.6 { Count down to 2015 decade 
report, Liu L, H.L Johnson et al (2012), Zimba E. M.V Kinney et al (2012)}. The 
reported neonatal mortality rate for 2004 was 26 per 1,000 live births and 29 per 
1,000 live births in 2008{Count down to 2015 decade report, Liu L, H.L Johnson et al 
(2012), Zimba E. M.V Kinney et al (2012)}. Neonatal deaths account for 31% of all 
the under-5 deaths in Malawi and nearly 50% of infant deaths. The top 3 causes of 
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neonatal deaths in Malawi are similar to the global ones namely; prematurity 32%, 
asphyxia 26% and infections 28% {, Liu L, H.L Johnson et al (2012), Zimba E. M.V 
Kinney et al (2012)}. It therefore follows that efforts aimed at reducing neonatal 
deaths would go along way to reduce childhood deaths {Liu L, H.L Johnson et al 
(2012), Zimba E. M.V Kinney et al (2012)}. 






1.2 Diagnosis of severe neonatal sepsis and meningitis 
1.2.1 Clinical diagnosis of severe neonatal sepsis and meningitis 
Severe neonatal sepsis is defined as sepsis within the first 28 days of life {Lawn J. E, 
S Cousens et al (2005)}.In the literature; severe neonatal sepsis may be defined both 
clinically and/or microbiologically, by positive blood and/or cerebrospinal fluid 
cultures. However, for the purposes of this review and in line with current thinking, 
sepsis will be regarded as a clinically defined syndrome where there is a systemic 
response to a possible infection {Critical care Medicine Consensus conference 
(1992)}. 
This systemic response is characterized by two or more of the following: fever or 
hypothermia, tachycardia, tachypnoea or hyperventilation and abnormal white 
blood cells or increase in immature forms {Critical care Medicine Consensus 
conference (1992)}. However there are other conditions in a neonate which can 
mimic severe neonatal sepsis. These include congenital cardiac anomalies, birth 
asphyxia and inborn errors of metabolism. This makes confirmation of the diagnosis 
of severe neonatal sepsis challenging {Anderson-Berry A., L.Bellig et al (2010)}. 
Currently, criteria for severe neonatal sepsis usually include documentation of 
infection in a new-born infant with a serious systemic illness in which non-infectious 
explanations for the abnormal pathophysiologic state are excluded or unlikely 





1.2.2 Laboratory Diagnosis of Severe neonatal sepsis 
Diagnosis of severe neonatal sepsis still poses a major challenge to both the 
clinician and the laboratory {Mishra U.K, S.E Jacobs et al (2006)}.The current gold 
standard for the diagnosis of severe neonatal sepsis is a positive blood culture  
which in itself has challenges   {Mishra U.K, S.E Jacobs et al (2006}. The drawback 
with blood cultures include the 24-48 hour assay time and the low yield of positive 
cultures {Squire E, B Favara et al (1979)}. Cultures are not free from error because 
they can be falsely sterile, as suggested by blood cultures taken post-mortem 
{Squire E, B Favara et al (1979)}. In this study babies who had died from presumed 
severe neonatal sepsis and had initial blood cultures negative had repeat cultures 
after death which subsequently were positive. The low yield from blood cultures 
may also be caused by insufficient sample volumes, intermittent or low-density 
bacteraemia, or suppression of bacterial growth by earlier antibiotic administration 
{Claudio C, A. Panero et al (2004)}. 
It would be useful to have a cheap bedside test with good sensitivity and specificity 
for the diagnosis of severe neonatal sepsis. This would ensure that appropriate 
treatment is instituted early and that unnecessary use of antibiotics is avoided. 
A test with a rapid turnaround time with 100% sensitivity, rather than high 
specificity, which allows accurate diagnosis and appropriate antimicrobial treatment 
or which allows antibiotics to be withheld in non-infected infants, is desirable 
especially in this era of multidrug resistance{ Mishra U.K, S.E Jacobs et al (2006}. 
There are newer diagnostic tests which in combination will ensure greater 
diagnostic accuracy for severe neonatal sepsis but they are not routinely available 
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to the laboratory { Mishra U.K, S.E Jacobs et al (2006}.The newer diagnostic tests 
are grouped into acute phase reactants, cell surface markers, granulocyte colony 
stimulating factor, cytokines, molecular genetics and molecular and cellular 
proteomics{Tripathi S, G.K Malik et al (2010)}. These will be discussed below. 
Acute phase reactants 
These endogenous peptides are produced by the liver as part of an immediate 
response to infection or tissue injury. These reactants include C-reactive protein 
(CRP), procalcitonin, fibronectin, haptoglobin, lactoferrin, neopterin and 
oromucosoid{ Tripathi S, G.K Malik et al (2010)}. CRP has been most extensively 
investigated {Fowlie P.W, B. Schmidt et al (1998)} but there has been more recent 
interest in procalcitonin as a marker of severe neonatal sepsis. 
CRP is synthesized by the liver within six to eight hours of exposure to an infective 
process or tissue damage, with a half life of 19 hours, and may increase more than 
1000 fold during an acute phase response{Vigush D.M, M.B Pepys et al (1993)}. 
Serial measurements of CRP are therefore important{ Tripathi S, G.K Malik et al 
(2010)}. The ranges of sensitivity and specificity for diagnosis of early onset severe 
neonatal sepsis range between 43-90% and 70-78% respectively across more than 
10 studies{ Fowlie P.W, B. Schmidt et al (1998)} }. Specificity and positive predictive 
value of CRP for late onset sepsis increases from 93% to 100% respectively making it 
a more reliable marker of late neonatal infection{Ng P.C, S.H.Chenget al (1997)}. 
CRP as a diagnostic marker in neonates has higher sensitivity and specificity than 
total neutrophil count and immature to total neutrophil ratio{Da Silva O., A. Ohlsson 
et al (1995)}. In the majority of published reports, upper limits for CRP during the 
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neonatal period have been obtained from symptomatic uninfected patients with 
only few studies having obtained the upper limit in healthy newborns{Mathers N.J, 
F Pohlandt et al (1987)Pourcyrous M, H.S Bada et al (1991), Shine B, J.Gould et al 
(1985)}. Most of the studies on healthy newborns were cross-sectional with small 
sample sizes ranging from 16 to 69 and the sampling times were not specified 
{Chiesa C, Signore F et al (2001)}. The upper limits for CRP in the studies ranged 
from 5mg/litre to 10mg/litre. It is widely accepted that a CRP of  > 10mg/litre is 
suggestive of infection in a newborn{Van den Hoogen A, L.J Gerards et al (2009)}. 
Procalcitonin is another important acute phase reactant produced by monocytes 
and hepatocytes. It begins to rise four hours after exposure to bacterial endotoxin, 
peaking at six to eight hours, and remaining raised for at least 24 hours with a half 
life of 25 to 30 hours {Dandona P, D. Nix et al (1994)}.The sensitivity of procalcitonin 
at birth is low ranging from 70-80% but increases thereafter {Chiesa C, G Pelligrini et 
al (2003)} making serial measurements useful as is the case with CRP { Dandona P, 
D. Nix et al (1994}.  
 One needs to be aware of the  natural fluctuation that procalcitonin presents in the 
immediate postnatal period that necessitates very careful adjustments in the 
normal ranges {Assuma M, F Signore et al (2000).The fluctuation may explain the 
conflicting cut-off points for abnormal values that have been reported for 
procalciton{Franz A.R, M Kron et al (1999)}.  It may be superior to other acute phase 
reactants with sensitivity and specificity ranging from 87% to 100% but it is not a 
readily available diagnostic assay in most institutions in developed countries as it is 
expensive {Ballot D E, O Perovic et al (2004)}.  
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Cell surface markers 
There has been advances in flow cytometric technology which have opened up new 
ways of detecting cell surface antigens on blood cells.This technology is better than 
the conventional immunological assay methods for localising the activated markers 
to a specific cell type {Simms H H, R. D’Amico et al (1995)}. Assessing the cellular 
response to the cytokines may be a better way of identifying early immunological 
response to bacterial invasion than circulating concentrations of cytokines which 
may not necessarily reflect their biological activities {Lehr H A, F. Krombach et al 
(1995) }. Cell surface markers CD11b and CD64 appear to be promising markers for 
the diagnosis of early and late onset infections {Weirich E, R.L Rabin et al (1998)}. 
CD11b is a subunit of the 2 intergrin adhesion molecule which is normally expressed 
at a very low concentration on the surface of non-activated neutrophils {Weirich E, 
R.L Rabin et al (1998). There is a 2-4 fold increase in neutrophil CD11b expression in 
infants with blood culture positive sepsis {{Weirich E, R.L Rabin et al (1998)}. The 
sensitivity and specificity of CD11b for diagnosing early onset severe neonatal sepsis 
are 86.3-100% and 100% respectively {Nupponen I, S. Andersson(2001) et al}. 
However CD11b has been noted to increase in preterm infants with respiratory 
distress syndrome who are mechanically ventilated {Turunen R, I Nupponen I et al 
(2006)}. Mechanical ventilation is thought to induce the rise making CD11b not a 
good marker for severe neonatal sepsis in these preterm ventilated babies { 
Turunen R, I Nupponen I et al (2006)}.  On the other hand CD64 which is also a 
neutrophil cell surface marker which when compared with CD11b and two 
lymphocyte surface markers (CD25, CD45RO) has a better sensitivity 97%, specificity 
90% and negative predictive value 99% as a diagnostic marker of early onset 
19 
 
neonatal infection both at the onset of infection and 24 hours later { Turunen R, I 
Nupponen I et al (2006)}.These promising white cell markers require flowcytometry 
and are not readily available diagnostically { Turunen R, I Nupponen I et al (2006)}. 
 
Granulocyte colony stimulating factor 
Granulocyte colony stimulating factor (GCSF), a mediator produced by the bone 
marrow, facilitates proliferation and differentiation of neutrophils, and has been 
proposed to be a reliable infection marker for early diagnosis of severe neonatal 
sepsis {Mishra U.K, S.E Jacobs et al (2006)}. A concentration of  > 200 pg/ml has a 
high sensitivity (95%) and negative predictive value (99%) for predicting early onset 
neonatal bacterial and fungal infections {Fowlie P.W, B Schmidt et al (1998)}.  
 
Cytokines 
Neonates initially depend on innate (natural, non specific) immunity as antigen 
specific immunity develops later on at 2 years of age for encapsulated bacteria{ 
Fowlie P.W, B Schmidt et al (1998)}. This innate immunity includes phagocytosis (by 
monocytes, tissue macrophages and neutrophils),natural killer cells, and humoral 
mediators (CRP, complement and  maternal antibodies) {Mishra U.K, S.E Jacobs et al 
(2006)}.   
In response to antigens such as bacterial endotoxins {Schultz C, C Rott et al (2002)} 
activated tissue macrophages produce TNF and IL1. These proinflammatory 
cytokines stimulate endothelial cells to express receptors for intercellular adhesion 
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molecule on white blood cells. This initiates the cytokine cascade towards increased 
production of IL6, IL8, and chemokines {Berner R, Niemeyer C.M et al (1998)}. Some 
bacteria activate epithelial cells directly to produce inflammatory cytokines. 
Newborn infants display a higher percentage of IL6 and IL8 positive cells than do 
adults {Berner R, Niemeyer C.M et al (1998}.There is a sharp rise in IL6 
concentration on exposure to bacterial products, which precedes the increase in 
CRP. Umbilical cord blood IL6 has been consistently shown to be a sensitive marker 
for diagnosing early onset severe neonatal sepsis, with sensitivities of 87–100% and 
negative predictive values of 93–100% {Smulian J.C, A.M. Vintzileos et al (1999), Ng 
P.C, S.H Cheng et al (1997)}. IL6 has the highest sensitivity (89%) and negative 
predictive value (91%) at the onset of infection compared with other biochemical 
markers, including CRP, IL1β, TNFα, but sensitivity is reduced at 24 and 48 hours 
(67% and 58% respectively) because IL6 concentrations fall rapidly and become 
undetectable after 24 hours{Buck C, Bundschu J et al (1994)}. The combined 
measurement of IL6 (early and sensitive) with CRP (late and specific) in the first 48 
hours of presumed septic episodes improves the sensitivity compared with either 
marker alone {Buck C, Bundschu J et al (1994)}. 
IL8 is a proinflammatory cytokine that is predominantly produced by monocytes, 
macrophages, and endothelial cells, {Baggiolini M, A, Walz et al (1989)} with similar 
kinetics to IL6 {Buck C, Bundschu J et al (1994)}. It is produced in response to various 
stimuli such as LPS and TNF {Baggiolini M, A Walz et al (1989)}. IL8 is considered to 
be a highly accurate marker with sensitivities ranging from 80% to 91% and 
specificities from 76% to 100%. IL8 and IL8 mRNA concentrations are substantially 
higher in infected than non‐infected newborns {Buck C, Bundschu J et al (1994)}.}. 
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The simultaneous measurement of either CRP {Franz A.R, G Steinbach et al (2001), 
Franz A.R, G Steinbach et al (1999)} or neutrophil cell surface marker CD11b with IL8 
further enhances the diagnostic value in the diagnosis of severe neonatal sepsis. A 
recent multicentre randomized controlled trial of 1291 clinically stable infants with 
clinical signs or obstetric risk factors suggesting early onset severe neonatal sepsis 
reported that the combination of IL8 >70 pg/ml and/or CRP >10 mg/l significantly 
reduced antibiotic therapy from 49.6% to 36.1% (p<0.0001) without missing 
infections; sensitivity was 80%, specificity 87%, positive predictive value 68%, and 
negative predictive value 93%{ Franz A.R, Bauer et al (2004)}. 
Another group of proinflammatory cytokines often linked with sepsis is the IL1 
family, including IL1α, IL1β, and IL1 receptor antagonist (IL1ra). The diagnostic 
usefulness of IL1β is minimal given conflicting reports of both increasing {89, Atici A, 
M Satar et al (1996), Buck C, Bundschu J et al (1994)} and decreasing {Atici A, M 
Satar et al (1996)} concentrations associated with sepsis. In contrast, concentrations 
of IL1ra have been shown to be consistently increased in septic patients with 
concentrations of 6–30 µg/l {Kuster H, M. Weiss et al (1998} compared with lower 
concentrations in uninfected neonates of 2–3 µg/l. IL1ra is therefore a better 
marker than IL1 β. TNFα is a proinflammatory cytokine that stimulates IL6 
production and has a broad spectrum of biological actions on several types of target 
cell, both immune and non‐immune. Newborns developing early onset infection are 
born with higher TNFα concentrations than non‐infected infants { Kowalik K, M.B. 




Molecular detection of bacteria 
There have been an increasing number of reports on the use of nucleic acid 
amplification techniques such as PCR in the detection of bacterial genomes in blood 
cultures {Tripathi S. and G.K Malik (2010), Maiwald M (2004)}. Polymerase chain 
reaction relies on the fact that bacteria specific 16srRNA gene is highly conserved in 
all bacterial genomes {43 Maiwald M (2004)}. Amplification targeting of this 
16srRNA gene is a potentially valuable clinical tool in samples with low copy 
numbers of bacterial DNA. PCR can also be targeted for species specific detection of 
bacteria in clinical samples as the gene has divergent regions nested within it  
{{Maiwald M et al (2004)}.  
These newer tests are promising but at the moment most of these diagnostic tests 
are available in a few industrialised countries where the burden of neonatal 
infections is least. These tests have to be used in combination making the 
laboratory work up too expensive and unaffordable to many. 
1.2.3 Diagnosis of Severe neonatal sepsis in the developing world 
In the low and middle income countries most of the diagnosis is based on clinical 
signs and symptoms as laboratory confirmation is frequently unavailable. There 
have been a number of studies that have attempted to develop an algorithm of 
clinical symptoms and signs that is sensitive enough for the diagnosis of severe 
neonatal sepsis in the absence of laboratory confirmation. In other studies the 
presence of two or three categories {by organ system} of clinical signs of infection in 
the infant has been taken to strongly support a diagnosis of sepsis {Buck C, 
Bundschu J et al (1994), Messer J, D. Eyer et al (1996)}. A multi-centre prospective 
study developed an algorithm that includes seven signs and symptoms: history of 
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difficulty feeding, movement only when stimulated, temperature below 35.5 C or 
37.5 C or more, respiratory rate over 60 breaths per minute, severe chest in 
drawing, and history of convulsions – to predict the need for hospitalisation in 
young infants presenting to health facilities, particularly the first week of life {Young 
Infants study group (2008)}. The presence of any one sign had high sensitivity (87%) 
and specificity (74%). Even though this algorithm is very helpful in resource 
restrained countries where diagnostic tests are scarce other cases of severe 
neonatal sepsis would be missed. On the other hand the symptoms and signs are 
not pathognomic of severe neonatal sepsis as such one would also run into 
problems of over treatment {Kliegman R.M, R.E. Behrman et al (2011)}. It is 
therefore important that studies continue to explore affordable sensitive and 
specific laboratory tests that can aid in the diagnosis of severe neonatal sepsis.  
1.3. Aetiology of severe neonatal sepsis 
Severe neonatal sepsis is divided into early and late onset.  Differentiation is 
important as early onset  is more likely to reflect vertically acquired infection 
whereas late onset reflects community acquired or nosocomial infections { Seale 
A.C, H. Blencowe et al (2013), Lawn J.E, H. Blencowe et al (2013), Blencowe H, T.Vos 
et al (2013), Seale A.C, M Mwaniki et al (2009), Gordon A.L, M. English et al (2005), 
Osrin D, S. Vergnano et al (2004)Heath P.T, N.K Nik Yusoff et al (2003), Bennet R, 
S.Berdahl et al (1989)}. 
 The outcome also differs between early onset and late onset severe neonatal sepsis 
with mortality being high in early onset severe neonatal sepsis. Few studies in sub 
Saharan Africa differentiate between early and late onset severe neonatal sepsis. 
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{Seale A.C, H. Blencowe et al (2013), Lawn J.E, H. Blencowe et al (2013), Blencowe 
H, T.Vos et al (2013), Seale A.C, M Mwaniki et al (2009), Gordon A.L, M. English et al 
(2005), Osrin D, S. Vergnano et al (2004)Heath P.T, N.K Nik Yusoff et al (2003),  
Bennet R, S.Berdahl et al (1989)}. 
 
1.3.1 Early Onset Severe neonatal sepsis and Meningitis 
 Early-onset sepsis usually results from organisms acquired intrapartum. 
Transplacental infection or an ascending infection from the cervix may be caused by 
organisms that colonize in the mother’s genitourinary tract, with acquisition of the 
microbe by passage through a colonized birth canal at delivery {Klinger G., I Levy et 
al (2009), American academy of paediatrics (2003), Seaward P.G, M.E Hannah et al 
(1998)}.   
In the industrialized countries infectious agents associated with severe neonatal 
sepsis have changed over the past 50 years. Staph aureus and E. coli were the most 
common bacterial pathogens causing early onset severe neonatal sepsis during the 
1950s in the United States {Anderson-Berry A., L. Bellig et al (2010)}. Over the 
ensuing decades Group B streptococcus (GBS) and gram-negative enteric organisms 
(predominantly E. coli) have accounted for most cases of early onset severe 
neonatal sepsis in the developed countries{ Seale A.C, H. Blencowe et al (2013), 
Lawn J.E, H. Blencowe et al (2013), Blencowe H, T.Vos et al (2013), Seale A.C, M 
Mwaniki et al (2009), Gordon A.L, M. English et al (2005), Osrin D, S. Vergnano et al 
(2004)Heath P.T, N.K Nik Yusoff et al (2003)},  Bennet R, S.Berdahl et al 
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(1989)}.Trends in the epidemiology of early onset sepsis show a decreasing 
incidence of GBS sepsis.  
Other organisms that have been known to cause early onset severe neonatal sepsis 
include other gram negative enteric bacilli e.g. Klebsiella spp, gram-positive 
organisms like Listeria monocytogenes, enterococci (e.g. Enterococcus faecalis, 
Enterococcus faecium), group D streptococci (e.g., Streptococcus bovis), alpha 
hemolytic streptococci, Streptococcus pneumoniae and Staphylococci {Seale A.C, 
Mwaniki M et al (2009), Tausch W.H and R.A Ballard (1998) ,Anderson-Berry A, 
L.Bellig et al (2010), Chan K.Y, H.S Lam et al (2009), Byington C.L, F.R Enriquez et al 
(2004)}. 
 
1.3.2 Late Onset Severe neonatal sepsis and Meningitis 
Late onset sepsis is usually acquired from the environment either in the hospital 
(nosocomial) or more commonly in the community. The neonate’s skin, respiratory 
tract, conjunctivae, GI tract and Umbilicus may become colonized from the 
environment, leading to the possibility of late onset sepsis from invasive 
microorganisms, Indwelling lines, vascular or Urinary catheters or contact from 
caregivers with bacterial colonization can act as vectors for the colonization { Shah 
D.K, L.W., Doyle et al (2008), Adams-Chapman I, B.J., Stoll et all (2006), Stoll B.J., N. 
Hansen et al (2002), Hack M.D, D. Wilson-Costello et al (2000), Stoll B.J, T. Gordon 
et al (1996) , Tausch W.H and R.A Ballard (1998) ,Anderson-Berry A, L.Bellig et al 
(2010)  American Academy of paediatrics(2003)}. 
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 Coagulase negative staphylococci, S. aureus and group B streptococci (S. agalactiae) 
are the dominant causes of late onset severe neonatal sepsis in the developed 
countries {11}. Other organisms that can causes late onset severe neonatal sepsis 
are  E coli, Klebsiella, Pseudomonas, Enterobacter, Candida, Serratia,Acinetobacter 
and anaerobes {Tausch W.H and R.A Ballard (1998) ,Anderson-Berry A, L.Bellig et al 
(2010), Osrin D, S. Vergnano et al (2004), Heath P.T, N.K Nik Yusoff et al (2003)}.  
The pathogens most often implicated in severe neonatal sepsis in developing 
countries differ from those seen in developed countries. Gram negative organisms 
are more common and mainly include Klebsiella sp., Escherichia coli, Pseudomonas 
sp. and Salmonella. Gram positive organisms that  are most commonly isolated 
include Staphylococcus aureus, coagulase negative staphylococci, Streptococcus 
pneumoniae and Streptococcus pyogenes { Osrin D, S. Vergnano et al (2004), Heath 
P.T, N.K Nik Yusoff et al (2003)}. 
Coagulase negative staphylococci are important causes of septicaemia in patients 
with compromised host defences such as newborn infants, and especially in the 
premature babies receiving invasive procedures. In addition to being a cause of 
severe neonatal sepsis, the ubiquitous nature of coagulase-negative staphylococcus 
as part of the normal skin flora makes it a frequent contaminant of blood cultures. 
Thus a blood or CSF culture growing coagulase negative staphylococcus may 
represent a contaminated sample rather than true coagulase negative 
staphylococcal septicaemia. The clinical setting (high risk in preterm babies 
undergoing invasive procedures), colony counts and presence of 
polymorphonuclear (PMN) cells on gram stain of the submitted specimen often help 
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to differentiate true infection and positive culture from a false-positive or 
contaminated specimen  {Shet A, Ferrieri et al (2004), Anderson-Berry A, L Bellig et 
al(2010)}. 
 GBS was infrequently reported in the developing world until recently {Shet A, 
Ferrieri et al (2004)}. A multicentre study of the bacterial aetiology of serious 
infections in infants of <3 months of age by World Health Organisation reported a 
striking absence of GBS {The Young infant study group (1999)}. This was particularly 
surprising because the prevalence of maternal carriage of GBS in developing 
countries, including sub Saharan Africa is similar to that identified in populations in 
the United States. However recent studies from Kenya {Berkley J.A, B.S Mwangi et al 
(2005)}, South Africa {Bomela HN, D.E Ballot et al 2001;}, Zimbabwe{ Nathoo K.J, P.R 
Mason et al (1990} and Malawi {Milledge J, J.C Callis et al (2005),Gray K.J (2007)} 
suggest that GBS is emerging as an important cause of severe neonatal sepsis in 
Africa. 
The reason for the differences in the pathogens causing severe neonatal sepsis 
across the world are not well known These could perhaps reflect an epidemiological 
transition in some countries or it could reflect an epidemiologic bias linked to the 
fact that most early onset sepsis babies in the developing world die at home before 
reaching the health facilities and they do not appear in the statistics and the 
causative organisms are never known {Shet A, Ferrieri et al (2004)}. The differences 
in the definition of early onset severe neonatal sepsis, inability to culture certain 
organisms e.g. Listeria monocytogenes and differences in surveillance periods could 
28 
 
also have an impact on the wide variety of bacteria described in different countries 
{Tausch W.H and R.A Ballard (1998),  Shet A, P Ferrieri et al (2004)}. 
1.3.3 Non-bacterial Causes of Severe neonatal sepsis and Meningitis 
 Severe neonatal sepsis and meningoencephalitis can also be caused by a variety of 
viruses, including herpes simplex virus, enterovirus, adenovirus, cytomegalovirus, 
HIV, respiratory syncytial virus, and rubella. Other sexually transmitted diseases 
have also been implicated in neonatal infections. These include syphilis and 
Trichomonas vaginalis. Toxoplasmosis and candida can also cause neonatal 
infections {Tausch W.H and R.A Ballard (1998), Anderson-Berry A, L. Bellig et al 
(2010)}. 
 In malaria endemic areas, malaria has also been found in neonates masquerading 
as septicaemia {Van den Hoogen A, L.I Gerards et al (2009),  Klinger G., I Levy et al 
(2009)}. 
1.4 Treatment of Severe neonatal sepsis and Meningitis 
It is important to initiate treatment promptly once there is suspicion of severe 
neonatal sepsis, severe neonatal pneumonia or neonatal meningitis as the neonate 
is a relatively immunocompromised host { Seale A.C, H. Blencowe et al (2013), Lawn 
J.E, H. Blencowe et al (2013), Blencowe H, T.Vos et al (2013), Seale A.C, M Mwaniki 
et al (2009), Gordon A.L, M. English et al (2005), Osrin D, S. Vergnano et al 
(2004)Heath P.T, N.K Nik Yusoff et al (2003)},  Bennet R, S.Berdahl et al 
(1989)}.Treatment consists of intravenous antibiotics with supportive treatment 
tailored as per the neonate’s needs. The duration of antimicrobial therapy for 
neonatal meningitis is 14-21 days whereas 7-10 days may be appropriate for severe 
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neonatal sepsis (Tausch W.H and R.A Ballard (1998), Anderson-Berry A, L. Bellig et al 
(2010)}. 
The antibiotic combination prescribed in most countries for the treatment of severe 
neonatal sepsis is penicillin together with an aminoglycoside. The biggest challenge 
to this combination is the development of resistance {Tausch W.H and R.A Ballard 
(1998) Anderson-Berry A, L. Bellig et al (2010), Red Book (2003)}. There are an 
increasing number of reports of multi-resistant bacteria causing severe neonatal 
sepsis in developing countries, particularly in intensive care settings. There are few 
studies which compare antibiotic susceptibility over time in the same unit, but 
where data are available they show increasing resistance to commonly used 
antibiotics. Most gram negative bacteria are now resistant to gentamicin.  The 
emergence of a reduction in the susceptibility to third generation cephalosporins 
and quinolones is worrying {American academy of paediatrics (2003) Tausch W.H 
and R.A Ballard(1998), Anderson-Berry A., L Bellig et al (2010)}.  
There have been other therapies investigated in the treatment of severe neonatal 
sepsis; however no substantial clinical trials have shown that these treatments are 
beneficial. These therapies include granulocyte transfusion, intravenous immune 
globulin (IVIG) replacement, exchange transfusion, and the use of recombinant 
cytokines {Anderson-Berry A., L Bellig et al (2010)}. 
Granulocyte transfusion has been shown to be suitable for infants with significant 
depletion of the storage neutrophil pool; however documentation of a depleted 
storage pool requires a bone marrow aspiration, which is invasive. The granulocyte 
transfusion has to be administered quickly to be beneficial. The transfusion has 
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potential side effects including graft versus host disease, transmission of CMV or 
hepatitis B and pulmonary sequestration is considerable. This therapy is still 
experimental  {Anderson-Berry A., L. Bellig et al (2010)}. 
IVIG infusion has been studied as a possible therapy for severe neonatal sepsis to 
provide type specific antibodies to improve opsonisation and phagocytosis of 
bacterial organisms and improve complement activation and chemotaxis of 
neonatal neutrophils. However the effect has been transient and clinically available 
IVIG solutions do not contain type specific antibody and adverse effects associated 
with the infusion of any blood product can follow. At present, the data do not 
support the routine use of IVIG in severe neonatal sepsis {Anderson-Berry A., L. 
Bellig et al (2010)}. 
Recombinant human cytokine administration to stimulate granulocyte progenitor 
cells has been studied as an adjunct to antibiotic therapy. This has shown promise in 
animal models especially for GBS sepsis but require pre-treatment or immediate 
treatment to demonstrate efficacy. The use of granulocyte-macrophage colony 
stimulating factor (GM-CSF) and granulocyte colony stimulating factor (G-CSF) has 
been studied in clinical trials but their use in clinical neonatology remains 
experimental {Anderson-Berry A., L. Bellig et al,  Moraes-Pinto M.I, F. Verhoeff et al 
(1998)} 
1.5 Impact of maternal HIV on newborn immunity 
The neonate can be regarded as an immune compromised host especially when 
premature and are therefore at a higher risk of catching infections. Neonates have 
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extremely low immunoglobulin (Ig) levels except for IgG to specific maternal 
antigens transferred passively across the placenta during the last trimester of 
pregnancy {Stiehm E.R, H.H. Fudenberg et al (1966), Levy O (2007), Moraes-Pinto 
M.I, F. Verhoeff et al (1998)}. T cell function is relatively unimpaired but 
complement activity is half that of healthy adults {Stiehm E.R, H.H. Fudenberg et al 
(1966),  Moraes-Pinto M.I et al (1998), Kemp A.S, D.E, Campbell et al (1996)}. 
Neonates have a low neutrophil storage pool, and their existing neutrophils have 
impaired capacity to migrate from the blood to sites of infection {Levy O, S. Martin 
et al (1999)}. The basal expression of Toll-like receptors (TLRs, receptors that detect 
the presence of microbes) is similar in the neonate and adult {Kemp A.S et al 
(1996)}. However, innate immune responses of neonatal mononuclear cells are 
characterised by markedly reduced release of the proinflammatory Th1-polarizing 
cytokines tumour necrosis factor-alpha (TNF-) and interferon-gamma (IFN-).  
Several clinical conditions can interfere with the materno-fetal transport of specific 
IgG antibodies across the human placenta. These include prematurity, maternal 
hypergammaglobulinemia, maternal HIV infection and placental malaria {Moraes-
Pinto M.I, F. Verhoeff et al (1998)}. It has been noted that among South African 
infants, antenatal HIV exposure was associated with lower specific antibody 
responses in exposed, uninfected infants compared with unexposed infants at birth. 
These HIV exposed uninfected infants had lower levels of specific antibodies to 
Haemophilus influenza b, pertussis, pneumococcus and tetanus {Kemp A.S, D.E 
Campbell et al (1996), Jones E.C, S Naidoo et al (2011)}. One would therefore expect 
that HIV exposed non-infected babies would be at a greater risk of developing 
severe neonatal sepsis compared to babies born from HIV non-infected mothers 
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and perhaps have a worse clinical course leading to a poorer outcome. This has yet 
to be fully established. 
In infants who acquire HIV in utero and around the time of delivery, disease 
progression occurs very rapidly in the first few months of life often leading to death 
{Meyers T., H. Moultrie et al (2007), Newell M.L, H Coovadia et al (2004}. One would 
expect that the risk of severe neonatal sepsis will be considerably increased in these 
HIV infected babies. There is need for more data on the outcome of neonatal 
infections in HIV exposed babies. 
1.6 Outcome of severe neonatal sepsis and meningitis 
1.6.1 Outcome of Severe neonatal sepsis 
Term infants are not likely to experience long term complications of severe 
neonatal sepsis if the diagnosis is made early enough and appropriate treatment 
instituted {Anderson-Berry A., L Bellig et al (2010)}. However if early signs and or 
risk factors are missed the mortality rate increases. Severe neonatal sepsis 
(especially early onset) has been shown to carry a high mortality risk {Anderson-
Berry A, L. Bellig et al (2010)}. In the developing world where the majority of 
neonatal infections are the mortality rate ranges from 30 to 50% { Seale A.C, H. 
Blencowe et al (2013), Lawn J.E, H. Blencowe et al (2013), Blencowe H, T.Vos et al 
(2013), Seale A.C, M Mwaniki et al (2009), Gordon A.L, M. English et al (2005), Osrin 
D, S. Vergnano et al (2004)Heath P.T, N.K Nik Yusoff et al (2003)},  Bennet R, 
S.Berdahl et al (1989)}.The mortality rate is much higher in cases of neonatal 
meningitis with rates above 50%. 
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Severe neonatal sepsis has been shown to have long term effects on 
neurodevelopment especially in preterm and very low birth weight infants { Shah 
D.K, L.W., Doyle et al (2008), Adams-Chapman I, B.J., Stoll et all (2006), Stoll B.J., N. 
Hansen et al (2002), Hack M.D, D. Wilson-Costello et al (2000), Stoll B.J, T. Gordon 
et al (1996)}. The developing brain, particularly the periventricular white matter, is 
vulnerable to cytotoxic and hypoxic/ischaemic injury, which places these infants at 
increased risk for abnormal cognitive and motor functioning. Recent studies have 
linked infection associated with chorioamnionitis, sepsis and necrotizing 
enterocolitis with adverse neurodevelopmental outcome and impaired growth in 
preterm infants {Shah D.K, L.W., Doyle et al (2008), Adams-Chapman I, B.J., Stoll et 
all (2006), Stoll B.J., N. Hansen et al (2002), Hack M.D, D. Wilson-Costello et al 
(2000), Stoll B.J, T. Gordon et al (1996)}. 
 An association between infection and brain injury including severe intraventricular 
haemorrhage and periventricular leukomalacia has been shown by other 
investigators {  Shah D.K, L.W., Doyle et al (2008), Adams-Chapman I, B.J., Stoll et all 
(2006), Stoll B.J., N. Hansen et al (2002), Hack M.D, D. Wilson-Costello et al (2000), 
Stoll B.J, T. Gordon et al (1996)}. 
 It has been postulated that exposure of the preterm brain to inflammatory 
mediators during infectious episodes contributes to brain injury and poor 
developmental outcome { Shah D.K, L.W., Doyle et al (2008), Adams-Chapman I, 
B.J., Stoll et all (2006), Stoll B.J., N. Hansen et al (2002), Hack M.D, D. Wilson-




1.6.2 Outcome of neonatal meningitis 
Meningitis in neonates can progress rapidly to serious complications {Anderson-
Berry A, L. Bellig et al (2010)}. These include cerebral oedema, hydrocephalus, 
haemorrhage, ventriculitis, abscess formation and cerebral infarction. Cerebral 
oedema, hydrocephalus and haemorrhage each may cause increased intracranial 
pressure, with potential for secondary ischemic injury to the brain { Heath P.T, N.K., 
Nik Yusoff et al (2003), Stevens J.P., M., Eames et al (2003), Bedford H, J. Delouvois 
et al (2001), Holt D.E, Halket et al (2001), Delouvois J., T. Blackburn et al (2001)}.  
Cerebral oedema can result from vasogenic changes, cytotoxic cell injury and 
inappropriate antidiuretic hormone secretion {Anderson-Berry A., L Bellig et al 
(2010)}.  
Hydrocephalus which develops as a result of debris obstructing CSF flow through 
the ventricular system or dysfunction of the arachnoid villi has been reported to 
occur in as many as 24% of neonates with bacterial meningitis {Heath P.T, N.K., Nik 
Yusoff et al (2003), Stevens J.P., M., Eames et al (2003), Bedford H, J. Delouvois et al 
(2001), Holt D.E, Halket et al (2001), Delouvois J., T. Blackburn et al (2001)}.  
Meningitis has been shown to be associated with 1.6% of all cases of neonatal 
arterial stroke and 7.7% of venous infarcts {Heath P.T, N.K., Nik Yusoff et al (2003), 
Stevens J.P., M., Eames et al (2003), Bedford H, J. Delouvois et al (2001), Holt D.E, 
Halket et al (2001), Delouvois J., T. Blackburn et al (2001), Fitzgerald K.C, M.R 
Golomb et al (2007), Ment L.R, R.A Ehrenkranz et al (1986)}. 
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Survivors of neonatal meningitis are at a significant risk for moderate to severe 
disability; 25-50% have significant problems with language, motor function, hearing, 
vision and cognition and five to twenty percent have future epilepsy { Heath P.T, 
N.K., Nik Yusoff et al (2003), Stevens J.P., M., Eames et al (2003), Bedford H, J. 
Delouvois et al (2001), Holt D.E, Halket et al (2001), Delouvois J., T. Blackburn et al 
(2001)}. 
Survivors of neonatal meningitis are also more likely to have more subtle problems, 
including visual deficits, middle ear disease and behavioural problems { Heath P.T, 
N.K., Nik Yusoff et al (2003), Stevens J.P., M., Eames et al (2003), Bedford H, J. 
Delouvois et al (2001), Holt D.E, Halket et al (2001), Delouvois J., T. Blackburn et al 
(2001)}.  Recent data suggests that as high as 20% of children who were being 
identified as normal at 5 year follow-up may have significant educational difficulties 
lasting into late adolescence {Heath P.T, N.K., Nik Yusoff et al (2003), Stevens J.P., 
M., Eames et al (2003), Bedford H, J. Delouvois et al (2001), Holt D.E, Halket et al 
(2001), Delouvois J., T. Blackburn et al (2001)}. 
There are poor prognostic factors known to predispose to the development of 
complications from neonatal meningitis. These include low birth weight, 
prematurity, significant leucopenia or neutropenia, high CSF protein, delayed 
sterilization of the CSF, seizures lasting for more than 72 hours and coma {Heath 
P.T, N.K., Nik Yusoff et al (2003), Stevens J.P., M., Eames et al (2003), Bedford H, J. 
Delouvois et al (2001), Holt D.E, Halket et al (2001), Delouvois J., T. Blackburn et al 
(2001) , Volpe J.J (2008) }.  
36 
 
The use of acyclovir has reduced morbidity and mortality from herpes simplex virus 
meningitis yet 50% of the survivors will have neurological sequelae {Kimberlin D. 
(2004)}. 
There is an existing gap on the long term outcome of severe neonatal sepsis and 
meningitis in sub-Saharan Africa. It is important to establish what happens to the 
babies who have been discharged with a diagnosis of severe neonatal sepsis. 
Important questions to answer include what sequelae do they develop? What 
happens to their development? Are they still alive a few months down the line? If 
they die what is the cause of death? Are they at a higher risk of catching infections 
during the first year of life? 
 
1.7 Prevention of Severe neonatal sepsis and Meningitis 
The bulk of the 4 million annual global neonatal deaths (99%) occur in developing 
countries and approximately 36% are attributed to infections. In communities with 
high neonatal mortality rates, infections account for approximately half of all 
newborn deaths A.C, H. Blencowe et al (2013), Lawn J.E, H. Blencowe et al (2013), 
Blencowe H, T.Vos et al (2013), Seale A.C, M Mwaniki et al (2009), Gordon A.L, M. 
English et al (2005), Osrin D, S. Vergnano et al (2004)Heath P.T, N.K Nik Yusoff et al 
(2003)},  Bennet R, S.Berdahl et al (1989)}. Continued efforts are required to 
describe optimal community-based delivery of proven interventions and to identify 




Chlorhexidine is a broad-spectrum antiseptic that has been used extensively for 
many decades in hospital and other clinical settings. It has also been given as 
maternal vaginal lavage, full-body newborn skin cleansing, and/or umbilical cord 
cleansing to prevent infection in neonates {Mullany L.C, G.L Darmstadt et al (2006), 
Tielsch J.M, G.L Darmstadt et al (2005) Bakr A.F, T karkour et al (2005), Taha T.E, R.J. 
Biggar et al (1997)}. Recent evidence suggests that these chlorhexidine 
interventions may have significant public health impact on the burden of neonatal 
infection and mortality in developing countries. There is evidence that delivery of 
chlorhexidine solutions by vaginal lavage during labour and delivery, full-body 
newborn skin cleansing, and/or umbilical cord cleansing reduces neonatal bacterial 
colonization, infection and mortality {Mullany L.C, G.L Darmstadt et al (2006), 
Tielsch J.M, G.L Darmstadt et al (2005) Bakr A.F, T Karkour et al (2005), Taha T.E, R.J. 
Biggar et al (1997)}. Research on chlorhexidine use in newborns in developed 
countries has focused mainly on antisepsis of central venous catheters, as well as 
prevention of vertical transfer of microorganisms, especially group B streptococcus 
(GBS), from mother to newborn at the time of delivery {Adriaanse A.H, L.A.A. Kollee 
et al (1995), Burman L.G, P. Christensen et al (1992)}. In developing countries, 
investigators have examined the potential of chlorhexidine vaginal cleansing to 
reduce vertical transmission of HIV and prevent neonatal morbidity and mortality 
{Taha T.E, R.J Biggar et al (1997), Bakr A.F, T Karkour et al (2005)}. The evidence for 
impact of intrapartum vaginal cleansing with chlorhexidine on vertical transmission 
of HIV, neonatal colonization and infection with GBS, and on other infections has 
been reviewed by Cochrane meta-analyses {Denton G.W (2001), Stade B, V Shah et 
38 
 
al (2004), Lumbiganon P et al (2004)}. On the whole studies have shown a positive 
impact on the reduction of neonatal infections. 
Although the potential impact of chlorhexidine-based interventions has been 
demonstrated in a number of studies discussed above, there have been few well-
designed studies in low-resource settings. Given the burden of neonatal mortality in 
communities of developing countries, there is a need for simple interventions to 
reduce this burden {Mullany L, G. Darmstadt et al (2006)}.  
Group B streptococcus remains one of the top causes of early onset severe neonatal 
sepsis. Increased screening and intrapartum antibiotic treatment of GBS positive 
mothers has led to a substantial reduction in the contribution of GBS to early onset 
severe neonatal sepsis {Anderson-Berry A, L. Bellig et al (2010), Gordon A.L, M. 
English et al (2005}. This has mainly been done in the developed world and is yet to 
be routinely implemented in the developing world where the burden of the disease 
is. Intrapartum antibiotic use has not been shown to have an impact on late onset 








Figure 1.7 Incidence of Early-Onset Invasive Group B Streptococcal Disease in 
Black Neonates and White Neonates in Four Active Surveillance Areas (California, 













Figure 1.8 Incidence of Early- and Late-Onset Invasive Group B Streptococcal 
Disease in Three Active Surveillance Areas (California, Georgia, and Tennessee), 
1990 through 1998, and Activities for the Prevention of Group B Streptococcal 





In spite of universal screening, and the great progress that has been made, GBS-
early onset disease continues to occur and the GBS burden remains a significant 
public health issue {Anderson-Berry A., L. Bellig et al (2010), Schrag, S Zywicki et al 
(2000)}. Continuous efforts to improve screening for GBS status continue to be 
important and may be able to take advantage of new rapid diagnostic technologies. 
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The current screening-based strategy for prevention is highly effective but 
imperfect. Given the challenges, limitations and potential complications of maternal 
intrapartum prophylaxis, a new approach is still needed. Maternal immunization 
against GBS is an attractive alternative for the prevention of not only neonatal 
diseases but potentially also stillbirths and maternal diseases {Schrag, S Zywicki et al 
(2000)}. Vaccines against GBS may become the most effective and sustainable long-
term preventive strategy. 
1.8 Research question 
It is very clear that neonatal infections are a major contributor to neonatal deaths. 
Proper management of these infections is important in the reduction of neonatal 
mortality. In trying to address the problem of neonatal infections in Malawi we 
looked at the “Aetiology, and Outcome of Severe neonatal sepsis and Meningitis in 
Malawi”.  
1.9 Study hypothesis and objectives 
1.9.1 Hypothesis 
The risk of neurodevelopmental delay is increased by 10% at one year of age in 
infants who had an episode of severe neonatal infection compared to those who 
never had severe neonatal infection 
1.9.2 Study Objectives 
The following were the study aims: 
 To determine the aetiology, resistance pattern and outcome of bacterial 
severe neonatal sepsis, severe neonatal pneumonia and meningitis at 
Queen Elizabeth central hospital (QECH) in Malawi between June 2010 
and June 2013.  
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 To determine inpatient mortality outcomes of bacterial severe neonatal 
sepsis, severe neonatal pneumonia and meningitis cases at Queen 
Elizabeth central hospital (QECH) in Malawi between June 2010 and June 
2013.  
 To determine the mortality, neurodevelopmental and neurological 
outcomes at 6 and12 months of age of neonatal meningitis, severe 
neonatal pneumonia and severe neonatal sepsis cases discharged from 
QECH between June 2010 and June 2013 and residing within Blantyre 
urban. 
 To determine the impact of maternal HIV infection on the aetiology, 
mortality, neurodevelopmental and neurological outcomes at 6 and12 
months of age in neonatal meningitis, severe neonatal pneumonia and 
severe neonatal sepsis cases at QECH between June 2010 and June 2013. 
We aimed to better define the organisms that cause neonatal infections in Malawi 
and their resistance pattern. We also aimed to better define the outcome of severe 
neonatal sepsis both in the short term and long-term looking at mortality, and 
morbidity in the first year of life. We also described the neurological sequelae that 
these babies end up with and also their neurocognitive development.  
The information on aetiology will help in coming up with better treatment packages 
for severe neonatal sepsis and perhaps more lobbying for vaccines like the group B 









1.10 Thesis Plan 
Within this thesis all the methods will be summarised in chapter 2. The results will 
be set out in chapters 3 to 6 that cover the following; 
 Chapter 3- The clinical features and in hospital outcome of severe neonatal 
infection in Malawi in a prospective cross-sectional study 
 Chapter 4 The long term outcome of severe neonatal infection  in Malawi in 
a longitdunial prospective cohort study with the recruitment of controls 
from a nearby health centre.  
 Chapter 5 Predictors of poor neurodevelopmental outcomes in severe 
neonatal infection cases at 12 months of age in this cohort. 
 Chapter 6 Case series of MRI brain findings in severe neonatal infection 
cases at QECH in Malawi derived from the cross-sectional cohort. 
 In chapter 7, the overall results will be summarised and put in the context of the 












                                CHAPTER TWO 
MATERIALS AND METHODS 
2.1 Study Location 
Malawi is a landlocked country within the sub-Saharan region. It is located south of 
the equator. It shares boundaries with Zambia in the west and North West, 
Mozambique in the east, south and southwest and Tanzania in the north and north 
east (Fig. 2.1). Malawi is 901 kilometres long and has a width that ranges from 80 to 
161 kilometres. Malawi has an area of 118,484 km2 of which 94,276 km2 is land and 
the remaining area is mostly composed of Lake Malawi, which is about 475 
kilometres long and delineates Malawi’s eastern boundary with Mozambique. 
Malawi's climate is generally tropical continental with some maritime influences. 
Rainfall and temperature vary depending on altitude and proximity to the lake. 
There are 3 seasons in a year. A rainy season runs from November to April. The 
weather becomes cool from May to August and hot from September to November. 
The country is divided into three administrative regions, namely the northern, 
central and southern regions. The regions are further divided into 28 districts with 6 
districts in the northern region, 9 and 13 districts in the central and southern 
regions respectively. The study was conducted in the southern region in Blantyre 






















Fig 2.1 Map of Malawi 
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Malawi is one of the least developed countries in the world {CIA World Fact Book 
(2010)}. Malawi is currently ranked number 177 out of 184 countries on the Human 
Development Index by UNDP {UNDP Human Development reports 2013}. Over the 
past two decades the human development index for Malawi has been showing 
some improvement (Fig 2.2). 
 
Fig 2.2 Human Development index graph for Malawi compared to the rest of the 
world 
 The majority (80%) of the population live in the rural areas {CIA World Fact Book 
(2010), Republic of Malawi and World Bank (2006)}. Malawi’s economy heavily 
relies on agriculture {Republic of Malawi, Growth and Development strategy (2007), 
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Republic of Malawi and World Bank (2006)}. The agricultural sector accounts for 
35% of the GDP, industry for 19% and services for the remaining 46%.The 
agricultural sector also accounts for more than 80% of export earnings and it 
supports more than 85% of the population.        
 Tobacco has remained the most important export crop accounting for 70% of all 
export revenues from the agricultural sector {Republic of Malawi and World Bank 
(2006), Republic of Malawi, Growth and Development strategy (2007)}. There has 
been an increased pressure from the international community to limit tobacco 
production and this has led to a decline in the world prices {Republic of Malawi and 
World Bank (2006)}. This is likely going to place a heavy burden on the country’s 
economy.  
The country also relies heavily on tea, sugarcane and coffee, these three plus 
tobacco make up more than 90% of Malawi's export revenue {Malawi Wikipedia, 
Republic of Malawi and World Bank (2006), Republic of Malawi, Growth and 
Development strategy (2007)}. Other crops include cotton, corn, potatoes, 
sorghum, cattle and goats.  
Malawi has few exploitable mineral resources like uranium, bauxite {Republic of 
Malawi, Growth and Development strategy (2007)}.  
The economy is also dependent on substantial economic aid from the World Bank, 
International Monetary Fund and other donor countries {Republic of Malawi and 




Table 2.1 Malawi Demographic Indicators from the 1996-2008 Malawi Population 
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The Malawi population and housing census is conducted once every ten years 
however the estimated population for 2013 stands at 16,777,547. This shows that 





Fig 2.3 Malawi Population from the 1966 to 2008, and then extrapolated based on 
population growth estimates to 2030 
 
2.1.1 Blantyre 
Blantyre, the commercial and industrial capital of Malawi, is in the Shire Highlands 
and geographical centre of the Southern Region of the country and lies at 35° east 
of Greenwich Meridian and 15° 42" south of the Equator. 
50 
 
 The climate of Blantyre is influenced by its location in the tropical zone and 
altitude. Blantyre stands at an altitude of 1,039 m (3,409ft) above sea level. The 
climate in Blantyre is classified as humid subtropical-highland. Blantyre experiences 
the tropical continental climate with two distinct seasons in the year. The rainy 
season is from November to April, with continuing light cold showers from end of 
May to July. The dry season is from May to October.  
Blantyre had a population of 732,518 inhabitants in 2008 but it is now estimated to 
be over 1 million. The majority of the population are located in the urban area. The 
study took place at Queen Elizabeth Central Hospital (QECH) and Zingwangwa 
health centre in Blantyre City with full support and sponsorship from the Malawi 
Liverpool Wellcome Trust Clinical Research Programme (section 2.1.1.1). 
2.1.1.1 The Malawi Liverpool Wellcome Trust Clinical Research Programme. 
 The Malawi Liverpool Wellcome Trust (MLW) clinical research programme 
{https://www.mlw.medcol.mw} was established in 1995 and became a Wellcome 
Trust Major Overseas programme in 2003. It is situated within the Queen Elizabeth 
Central Hospital campus and is in close proximity to the University of Malawi, 
College of Medicine (CoM) to which it is affiliated. MLW has strong collaborative 
links with several clinical (Medicine, Paediatrics, Obstetrics & Gynaecology, Surgery, 
Community Medicine) and laboratory/ basic science CoM departments 
(Biochemistry, Microbiology, Pathology, Pharmacy/ Pharmacology). It also provides 
vital diagnostic laboratory services for patients who are seen at QECH. This includes 
parasitology, haematology, chemistry and microbiology services. This unique 
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arrangement has a major advantage to QECH which at the moment is the only 
public hospital in Malawi with access to this wide array of laboratory services. 
The vision of MLW is to be an internationally leading laboratory-based health 
research institution led by Malawian & International Scientists, improving the 
health of people in Malawi and elsewhere in the Region. 
MLW aims to:  
(1) Conduct internationally leading, cutting edge biomedical research focusing on 
health problems with a high disease burden in Africa in a place where these 
problems occur. There is an emphasis on increasing both the quantity and quality of 
research outputs, and ensuring that MLW research informs policy & practice 
(2) Provide excellence in research training for clinical and laboratory scientists both 
from the host country and abroad, generating a multidisciplinary team of Research 
Leaders, supported by a strong research infrastructure 
(3) Further strengthen the capacity of CoM to pursue research and research 
leadership at the highest level. As a Research Centre within CoM, MLW will provide 
mentorship and access to research infrastructure. 
MLW has established itself as an internationally recognised centre for research 
excellence and research training. MLW has an outstanding translational research 
portfolio that links a state-of-the–art laboratory research base to strong hospital 
and community-based research teams. Research is focused into four themes:  
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 Malaria: the basic biology, genetics, immunology and clinical manifestations 
of severe malaria. The clinical programs of phase III and IV studies focus on 
the optimization of case management program ranging from novel 
interventions for severe malarial anaemia, to programmatic use of first-line 
drugs. The mechanisms of antimalarial resistance and side-effects. The 
operational research focus is on the development of facility and community-
based methods for the monitoring & evaluation of malaria control progress. 
 TB & HIV: The assessment of novel diagnostics for TB & HIV. The development 
and large-scale testing of novel strategies to reduce the dual burden of these 
epidemics. HIV & TB pharmacology and systems biology. Improving access to 
TB & HIV care. Adolescent HIV. Assessing health seeking behaviour & 
treatment acceptability 
 Non-Communicable Diseases (NCDs): the origins, epidemiology and 
mechanisms of NCDs in Malawi. The development of affordable preventative 
and therapeutic interventions focusing on diabetes, hypertension, lung health, 
epilepsy and stroke 
 Microbes, Immunity and Vaccines: surveillance for respiratory pathogens and 
invasive bacterial disease. The molecular epidemiology, pathogenesis and 
management of bacteraemia, pneumonia and meningitis. Carriage studies. 
Immune responses to bacterial and viral pathogens that infect via the mucosa; 
influence of HIV on naturally acquired and vaccine induced immune 
responses; effects of clinical and subclinical infections on vaccine-induced 
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immunity; novel strategies for vaccine prevention. Assessing health seeking 
behaviour & treatment acceptability. 
 
This study was conducted under the Microbes, immunity and Vaccines theme. 
MLW in collaboration with the Blantyre Malaria Project (BMP) and the Department 
of Paediatrics and Child Health runs a paediatric research ward where the study 
participants were admitted and followed up. It generally acts as an inpatient facility 
for most of the paediatric research studies taking place at QECH. The ward provides 
high quality nursing care with an average nursing to patient ratio of 1:3 compared 
with 1:350 on the general wards. 
2.1.2 Study site 
The study took place at QECH and Zingwangwa health centre in Blantyre. QECH acts 
as both a tertiary and secondary level facility. Patients self-refer and are referred 
from surrounding district health centres and district hospitals in the southern region 
of Malawi. QECH is the only public district hospital in Blantyre which offers free 
health services and covers both the rural and urban settings of Blantyre. It also 
serves as a teaching hospital for the University of Malawi, College of Medicine. 
QECH has a separate paediatric accidents and emergency unit which caters for all 
children presenting to the hospital. The unit sees 96,000 children annually out of 
which 23,000 are admitted. These large numbers make QECH a suitable site for the 
study of a relatively rare disease such as neonatal meningitis and sepsis.  
Zingwangwa health centre on the other hand is a primary health care facility that 
serves a population of 147,679. It is situated about 7 km away from QECH.  Its close 
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proximity to QECH compared to other health centres in Blantyre made this a 
suitable site where healthy children could be enrolled. Its catchment area has 
similar characteristics to the other urban health centres in Blantyre. The study was 
staffed by one medical officer, two nurses and the principal investigator (specialist 
paediatrician).   
2.1.3 Study population 
This study recruited infants less than 2 months who presented to the paediatric 
Accident and Emergency unit at QECH with a clinical suspicion of severe sepsis or 
meningitis (cases); and young infants 3 months of age  (controls) attending the 
immunisation clinic at Zingwangwa Health Centre.      
2.1.4 Study design 
2.1.4.1 Design 
This study had two components, a hospital-based cross-sectional study and a 
prospective cohort study. The cross sectional study addressed the in-hospital 
microbiological aetiology and antimicrobial resistance pattern of severe neonatal 
sepsis and meningitis at QECH. The prospective cohort study addressed the 
outcome of severe neonatal sepsis and meningitis, inpatient and post discharge 
from QECH compared with control infants recruited at Zingwangwa health centre. 
2.1.4.2 Study duration 





2.1.4.3 Areas of potential Bias 
2.1.4.3.1 Representability of the study population  
QECH is a district general and tertiary hospital. It caters for both the urban and rural 
settings and as such has the benefit of its data representing both the rural and 
urban setting. However this might not be wholly representative of other districts 
that have a predominantly rural population. 
Zingwangwa Health Centre is a large busy health Centre which serves QECH 
catchment’s area and has similar socio-demographic characteristics to most urban 
Health Centres in Blantyre.  
2.1.4.3.2 Loss to follow up 
In order to minimise loss to follow-up only participants who resided within Blantyre 
urban were recruited in the prospective cohort arm upon discharge from hospital. 
The participants were given follow up cards and they were reminded of their 
scheduled appointments a week before the appointment date through phone calls 
to all who had phones. All the participants who had failed to turn up on their 
scheduled date were followed at home after 2 weeks from their failed scheduled 
visit. Reasons for loss-to-follow up were documented where possible. 
The proximity of Zingwangwa Health Centre to QECH made it easier to follow up 






2.1.4.4 Sample size  
2.1.4.4.1 Disease outcome for severe neonatal sepsis and meningitis 
A sample size was calculated that was able to detect a 10% difference in the 
prevalence of neuro developmental delay between the cases and controls.  
There is no baseline data for the prevalence of neuro-developmental delay and 
neurological sequelae in Malawian children. It was however estimated that the 
prevalence of developmental delay would be 8% in the general Malawian paediatric 
population. This estimate was arrived at after looking at the prevalence of 
developmental delay in some African settings namely; Uganda 6% and Rwanda 
(before the ethnic war) 5% for one year olds {Msellati P, P. Lepaje et al (1993), and 
Drotar D., K. Olness et al (1997)}. We postulated that the prevalence of 
developmental delay would be higher in Malawi than the 2 countries due to the 
high prevalence of HIV and poor socio-economic status compared to the 2 
countries. 
A sample size of 235 severe neonatal infection cases and 235 controls was required 
in order to detect the 10% difference between the cases and controls. In order to 
achieve this, the following steps were taken; 
Severe neonatal infection cases: In order to get the 235 severe neonatal infection 
cases we needed to recruit 1,000 eligible cases presenting at QECH. Mortality from 
these cases was postulated at 48%. This was based on a retrospective study done in 
Malawi on the aetiology of severe neonatal sepsis that found that in-hospital case 
fatality rates from severe neonatal sepsis was 48% {Milledge J, J. C Callis et al 
(2005)}. This meant that 520 babies would survive from their illness and around 400 
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of these would be coming from Blantyre urban. It was therefore planned that upon 
discharge a total of 235 babies from the 400 with neonatal meningitis and sepsis 
would be actively followed up till the age of one year.  
Controls: A total of 235 healthy babies were recruited at 3 months of age and 
actively followed for up to one year of age.  
This prospective cohort study had 80% power to detect a 10% difference between 
neuro-developmental delay and neurological sequelae in the cases and controls at 1 
year of age with 95% confidence, assuming a baseline prevalence of 8% in the 
control arm, and taking into account a 15% loss to follow up.    
 
2.1.4.4.2 Impact of maternal HIV 
The national HIV prevalence rate for Malawi is 11% but it is twice this figure for 
antenatal mothers (Gray K.J, G. Kafulafula (2011)}. We therefore expected that 
almost 20% of our mothers in this cohort would be HIV positive translating to 200 
HIV exposed babies. 
2.1.5 Study procedures 
 
2.1.5.1 Selection and withdrawal of study participants 
2.1.5.1.1 Cross sectional arm (Aetiology and drug-resistance)  
The sick neonates were recruited from the paediatric Accidents and Emergency 
department and the neonatal nursery at QECH. Study participants were admitted 
on the neonatal nursery and the paediatric research ward. Neonates from birth up 
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to 6 days of age were admitted to the neonatal nursery. These sick neonates who 
were admitted on the neonatal nursery came as referrals from QECH labour ward 
and postnatal ward or were referred from surrounding health centres. On the other 
hand neonates who were discharged well after delivery from QECH or surrounding 
health centres but who then developed symptoms suggestive of severe neonatal 
sepsis and meningitis were admitted to the paediatric research ward.  
2.1.5.1.2 Prospective cohort arm (Disease outcome for severe neonatal sepsis and 
meningitis) 
Selection of exposed group:  
The neonates who came from Blantyre urban were invited into the disease outcome 
study upon discharge. The first child to be discharged for the day and fulfilled the 
inclusion/ exclusion criteria were invited into the study. If they declined, the next 
child was approached. 
 Selection of non-exposed group: Healthy infants were recruited from the 
vaccination clinic at Zingwangwa Health Centre. Healthy babies aged 3 months with 
no history of severe neonatal sepsis, severe neonatal pneumonia or neonatal 
meningitis were invited to join the study if they fulfilled the inclusion criteria. The 
mothers or guardians were asked if their baby had a history of a febrile illness 
within the first 4 weeks of life that required hospitalisation or use of injectable 





2.1.5.2 Subject screening 
2.1.5.2.1 Aetiology, Resistance and Short term outcome 
Babies less than 2 months of age who presented to the Accidents and Emergency 
unit and the neonatal unit at QECH were assessed for symptoms and signs of severe 
neonatal sepsis, severe neonatal pneumonia and meningitis using the clinical 
definition (section 2.1.5.4). Standard investigations outlined below (section 
2.1.5.5.1) were done. Children who fulfilled the inclusion criteria were invited to 
join the study.  
2.1.5.2.2 Long-term outcome 
Subject screening exposed: children who were admitted with the diagnosis of severe 
neonatal sepsis, severe neonatal pneumonia or meningitis and were recruited in the 
cross sectional study were invited into the long term outcome study provided they 
came from Blantyre urban. 
Subject screening non-exposed: All the babies who were enrolled at Zingwangwa 
Health centre were recruited in the prospective cohort arm 
2.1.5.3 Subject enrolment 
The mothers were informed of the study by one of the study team members from 
QECH and Zingwangwa Health centre (Refer to patient information sheet in the 
appendix). Parental permission to be involved in the study was sought by the study 





2.1.5.3.1    Inclusion and exclusion criteria  
Inclusion criteria severe neonatal sepsis severe neonatal pneumonia or meningitis 
(cases).  
 Babies less than 2 months of age admitted to Queen Elizabeth Central 
Hospital in whom a clinical suspicion of severe neonatal sepsis, severe 
neonatal pneumonia or meningitis (as defined in section 2.1.5.4) was made. 
 Babies less than 2 months of age admitted to QECH with a clinical suspicion 
of severe neonatal sepsis severe neonatal pneumonia, or meningitis that 
came from Blantyre urban setting for the disease outcome arm of the study. 
Exclusion criteria severe neonatal sepsis, severe neonatal pneumonia or neonatal 
meningitis (cases)  
  Known to have a neurological problem like neural tube defects, 
microcephaly and hydrocephalus prior to the onset of the study. 
  Prior history of birth asphyxia. Birth asphyxia was a clinical diagnosis made 
in babies who had APGAR scores of less than 6 at 5 minutes after birth. Birth 
asphyxia impacts neurodevelopment negatively and would have been a 
significant confounder in this study since neurodevelopment was one of the 
main outcomes of the study. 
 Nosocomial infection, i.e babies who had been inpatients for some other 
reason and then develop severe neonatal sepsis, severe neonatal 
pneumonia or neonatal meningitis after 72 hours of in hospital stay. Co-
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morbid conditions that had led to the neonate’s admission in hospital were 
deemed to be potential confounders. 
 Other major congenital abnormalities like Trisomy 21. 
 Prematurity less than 32 weeks of gestation or very low birth weight of less 
than 1500g.  Prematurity was estimated using maternal expected date of 
delivery recorded in her health passport and birth weight of less than 1500g. 
Prematurity especially less than 32 weeks is also known to negatively impact 
on neurodevelopment. 
 Parenteral antibiotics for at least 24 hours prior to admission to QECH. This 
would have affected blood culture growth of bacterial organisms. 
 A previous history of severe neonatal sepsis, severe neonatal pneumonia or 
neonatal meningitis (documented in the health passport or by maternal 
history). 
Inclusion criteria controls 
 Healthy babies 3 months of age with no previous history of severe neonatal 
sepsis, severe neonatal pneumonia or neonatal meningitis and reside within 
Blantyre urban. 
Exclusion criteria controls 
 Known to have a neurological problem like neural tube defects and 
hydrocephalus prior to the onset of the study. 
  Prior history of birth asphyxia (as above). 
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 Other major congenital abnormalities. 
 Prematurity less than 32 weeks of gestation or very low birth weight of less 
than 1500g (as above). 
 
2.1.5.4 Clinical diagnosis of severe neonatal sepsis, severe neonatal pneumonia or 
neonatal meningitis 
A clinical diagnosis of severe neonatal sepsis, severe neonatal pneumonia or 
neonatal meningitis was considered if a baby presented with any of the following: 
 Fever or hypothermia  
 Tachycardia  and/or capillary refill time of </= 2 seconds 
 Tachypnoea, apnoea or hyperventilation, marked chest recessions 
 Irritability and convulsions  
 Difficulty feeding  
 Poor colour e.g. very pale, dusky or grey.  
 Bulging or tense fontanelle 
 Umbilical redness extending at least 1cm to the skin. 
All these cases were treated for at least 5 days with parental antibiotics. 
2.1.5.5 Participant management at QECH during hospitalisation 
A Performa (appendix) was used to record demographic details, maternal, antenatal 
and delivery history and findings of a full history and examination undertaken. All 
babies who were enrolled in the study with a diagnosis of severe neonatal sepsis, 
severe neonatal pneumonia or neonatal meningitis were started on parenteral 
broad spectrum antibiotics- Penicillin and gentamicin as first line and ceftriaxone as 
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second line therapy according to QECH standard guidelines. The penicillin dose for 
severe neonatal sepsis was 50,000 international units per kilogramme body weight 
twice daily during the first week of life and 25,000 international units per 
kilogramme body weight every 6 hours beyond the first week of life. Gentamicin 
was given at a dose of 5mg per kilogramme once daily. Ceftriaxone was given at a 
dose of 50 mg per kilogramme body weight once daily.  Penicillin and ceftriaxone 
doses were doubled in neonates with meningitis.  Convulsions were treated with 
intramuscular phenobarbitone 20mg per kilogramme body weight as the first line 
with phenytoin being the second line. 
Monitoring and supportive care was standardized and carried out according to the 
paediatric unit at QECH and the paediatric research ward protocols (see appendix). 
Care was provided by study staff, nurses and clinicians working on the units.  
 2.1.5.5.1 Laboratory Investigations 
Study participants had the following laboratory investigations; blood culture, Full 
Blood Count, random blood glucose, Packed Cell Volume,  C-Reactive Protein, 
malaria parasite thick film, urea and electrolytes,  infant VDRL if there was a 
suspicion of congenital syphilis and cerebro-spinal fluid (CSF) analysis. All the 
samples were taken on admission prior to commencing antibiotics. In neonates that 
were deemed to be too sick lumbar puncture was deferred. CSF samples were 
stored for future molecular diagnostics. PCR analysis on the CSF samples would 
further increase the yield of positive cultures and thereby improve the confidence 
in the final diagnosis of these neonates. It would help pick out the ones that would 
be falsely labelled as not having meningitis just based on routine CSF culture which 
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is not as sensitive as PCR. All these investigations were done by the MLW Core 
Laboratory except for VDRL which was done by the QECH laboratory according to 
standard protocols. 
Standard operating procedures were put in place for blood culture sampling to 
minimise contamination rate.  
A positive CSF was defined as one in which an organism was identified on a gram 
stain or by culture and/ or the white cell count was >30 cells/microml in a low birth 
weight baby and >20/microml in a full term neonate {Neonatal Handbook}. 
Biochemistry tests on the CSF included protein and glucose. An abnormal CSF 
glucose was considered at a level that is less than 2/3 the blood glucose level at the 
time the lumbar puncture was performed. An abnormal CSF protein was considered 
at a level of more than 0.7g/litre. A positive CRP was considered at a value of 
greater than 5mg/L {Neonatal Handbook}. 
The mothers were tested for HIV infection using 2 rapid tests for HIV 1 and HIV 2 
namely; Determine and Unigold rapid tests (Abbot and Biotech laboratories). In 
case of discrepancy between the 2 (Determine and Unigold), the SD Bioline HIV Ag-
Ab combo rapid test was used as a tie breaker. The seropositive (i.e. HIV exposed) 
babies had an HIV DNA PCR (Roche Amplicor) done at 6 weeks according to national 
guidelines. HIV testing was only done if the guardians/parents had accepted testing 
after pre-counselling. All the study nurses were trained counsellors and they offered 
post-test counselling to all. All HIV tests were done by the MLW Core Laboratory 
according to standard protocols. 
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2.1.5.5.2 Imaging Studies 
Two imaging studies were undertaken on selected neonatal meningitis cases. These 
included cranial ultra sound scan and magnetic resonance imaging (MRI) of the 
brain. These cranial ultra sound scans were done by the QECH radiology and 
paediatric department whilst the MRI scans were done at the QECH MRI facility run 
by the Blantyre Malaria Project. The MRI scans were reported by a specialist 
neuroradiologist. These scans were done in patients whose neurological condition 
were not improving or had deteriorated whilst on the ward. These mostly included 
patients who had refractory seizures or remained comatose after several days of 
treatment 
2.1.5.6 Subject follow up - long-term outcome component   
  
2.1.5.6.1 Follow-up of cases and controls 
Neonates who upon discharge were recruited in the disease outcome study were 
followed up at 6 and 12 months of age at QECH. The control infants were also 
followed up at 6 and 12 months of age. At each follow up visit each infant had a 
neuro-developmental assessment, hearing screen and a full neurological exam by 
the study physician. Details of any admissions were also recorded. 
2.1.5.6.2 Neurodevelopmental assessment using the Bayley’s assessment tool 
The neurodevelopmental assessment was done using the Bayley scales of infant 
development III. The Bayley Scales of Infant Development (Bayley-III) are recognised 
internationally as one of the most comprehensive tools to assess children from as 
young as one month old and has been found to be highly effective in this 
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population. With Bayley-III, it is possible to obtain detailed information even from 
non-verbal children as to their functioning {Bayley Nancy (2006)}. It was for this 
reason that this tool was chosen in this study. It includes the following domains: 
 Psychomotor development: includes fine and gross motor assessment. 
Scores (raw and standardized) and classification (normal, moderate, severe 
delay) of the psychomotor section  of the Bayley scales of infant 
development III were used  
 Mental (cognitive) development: Scores (raw and standardized) and 
classification (normal, moderate, severe delay) of the mental section  of the 
Bayley scales of infant development III were used  
 Language development: Includes both receptive and expressive language. 
Scores (raw and standardized) and classification (normal, moderate, severe 
delay) of the language section of the Bayley scales of infant development III 
were used. 
A score of less than -2SD in any of the domains is indicative of developmental delay. 
All study team members were trained in neurodevelopmental assessments using 
the BSID III tool and developmental tips to be given to caregivers a week prior to 
the initiation of the study. The training involved both theoretical and practical 
sessions. The first 3 months of the study neurodevelopmental assessments on one 
participant were being done by 2 study team members and agreements were made 
on the scoring of each item. Areas of disagreement were referred to the principal 
investigator who would reassess the participant. During the rest of the study period 
the assessments were not done in pairs but by one individual with the principal 
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investigator doing spot checks on a biweekly basis. Refresher Bayley’s trainings 
were done on the last Saturday of every month during the study period.  
The Bayley’s assessment tool was validated for use in Malawian children in the HIV 
encephalopathy study in 2008 and in 2013 using data from this study we 
constructed BSID-III norms for cognitive, fine motor (FM), gross motor (GM), 
expressive communication (EC) and receptive communication (RC) subtests using 
5173 tests scores in 167 healthy Malawian children age range 6 weeks to 30 months 
{Cromwell E., Q. Dube et al (2014)}. Norms were generated using Generalized 
Additive Models for location, scale and shape, with age modelled continuously. 
Standard z-scores were used to classify neurodevelopmental delay. Weighted kappa 
statistics were used to compare the classification of neurological development using 
US-based and Malawian norms {Cromwell E., Q. Dube et al (2014)}. The generated 
Bayley’s norms for Malawian children were then used in the analysis of the cases 
recruited in this study. 
2.1.5.6.3 Neurological sequelae outcomes 
The following neurologic sequelae were assessed at 6 and 12 months of age; 
epilepsy, hydrocephalus, visual loss and hearing loss. All other anomalies in the 
neurological exam like cranial nerve palsies, motor neurone lesions paresis were 
also documented. 
A diagnosis of hydrocephalus was made using both clinical (head circumference 




A diagnosis of epilepsy was made clinically with a history of recurrent seizures. All 
presumed febrile seizures were not regarded as epilepsy. 
Visual assessments were done as part of a full neurological exam and all cases of 
suspected visual impairment were then referred for a full ophthalmology 
examination and where a diagnosis of visual loss was made with formal testing by 
the following ; response to light, pupillary response, ability to follow a target, cover 
and uncover test and visually evoked response testing. 
Hearing screens were done using auto acoustic emission and all infants who failed 
the test had a repeat test within a fortnight and if they failed the repeat they were 
referred for specilaist ENT review from where a definitive diagnosis of hearing loss 
was made with formal testing by otoacoustic emissions (OAEs) and auditory brain 
stem response (ABR).  
2.1.5.7    Subject withdrawal 
 Reasons for loss-to-follow up were documented as much as possible. Caretakers 
were free to withdraw their children from the study at any time point if they wished 
to do so. If a subject misses their study visit and upon being followed up at home 
did not turn for their visit within a fortnight were considered as lost to follow-up.  
2.1.6 Data collection and management 
All data were collected using standard data collection instruments. The study 
participants were identified by study ID code numbers. All documents containing 
participant data and forms linking patient personal information to study ID code 
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numbers were kept in securely locked filling cabinets. Only the principal and co-
investigators had access to these files. The cabinet was kept in a lockable room. 
A study specific database was constructed to capture and link all clinical, diagnostics 
and laboratory data. The database was password protected and only accessible to 
the principal investigator and members of the data team involved in data 
processing, data management and analysis. Descriptive statistical analyses were 
utilized for accuracy assessment of variables, detecting out of range, implausible 
values and outliers. 
2.1.7 Statistical analysis 
Statistical analysis was done using STATA version 12 (Statacorp, USA) and Graph pad 
prism software (GraphPad Software Inc.,USA).  
Baseline socio-demographic, clinical, biological and anthropometric characteristics 
of the study participants were described using standard descriptive statistics. 
Appropriate summary statistics i.e. mean and standard deviation, median and inter-
Quartile Range (IQR), were used for continuous data. For categorical data 
proportions or percentage of participants within a selected category has been 
reported.  
2.1.7.1 Descriptive analysis of severe neonatal sepsis and meningitis cases 
Clinical variables for the severe neonatal sepsis and meningitis cases including fever, 
cough, poor feeding, convulsions, vomiting, irritability, duration of symptoms, 
gestation at birth, mode of delivery, pulse rate, respiratory rate, capillary refill time, 
level of consciousness using the AVPU score(A-alert, V-responding to voice, P-
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responding to pain and U- unresponsive), head circumference, blood pressure, 
oxygen saturation, lactate, malaria film, haemoglobin, WBC, HIV status, serum 
sodium and potassium, blood glucose on admission, duration of hospital stay, final 
outcome in hospital, CRP, bacterial organisms grown in blood culture and their 
resistance pattern. The severe neonatal sepsis and meningitis cases have been 
divided into 2 categories: 
 Early onset (< 7 days) 
 Late onset (7days-60 days) 
The severe neonatal sepsis and meningitis cases were analysed as separate 
categories.  For each of the categories descriptive statistics has been provided. 
A comparison between severe neonatal sepsis and meningitis on the same variables 
was also done.  
Appropriate statistics were done for both continuous and categorical data as above. 
Significance tests were performed on the following to assess whether there is a 
significant difference between those with early onset and those with late onset 
disease and those with severe neonatal sepsis and meningitis: duration of 
symptoms, bacterial organisms grown, and duration of hospital stay, HIV status, sex 
and final outcome in hospital. Two sample t-tests were used to test normally 
distributed continuous variables, while Mann-Whitney-U tests were used to test 
non-Normally distributed continuous variables; for binary variables, Fisher’s exact 
tests were used. Significance was set at 5% and confidence interval at 95%.  The 




Neonatal meningitis cases 
The following CSF variables were summarised for the meningitis cases; WBC, 
percentage lymphocytes, percentage polymorphs, glucose, protein levels, culture 
results and resistance pattern of the organisms. Other clinical variables including 
MRI head scans were recorded. Descriptive statistics as provided above have been 
done. 
2.1.7.2 Follow-up data and losses to follow-up 
The number and percentage of study participants attending scheduled follow-up 
visits at 1 month post discharge,  6 months and 1 year of age for the severe 
neonatal sepsis and meningitis cases was recorded and was compared with number 
(percentage) of controls at 6 months and 1 year of age. The reasons where known, 
have been documented. This has been presented as a flow diagram (see Chapter 4). 
2.1.7.3 Analysis of long term outcomes 
There were 3 outcome measures namely; 
i. Mortality within the first year of life. 
ii. Neurodevelopment scores (Bayley’s III) within the first year of life. 
iii. Neurological sequalae within the first year of life( defined as motor 
deficits, hydrocephalus, visual loss or deafness) 





2.1.7.3.1 Comparison of first outcome between the groups 
The number of deaths within each group was reported as numbers (and 
percentages). The interval (in months) from enrolment to death has been 
summarized by Kaplan-Meier curves overall and then for important sub-groups 
separately (with comparisons by the log rank test). The Cox proportional hazards 
regression model was then fitted, to identify risk factors for death.  Three different 
models were used:  
a)  Including the neonatal infection effect only using the infection indicator 
variables. 
b) Including the neonatal infection effect together with design factors namely sex 
and gestation age 
c) Adjusting for design factors as well as post design baseline factors like; HIV status. 
Hazards ratios (and 95% CIs) have been summarized for all risk factors and 
confounding variables.  Multiple logistic model-odds ratio was also done. 
2.1.7.3.2 Comparison of second outcome 
There are 3 outcome measures for the second outcome namely: psychomotor, 
mental (cognitive), language development scores. These have been considered as 
separate outcomes at different time points 6 and 12 months of age and logistic 
regression analysis has been performed. Covariates were evaluated for effect 
modifying and confounding and appropriate multivariate backward elimination 
models were constructed to evaluate the measure of association between exposure 
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and outcome. The covariates include gender, timing of infection, and maternal HIV 
status. 
2.1.7.3.3 Comparison of third outcome  
The number of neurological sequelae has been reported as numbers and 
percentages. Differences between the 2 groups were analysed using Fischer exact 
tests. 
2.1.8 Ethical approval 
The study was granted approval by the College of Medicine Research and Ethics 













                              CHAPTER THREE 
 
CLINICAL FEATURES AND IN-HOSPITAL OUTCOME OF SEVERE 
NEONATAL SEPSIS AND MENINGITIS IN MALAWI – A 
HOSPITAL-BASED CROSS SECTIONAL STUDY 
 
 3.1 Introduction 
It has been discussed in chapter one that severe neonatal infection causes nearly 
25% of all deaths within the first 4 weeks of life in Malawi {Zimba, E., M.V Kinney et 
al. (2012)}.  It is important that prevention and proper management of severe 
neonatal infection cases is done so as to reduce deaths that result from infection.  
Proper management of neonatal infection relies on early identification of the cases, 
investigations and prompt treatment {Lawn J, A. Lee et al (2009)}. The current gold 
standard for the diagnosis of severe neonatal sepsis is a positive blood or cerebral 
spinal fluid (CSF) culture which in itself has challenges {Claudio C, A., Panero et al 
(2004), Squire E, B. Favara et al (1979)}.  
In most of the developing world blood and CSF cultures are not routinely done and 
the diagnosis is largely clinical and as such having clinical signs and symptoms as 
developed by “The Young infants Clinical Signs Study group” that better predict 
illness in this age group is useful in these settings {The Young infants Clinical Signs 
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Study group, (2008), Vergnano S., M. Sharland et al (2005)}. These signs and 
symptoms include: history of difficulty feeding, movement only when stimulated, 
temperature below 35.5 C or 37.5 C or more, respiratory rate over 60 breaths per 
minute, severe chest in drawing, and history of convulsions. These signs and 
symptoms were used in this study. 
However even though these signs and symptoms are good predictors of severe 
illness in this age group knowledge of the aetiological organisms is of paramount 
importance as it will guide the type and duration of antibiotics to be used when 
treating these neonates.  
There have been differences reported in the aetiology of severe neonatal infections 
in the developed and developing world with gram positives being the main cause in 
the developed world and gram negatives being the predominant cause in the 
developing setting {Vergnano S., M. Sharland et al (2005), Ganatra H.A., B.J., Stoll et 
al (2010)} . In Malawi the antenatal carriage of GBS has been reported to be 21% 
which is similar to the USA and as such one would expect a high burden of GBS 
disease in the neonatal period which has not been the case {Gray K.J, G. Kafulafula 
et al (2011), Milledge J., J.C.J Calis et al (2005)}. The data was however 
retrospectively collected and as such it would be important to prospectively collect 
data so as to better describe the aetiology of severe neonatal sepsis and meningitis 
in Malawi {Milledge J., J.C.J Calis et al (2005)}. 
It is also important to monitor the microbial sensitivity pattern of the organisms 
grown in the cultures especially at a time where there is emerging resistance to the 
standard antibiotics {Blackburn R.M, N.Q Verlander et al, (2009)}. It is difficult to 
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compare antibiotic resistance between countries because the epidemiology of 
neonatal sepsis is extremely variable {Vergnano S., M. Sharland et al (2005)}. 
However in Malawi resistance to first line antibiotic therapy amongst neonatal 
infection cases was reported at 22% between 1996 and 2001 {Milledge J., J.C.J Calis 
et al (2005)}. Further retrospective audit in Malawi between 2002 and 2007 did 
show an overall resistance to first line therapy of 28% {Gwee A., E. Molyneux et al 
(2012)}. Another audit in bacterial meningitis amongst young infants less than 2 
months of age in Malawi showed that more isolates were susceptible to ceftriaxone 
than to the combination of penicillin and gentamicin (99.1% vs. 91.8%, Fisher’s 
exact test P = 0.006). In particular, Gram negative isolates were significantly more 
susceptible to ceftriaxone than to gentamicin (97.3% vs.  85.1%, Fisher’s exact test P 
= 0.020). Penicillin and gentamicin provided less coverage for Gram-negative than 
Gram- positive isolates  (86.0% vs. 95.1%,P = 0.012) {Swann O, E.M Molyneux et al 
(2014)}. 
The resistance pattern trend in Malawi indicates an increase as such closely 
monitoring the resistance pattern is of importance in Malawi and across the globe. 
 
 
3.2 Aims of the Study 
The study was set out to describe the clinical features, microbiological aetiology, 
antimicrobial resistance pattern and in hospital outcome of severe neonatal sepsis, 
severe neonatal pneumonia and neonatal meningitis cases at Queen Elizabeth 
Central Hospital (QECH) in Malawi between June 2010 and June 2013. 
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3.3 Materials and methods 
These are set out in Chapter 2. In brief, this cross sectional study took place at QECH 
in Blantyre which is the largest tertiary unit in Malawi. Infants less than 2 months 
were recruited who presented to the paediatric Accident and Emergency unit and 
the neonatal unit at QECH with a clinical suspicion of severe neonatal sepsis, severe 
neonatal pneumonia or neonatal meningitis and had met the inclusion criteria. The 
study was conducted over a 3 year period from June 2010 to June 2013. 
The study aimed to include 1,000 eligible babies less than 2 months who were 
admitted during weekdays and during working hours with a diagnosis of severe 
neonatal sepsis, severe neonatal pneumonia or neonatal meningitis at QECH 













3.4.1 Study demographics 
 During the study period from May 2010 to June 2013, a total of 1,200 cases of 













Fig 3.1 Study flow chart Aetiology and Outcome of Severe neonatal sepsis and 
meningitis  
 
1,200 Presumed severe neonatal 
infections cases screened at QECH 




















248-Severe neonatal sepsis      
90-Severe neonatal 
pneumonia                           
74-Neonatal meningitis  
 
405 had outcome data  360 
survived,     45 died (11%) 
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The top 2 causes of ineligibility were prior antibiotic use and co-morbid conditions 
mostly birth asphyxia. A total of 412 children were recruited in the study out of 
which 74(18%) had neonatal meningitis, 247(60%) had severe neonatal sepsis, 
90(22%) had severe pneumonia. Severe pneumonia was a clinical diagnosis made in 
participants who had tachypnoea, and significant chest findings like crepitations, 
bronchial breath sounds. The age range was 1 to 60 days old with a median of 15 
days and an interquartile range of 8 to 29 days. The majority of the cases 315(76%) 
were late onset and 221(54%) were males. Gestation at birth was available for 371 
cases out of which 317(85%) were born at term. Place of delivery was available for 
380 cases. The majority of the cases 345(91%) were born at a health facility, 4(1%) 
were born on the way to the hospital and 31(8%) were either born at home or at a 
traditional birth attendant. 374 cases had mode of delivery recorded, with 330(88%) 
having been delivered through spontaneous vertex delivery, 38(10%) were born 
through caesarean section and 6(2%) were either breech deliveries or vacuum 
extraction. The majority 350 (94%) were singleton pregnancies and the remaining 
24(6%) were twin. Only one set of twins was enrolled. 40 severe neonatal infection 
cases were treated with less than 5 days of parental antibiotics most of whom died 
early on in their hospital admission, 120 had 5 days,194 had between 6 and 14 days 
of antibiotics and 58 had between 14 and 28 days of parenteral antibiotics. 150/412 










Age(days) at recruitment (n=412) 
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HIV status (n=366) 
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Mode of delivery 
Spontaneous Vertex Delivery 
Caesarean section 
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74/412   (18%) 








3.4.2 Clinical features of neonatal infection cases 
The commonest symptom on admission was fever (379/412 (92%)). Thirty-eight 
(10%) of these babies had been given an antipyretic before their arrival at Queen 
Elizabeth Central Hospital.  Temperature was recorded in 375 cases on admission: 
238 (63%) were febrile, 104(28%) normothermic and 33(9%) were hypothermic. The 
median temperature on admission was 38oC (range 32oC to 42.6oC; IQR 36.9oC to 
38.8oC).  Four babies had unrecordable low temperatures. Difficulty in breathing 
was the second commonest symptom occurring in 201(49%) of the cases. 
Respiratory rate was measured in 343 cases on admission and 165 (48%) were 
tachypnoeic with a rate greater than 60 cycles per minute. 113 (33%) were hypoxic 
on admission defined as an oxygen saturation of less than 90%. Poor feeding was 
reported in 103(28%), vomiting in 87(23%), convulsions in 45(12%) and diarrhoea in 
34(9%) of the cases. Sixty five cases (17%) were comatose defined as a score of P 
(response to pain) and below on the AVPU score on admission. One hundred and 
sixty six cases had blood pressure measurements on admission and the median 
systolic blood pressure was 72 (range of 30 to 124; IQR 63-88).  Two hundred and 
one (57%) cases were tachycardic on admission defined as a pulse rate above 160 







Table 3.2 Clinical Features of neonatal infection cases on admission 
Symptoms on admission                                              Percentage affected 
Fever    379/412 (92%)  
Poor feeding  
 
 115/412 (28%) 
Difficulties in breathing 
 
 201/412 (49%) 
Cough  
 
 136/412 (33%) 
Vomiting 
 
 87/378    (23%) 
Jaundice 46/275     (17%) 
Convulsions 
 
45/378     (12%) 
Diarrhoea 
 
34/377     (9%) 
Signs on admission 
 
Comatose ( AVPU=P and U) 
 
65/379     (17%) 
Blood Pressure (systolic) n= 166 
Median(IQR, range) 
 
72   (63-88; 30-124) 
 
Pulse rate n= 354, Median(IQR, range) 
 
165 (148-180;13-254) 
Respiratory rate n= 343, Median(IQR, range) 
 
60   (48-72;10-99) 
Temperature (0 c) n= 375, Median(IQR, range) 
 
38   (36.9-38.8;32-42.6) 
SaO2 n=350, Median(IQR, range) 
 









3.4.3 Haematology and Biochemistry Results for all Neonatal infection cases 
Sixty one cases (18%) had haemoglobin of less than 10g/dl. The median 
haemoglobin level was 12.7g/dl (range 1.1 to 27.8 g/dl IQR 10.7 to 15.5g/dl).The 
prevalence of anaemia (haemoglobin of less than 10g/dl) was highest in the severe 
pneumonia group (24/81 cases (30%)) the meningitis group came second (12/56 
{21%}) and lastly the sepsis group 25/200 (12.5%). The difference in the prevalence 
of anaemia amongst the 3 groups was statistically significant with a chi square p 
value of 0.019). Forty of the sixty one cases of anaemia had their HIV exposure 
status determined and 20 (50%) were HIV exposed. The prevalence of anaemia was 
higher in the HIV exposed group (20/120 {17%}) compared to the HIV non-exposed 
group (20/206 {9%}) but the difference was not statistically significant (p= 0.065). 
The median white cell count was 11.4 (range 0.5-76, IQR 7.8-16.3). The median 
platelet count was 283 (range 5.2-910, IQR 192- 406). The median CRP was 13.1 
(range 1-435, IQR 3.5 to 84.3) CRP value of more than 5mg/dl was regarded as 
raised and 162 out of 239 cases (68%) had a raised CRP. There was a difference in 
the prevalence of raised CRP between severe neonatal sepsis, meningitis and severe 
pneumonia. 34/41 cases of neonatal meningitis (83%) had a raised CRP compared 
to 94/146 (64%) for severe neonatal sepsis and 34/52 (65%) for pneumonia but the 
difference between the 3 groups was not statistically significant (p=0.068). The CRPs 
were not run in real time and so repeat samples were not collected. Serum sodium 
levels were determined in 330 (80%) cases and 74 cases (22%) were hyponatraemic 
(sodium < 135 mmol/l) and 67 (20%) were hypernatraemic (sodium >145mmol/l). 
Of the one hundred and ninety four cases of severe neonatal sepsis who had their 
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serum sodium analysed 34 (17.5%) were hyponatraemic and 51(26%) were 
hypernatraemic. Fifteen (28%) of fifty four cases of meningitis were hyponatraemic 
and 10 (19%) were hypernatremic, whereas for severe pneumonia 25 (30%) of 82 
cases were hyponatraemic and 6 (7%) were hypernatremic.  























Parameter Median (IQR, Range) 
 
Haemoglobin g/dl  
(n=337)  
 
12.7 (10.7-15.5, 1.1-27.8) 
WBC x106/L 
 (n=335)  
 




283 (192-406, 7-775) 
CRP  mg/dl  
(n=239) 
 
13.1 (3.5-84.3, 1-432) 
Sodium  mmol/L  
(n=330) 
 
138 (135-144, 120-206) 
 
Urea  mg/dl 
 (n=324) 
 
4.8 (3.4-8.9,  1-150) 
Lactate  mmol/L  
(n=323) 
 




Table 3.4 Prevalence of abnormal Haematology, biochemistry results amongst 























































3.4.4 Aetiology of Neonatal Infections 
As shown in table 3.5, a total of 368 blood cultures were done out of which 42(11%) 
grew a significant organism. Culture positivity rate was higher in the late onset 
group 37/277 (13%) versus 5/89 (6%) in the early onset group. Group B streptococci 
(GBS) were the commonest bacteria grown in both blood and cerebral spinal 
fluid(CSF) culture representing 40% and 48% respectively of significant organisms 
grown (table 3.5 ). All but one of the GBS grown in blood or CSF culture was in late 
onset disease group. Staphylococcus aureus was the second commonest organism 
grown in blood culture (24%), followed by Streptococcus pneumoniae (12%) which 
was also the second commonest CSF isolate (30%). The one case of Haemophilus 
influenza type b (Hib) was a six week old baby who had not been immunised against 
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Hib. Contaminants grew in 86/368 (23%) and the commonest organism was 
coagulase negative staphylococci.  
Table 3.5 Distribution of bacterial isolates in Blood and CSF culture in severe 
neonatal infection cases (n=366) 




Group B streptococci 






















































































































Antimicrobial sensitivity for isolates grown in blood and CSF culture 
Group B streptococci grown in both blood and CSF cultures were sensitive to 
penicillin and ceftriaxone however 20% of the Streptococcus pneumoniae were 
resistant to penicillin. On the other hand gram-negative isolates were multidrug 
























































































































































































Amikacin Not tested Not tested Not tested Not tested 2/2(100) Not tested Not tested 




Table 3.7 Antimicrobial Sensitivity pattern for organisms grown in cerebral spinal fluid culture from neonatal meningitis cases (n=33) 




























































































































All the cases enrolled in the study had a blood film for malaria parasites but none of 
the cases had a positive film for malaria. 
3.4.5 Morbidity and mortality outcomes of severe neonatal sepsis severe neonatal 
pneumonia and meningitis 
Four hundred and five (98%) of 412 babies with severe neonatal sepsis, severe 
neonatal pneumonia or neonatal meningitis had outcome data available. Five 
mothers had absconded with their babies from hospital and two files had gone 
missing. 
Three hundred and sixty cases (89%) survived to discharge.  320 (79%) of the 
survivors had no neurological sequelae on discharge and 40 (11%) had sequelae. 
The sequelae included seizures, motor deficits, hearing loss, visual loss and 
hydrocephalus. The prevalence of neurological sequelae was higher in the 
meningitis group compared to the sepsis group (39% vs. 5%) p value <0.001. There 
were no cases with neurological sequelae in the pneumonia group on discharge. 
Overall mortality was 45/405 (11%). It was higher for meningitis: 15/74(20%) than 
severe neonatal pneumonia 8/90 (9%) and severe neonatal sepsis 22/247(9%).  
Logistic regression univariate analysis on factors associated with mortality  
In the univariate analysis using logistic regression, term gestation showed a 
significant risk reduction of mortality by 62%. Normal haemoglobin and fever were 
associated with a non-significant reduced risk of mortality in hospital by 44% and 
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38% respectively.  Thrombocytopenia, hypothermia, hypernatraemia, hypoxia and 
significant growth in blood or cerebral spinal fluid culture significantly increased the 
risk of in hospital mortality. On the other hand presence of convulsions was 
associated with a 2 fold non-significant risk of mortality, meningitis a 1.86 fold risk 




















OR (95% CI) *P value 







Hyponatraemia (sodium <135mmol/l) 
 
1.15(0.45-2.93) 0.770 









Severe neonatal sepsis 
 
1(0.42-2.34) 0.990 
Positive blood culture 
 
4.19(1.87-9.38) 0.000 
Positive cerebral spinal fluid culture 
 
4.02(1.6-10.07) 0.003 












Thrombocytopenia (Platelets <150) 
 
3.53(1.66-7.50) 0.001 





Table 3.9 Univariate logistic regression analysis on factors associated with 
neurological sequelae (n=405). 
Parameter 
 










Hyponatraemia (sodium <135mmol/l) 
 
1.36(0.55-3.35) 0.504 









Positive blood culture 
 
4.13(1.60-10.62) 0.003 
Positive cerebral spinal fluid culture 
 
12.43(4.94-31.27) <0.001 










Thrombocytopenia (Platelets <150) 
 
1.74(0.66-4.58) 0.260 
*Univariate Logistic regression p value 
 
In the univariate analysis using logistic regression, convulsions were associated with 
a significantly increased risk of neurological sequelae by 4.6, meningitis 14.64, 
significant growth in blood culture 4.13 and significant growth in cerebral spinal 
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fluid 12.43. There were no factors that were shown to significantly reduce the risk 
of developing neurological sequelae in hospital. 
Multivariate analysis  
In the multivariate analysis for the odds of death all variables that were univariately 
significantly associated with mortality were included. These variables included 
hypoxia, hypernatraemia, positive blood culture, positive CSF culture, term 
gestation, hypothermia and thrombocytopenia. We also included convulsions and a 
diagnosis of meningitis that are clinically known to increase the risk of dying in 
these severe neonatal infection cases. 
In the multivariate analysis for the odds of neurological sequelae all variables that 
were univariately significantly associated with neurological sequelae were included. 
These variables included positive blood culture, positive CSF culture, convulsions 
and diagnosis of meningitis. We also included hypothermia, hypoxia, prematurity, 
and a diagnosis of severe neonatal sepsis that are clinically known to increase the 









Table 3.10 Adjusted logistic model of the odds of death (n=405) 
Parameter OR (95% CI) *P value 
Hypoxia 6.75(1.96-23.32) 0.003 
Convulsions 0.94 (0.19-4.57) 0.940 
Meningitis 2.92(0.20-42.93) 0.434 
Severe neonatal sepsis  1.59 (0.33-7.63) 0.561 
Significant  blood culture 6.34(1.35-29.8) 0.020 
Significant  CSF culture 5.58(0.38-81.88) 0.210 
Term gestation 0.12(0.027-0.53) 0.005 
Hypothermia 0.77(0.13-4.66) 0.770 
Fever 0.28(0.07-1.1) 0.070 
Thrombocytopenia 1.12(0.30-4.14) 0.860 
Hypernatraemia  8.34(1.95-35.70) 0.004 
*Adjusted logistic regression p value 
In all adjustments hypoxia, and significant blood culture growth increased the odds 
of dying in hospital. The highest risk was from hypernatraemia with a significant 
odds ratio of 8.34, hypoxia had an odds ratio of 6.75 and significant blood culture 
growth had an odds ratio of 3.89. There was a reduction in the odds of death by 






Table 3.11 Adjusted logistic model of the odds of neurologic sequelae (n=405) 
Parameter OR (95% CI) *P value 
Hypoxia 3.55(0.82-15.44) 0.091 
Convulsions 0.45(0.08-2.52) 0.363 
Severe neonatal sepsis  0.17(0.024-1.12) 0.066 
Positive blood culture 2 (0.31-12.85) 0.467 
Positive  CSF culture 2.36(0.36-15.57) 0.371 
Term gestation 1.98(0.35-11.01) 0.441 
Hypothermia 0.15(0.007-3.12) 0.220 
Thrombocytopenia 6.08 (1.08-34.12) 0.040 
*Adjusted logistic regression p value 
In all adjustments babies that had a prolonged hospital stay had an increased risk of 
having neurological sequelae on discharge with an odds ratio of 10.88. 
Thrombocytopenia was also noted to be a risk factor with an odds ratio of 6.08 










3.5.1 Clinical features of severe neonatal sepsis and meningitis 
This chapter describes the aetiology and outcome of severe neonatal sepsis and 
meningitis in participants recruited in the study. A total of 412 participants were 
recruited over the 3 year period out of which 75% had late onset disease which is 
different from reports in the literature {Osrin D., S., Vergnano et al, (2004), Seale 
A.C, M. Mwaniki et al (2009)}. The reported prevalence of late onset disease ranges 
between 25 to 50 % {{Osrin D., S., Vergnano et al, (2004), Seale A.C, M. Mwaniki et 
al (2009)} } in the developing setting. The low rate of early onset disease observed 
in this study could be explained by several factors namely; 
 Poor referral systems; QECH being a referral facility receives patients from a much 
wider catchment area however  there are challenges with transportation of referred 
patients from the peripheral health centres and many times the guardians have to 
fend transport on their own. This results in delays in seeking care and since the 
mortality rate from early onset disease is high some of these babies can end up 
dying at home. In Malawi a recent survey in health centres in Blantyre district 
revealed that 60% of sick children who were referred to QECH did not end up there 
(unpublished ETAT MLW survey 2013). This is in keeping with findings from WHO 
Africa multicentre Community management of severe neonatal sepsis where up to 
60% of young infants who were referred from primary health centres did not end 
up at the secondary facility { Unpublished report}.  
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Beliefs in other alternative forms of therapy further complicate the challenges 
within the referral system. In a study done on knowledge, attitude and treatment 
preferences for neonatal sepsis in Ntchisi district, Malawi by Kakhobwe T. 
{Kakhobwe T et al (MMED thesis, (2010)} revealed that 83% of the mothers 
preferred to take their sick new born to a traditional healer before seeking help at a 
health facility {unpublished report}. This could have affected the number of 
neonates that presented at QECH. Cultural beliefs could have impounded this 
further. 
In this study neonates who had a history of birth asphyxia were excluded. The 
diagnosis of birth asphyxia was solely based on low APGAR score. It is widely 
accepted that the diagnosis of birth asphyxia also known as hypoxic ischaemic 
encephalopathy should include profound metabolic or mixed acidemia (pH < 7) in 
an umbilical artery blood sample, multi organ involvement and neonatal neurologic 
sequelae apart from low APGAR scores. This could have led to mislabelling of some 
cases thereby leading to ineligibility for the study. The low APGAR score could have 
been a sign of a sick septic newborn and as these cases were excluded from the 
study it could have further led to reduced numbers of early onset neonatal sepsis 
cases.  
In this study 91% of the participants were born at a health facility which is higher 
that the reported 71% for Blantyre (Malawi DHS 2010). Home deliveries pose a high 
risk to new-born infections and these babies would present with early onset 
disease. There is a possibility that the health seeking of the women who deliver at 
home is different from those who deliver at home. The hypothesized difference 
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could explain the unexpected high rates of health facility deliveries in this cohort. It 
would be important to explore the health seeking behaviour of mothers who deliver 
at home as this could have an impact on the type of care these women seek for 
their sick neonates. It could be postulated that these mothers who deliver at home 
are less likely to bring their babies to a health facility if they were unwell. A 
community based study would better answer this question. 
GBS was the commonest cause of severe neonatal infections in this cohort. These 
findings in this study could be a true reflection of the true epidemiology of GBS 
disease in Malawi. If that was the case then measures that have been known to 
reduce GBS early onset disease in the developed world cannot work in Malawi as 
they have not been proven to reduce late onset GBS disease. The only hope would 
be a GBS vaccine and currently there are GBS vaccine trials that are taking place in 
Southern Africa {Clinical Trials.gov: NCT01412801}. 
The culture positivity for this study was rather low and future work on molecular 
diagnostics is planned on stored samples from the participants to try and better 
understand the aetiology of severe neonatal infections in Malawi. 
The HIV exposure rate in the participants was much higher than the reported HIV 
exposure status observed in pregnant women in some centres in Blantyre (36% vs 
17%) {Dube Q. A. Vanrie et al (2012)}. Babies born from HIV infected mothers have 





3.5.2 Predictors of poor inpatient outcome in severe neonatal infection cases 
In all adjustments hypernatraemia, prematurity, hypoxia and significant blood 
culture growth were independently associated with an increased risk of in hospital 
mortality. The observation was in keeping with other studies {Weseem R., A.A., 
Shah et al (2005)}. It should be noted however that in most resource restrained 
settings biochemistry and microbiological testing is not available and as such the 
ability to pick up abnormalities in these parameters is limited. Governments need to 
invest more in health care so as to better manage these illnesses. 
3.6 Conclusion 
Group B Streptococcus has been identified as the main cause of severe neonatal 
infections in Malawi. However the majority of the infections were in late onset 
disease and further studies need to be done to better understand this change in the 
epidemiology of GBS disease. Clinical and laboratory parameters can be used to 











                         CHAPTER FOUR 
 
 
4. LONG TERM OUTCOMES OF  SEVERE NEONATAL SEPSIS 




Severe neonatal infections have been shown to have long term neurological impact 
on the survivors {Seale A.C, H. Blencowe et al (2013), Lawn J.E, H. Blencowe et al 
(2013), Blencowe H, T.Vos et al (2013), Gordon A.L, M. English et al (2005), Heath 
P.T, N.K Nik Yusoff et al (2003)},  Bennet R, S.Berdahl et al (1989)}. It is known that 
during the neonatal period the infant is prone to insults on the rapidly growing 
brain {Shane A.L, Stoll B.J et al}. 
Most of the studies on the long term impact of neonatal sepsis and meningitis have 
been done in the developed setting where the bulk of the cases are preterm low 
birth weight infants {Shah D.K, L.W., Doyle et al (2008), Adams-Chapman I, B.J., Stoll 
et all (2006), Stoll B.J., N. Hansen et al (2002), Hack M.D, D. Wilson-Costello et al 
(2000), Stoll B.J, T. Gordon et al (1996)}. The sepsis rate in premature infants has 
significantly risen in the last three decades because of increased survival of very low 
birth weight (VLBW) infants, prolonged stay in neonatal intensive care units where 
there is frequent exposure to protracted instrumentation, such as intravascular 
lines and endotracheal tubes {Klinger G, I Levy et al (2009)}. However, in the 
102 
 
developing setting the epidemiology of neonatal infections is different from the 
developed setting {Ganatra H.A, Stoll B.J et al (2010), Vergnano S., M. Sharland et al 
(2005)}. Term infants in the developing setting are as equally vulnerable to acquire 
infections as the preterm babies. This is as a result of the high rate of home 
deliveries, poor prenatal care, poor health systems, high HIV prevalence, harmful 
cultural practices on the new born like putting cow dung on the umbilical cord 
{Seale A.C, M Mwaniki et al (2009), Osrin D, S. Vergnano et al (2004)}. The low 
socio-economic status of these settings compounds the picture even more {Waseen 
R., A. A. and Shah (2005)}. In this study 85% of the severe neonatal infection cases 
were born at term (Chapter 3).  
It is noteworthy that even though the mortality rate from neonatal meningitis has 
improved over the last 3 decades, the morbidity rates have remained high with up 
to 50% of survivors of neonatal meningitis known to have complications {Heath P.T, 
N.K., Nik Yusoff et al (2003), Stevens J.P., M. Eames et al (2003), Bedford H, J. 
Delouvois et al (2001), Holt D.E, Halket et al (2001), Delouvois J., T. Blackburn et al 
(2001)}.  On the other hand neonatal sepsis in the absence of overt meningitis has 
been shown to increase the risk of developmental delay in very low birth weight, 
preterm babies in the developed setting {Shah D.K, L.W., Doyle et al (2008), Adams-
Chapman I, B.J., Stoll et all (2006), Stoll B.J., N. Hansen et al (2002), Hack M.D, D. 
Wilson-Costello et al (2000), Stoll B.J, T. Gordon et al (1996)}.  
There is however lack of data in resource-poor settings on the long term outcome 
of severe neonatal infections. Malawi is one of a number of countries within Sub 
Saharan Africa with a high HIV prevalence (12%) that continues to struggle with a 
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high new born mortality {Zimba, E., M.V Kinney et al. (2012), Unicef Malawi report 
(2013)}. Over the past decade the neonatal mortality rate in Malawi has remained 
static despite promising changes in the outcome of older children {Zimba, E., M.V 
Kinney et al. (2012)}. 
4.2 Aim of the Study 
The study set out to describe the long term outcome of neonatal sepsis and 
meningitis in Malawi 
4.3 Materials and methods 
This study took place at Queen Elizabeth Central hospital (QECH) and Zingwangwa 
health centre. The study was conducted from April 2010 to April 2013.  Ethical 
approval was obtained from the College of Medicine Research and Ethics 
Committee (Protocol number P.11/09/835). 
Young infants coming from Blantyre urban who were recruited in the hospital based 
cross sectional study (Chapter 2 and 3) were invited to join the prospective study 
upon discharge from QECH. The study also recruited young infants aged 3 months 
who had no episode of severe neonatal infection in the past from the immunisation 
clinic at Zingwangwa health centre. The infants from Zingwangwa health centre 
acted as controls. All the study participants were followed up to the age of 12 
months. 
The study aimed to recruit a total of 470 participants; 235 young infants aged 3 
months from Zingwangwa health centre and 235 severe neonatal infection cases 
from QECH. The study aimed to detect a 10% difference between 
neurodevelopmental delay in the severe neonatal infection cases and the controls 
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at 12 months of age (Chapter 2). Neurodevelopmental assessments were done at 6 
and 12 months of age using the Bayley scales of infant development III [56] 
All study participants had a detailed neurological examination and head 
circumference measurements at 6 and 12 months of age. Neonatal meningitis cases 
had hearing screens done at 6 months of age and if failed they were repeated 2 
weeks later. 
Statistical analysis was done using STATA version 12 (Statacorp, USA) and Graphpad 
prism6 software. 
4.4 Results 
4.4.1 Study Demographics 
During the study period from May 2010 to June 2013 a total of 472 young infants 
were recruited and followed up. These infants comprised 234 neonatal sepsis and 
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Fig 4.1 Long term outcome of neonatal sepsis and meningitis study flow diagram 
 
 
Eligible admitted neonatal 
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Enrolled -412; Neonatal Sepsis- 
337                                                        
Neonatal meningitis-74 
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240 eligible; 6 declined, 234 
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4.4.1.1 Neonatal sepsis and meningitis cases 
A total of 234 cases were enrolled upon discharge from hospital in the prospective 
study over a period of 3 years. 193 out of the 234 babies (82.5%) were seen alive at 
6 months of age and 9 had died representing a mortality rate of 3.8%. 32 infants 
were lost to follow-up representing a loss to follow up rate of 13.7% at 6 months of 
age. 
170 out of the 193 infants (83%) reviewed at 6 months were alive at 1 year of age. 
160 out of the 170 were reviewed but 10 had information about their survival 
obtained over the phone. There were 12 deaths between 6 and 12 months of age 
representing a mortality rate of 6.6% during this 6 months period. 11 infants were 
lost to follow up representing a rate of 9.4%. 
Overall, there were a total of 42 losses to follow up cases (18%) on this group over 
the 1 year period. 19 out of 42 (45%) loss to follow up cases were as a result of 
transfers to other districts as such they had to be withdrawn from the study. 8 out 
of the 42 (19%) had withdrawn from the study on their own accord. 
4.4.1.2 Otherwise healthy infants (control group) 
A total of 238 babies who had no episode of neonatal sepsis or meningitis were 
enrolled in this group. 207 out of 238 babies (87%) were seen alive at 6 months of 
age and 5 had died representing a mortality rate of 2.1%. 26 infants were lost to 
follow up representing a rate of 10.9% at 6 months of age. 
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188 out of the 207 infants (91%) were seen alive at 12 months of age. There were 9 
deaths between 6 and 12 months of age representing a rate of 4.5%. 10 babies 
were lost to follow up representing a rate of 15%. 
Overall, at the end of the study period there were a total of 36 losses to follow up in 
this group. 28 mothers had voluntarily withdrawn from this group representing 78% 
of all the losses to follow-up. 
4.4.2 Baseline Characteristics 
Gender distribution was similar in the 2 groups with males contributing 54% in the 
cases and 55% in the controls (table 4.1). There was a difference in HIV exposure 
status between the 2 groups with 36% of the participants in the neonatal sepsis and 
meningitis group being HIV exposed compared to 15.5% in the control group. The 
mothers in the sepsis and meningitis group were younger compared to the controls 











    Table 4.1 Baseline characteristics of all study participants (n=473) 
Characteristic 
 











HIV negative unexposed 
HIV positive 













32 /238 (10.5%) 
 
0/238 
Maternal age (years) 
 
 
Median 24 (range 12-42) 
IQR 20-28 





























4.4.2.1 Socio Demographics profile 
There were no major differences in the socio-demographic profile of the neonatal 
sepsis and meningitis group and the control group. 
The marital statuses of the mothers in both arms were similar with the majority of 
them being married; 88% in the neonatal sepsis and meningitis group and 87% in 
the control group. Most of the mothers had attained primary level education but 
only 9% of the cases and 12% of the controls were employed. Family income data 
was available in 52% of the cases (122/234) and 22% of the controls (53/238). 64 
out of 122 families (52%) and 26 out of 53 families (49%) of the control group were 
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earning less than 30 US dollars per month. The rest of the socio-economic data; 
toilet facilities, source of drinking water, wall and roofing material were all 
indicative of low socio-economic status in both groups (see table 4.2). 
Table 4.2 Socio-demographic profile of all study participants (n=473) 
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4.4.3 Long term impact of severe neonatal infections 
There were more cases of hydrocephalus observed in the infants that had severe 
neonatal infection (12/193[6%] participants followed up to the age of 6 months) 
compared to control infants (1/207 participants [0.005%]). All the hydrocephalus 
cases were evident by age 6 months. The prevalence of visual loss by age 6 months 
was also higher in the infection group (5/193 [0.03%]) as compared to control 
infants where none had visual loss. The prevalence of epilepsy at 1 year of age was 
9/162 (5.6%) in the cases (see table 4.3), compared with none in the control group. 
All the hydrocephalus, epilepsy and visual loss cases in the severe neonatal 
infections group were associated with meningitis. There were 68 cases of neonatal 
meningitis out of which 17.6% had hydrocephalus, 7.3% had visual loss and 13.2% 
had epilepsy.  Hearing tests were done in 52 neonatal meningitis cases out of which 
11 (21%) had bilateral hearing loss and 6 (12%) had unilateral hearing loss at 6 




4.4.3.1 Neurocognitive Outcomes at 6 Months of age 
A total of 301 infants had neurocognitive assessments done using the Bayley Scales 
of Infant and Toddler Development (BSID-III) tool at the age of 6 months, 
comprising 129(67%) infants who had severe neonatal infection and 171(83%) 
controls. We were unable to fully administer Bayley’s in 22 cases in the severe 
neonatal infection group and 8 in the controls. Bayley’s was not administered in 12 
cases (6.2%) in the severe neonatal infection group and 2(1%) in the controls mainly 
because of very severe developmental delay that made it impossible to administer 
any of the items. Out of the 107 neonatal infection cases that had full Bayley’s 
assessment 64 had neonatal sepsis, 23 had severe pneumonia and 20 had 
meningitis. The rate of neurodevelopmental delay at 6 months was higher in the 
group of infants that had an episode of severe neonatal infection ranging from 11% 
in the receptive language domain to 29% in the fine motor domain compared to 3% 
in the receptive language domain to 10% in the cognitive domain in infants that 
never had an episode of neonatal infections (see Table 4.3 below). Amongst the 
severe neonatal infection group infants those who had an episode of neonatal 
meningitis had the highest rate of developmental delay ranging from 26% in the 
receptive language domain to 47% in the fine motor domain. Neonatal sepsis 
followed the meningitis group with rates ranging from 6% in the expressive 
language domain to 25% in the fine motor domain and lastly the severe pneumonia 
group ranged from 0% in the receptive language domain to 24% in the fine motor 
domain (see Table 4.3). 
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4.4.3.1.1 Logistic regression univariate analysis on the association between severe 
neonatal infection and developmental delay at 6 months of age  
 
In the univariate logistic regression analysis of the risk of neurodevelopmental delay 
at 6 months of age, neonatal infection was associated with a 3.7-fold increase in the 
risk of delay in gross motor skills. There was also a 4.1-fold increase in the risk of 
delay in fine motor skills 3.5-fold increase in expressive language delay and 3.9-fold 
increase in receptive language skills delay. There was a non-significant trend 
towards an increased risk of delay in the cognitive domain of 1.63-fold (95% CI 0.79- 
3.36). (see Table 4.4). 
 Neonatal meningitis was associated with a statistically significant increased risk of 
developmental delay in all the domains compared to controls. There was a 12-fold 
increase in the risk of having delay in expressive language (P value of <0.0001) and 
cognitive development at 6 months of age (P value of <0.0001) , 11-fold increase in 
the risk of receptive language delay (P value of <0.0001), 10-fold increased risk of 
gross motor delay (P value of <0.0001) and nearly 9-fold risk of fine motor delay at 6 
months of age (P value of <0.0001)  ( Table 4.4). 
Neonatal sepsis was associated with a statistically significant increased risk of delay 
in fine motor skills of 3.4-fold (P value of <0.002) , receptive language of 3.53-fold (P 
value of <0.04)and gross motor of 2.92-fold(P value of <0.03) compared to infants 
that never had an episode of neonatal infection. There was a non-significant 
increased risk of delay in expressive language (1.8-fold; (p= 0.37) and cognitive skills 
(1.21-fold P=0.67) (see Table 4.4) 
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Neonatal severe pneumonia cases had no statistically significantly increased risk of 
delay in any of the domains compared to controls (Table 4.4). There was a trend 
towards increased risk of delay in the gross motor, fine motor and expressive 
language skills and a reduced risk of delay in the cognitive and receptive language 
domains. There was no evidence of delay at 6 months in receptive language among 








Table 4.4 Logistic regression univariate analysis on the association between severe neonatal infection and developmental delay at 6 
months of age  





























































































































4.4.3.2 Neurocognitive Outcomes at 12 Months of Age 
 
There was an increase in the rates of developmental delay in all the groups at 12 
months of age compared to age 6 months. The range of delay in the controls was 
from 4% in the expressive language domain to 15 % in the gross motor domain. This 
is in contrast to the range at 6 months of age which was from 3% in the receptive 
language domain to 10% in the cognitive domain. 
All cases that had severe neonatal infections had a range from 26% in the fine 
motor domain to 35% in the gross motor skills at 12 months of age. This was higher 
compared to a range of 11% in the receptive language domain to 29% in the fine 
motor domain at 6 months of age. 
The rate of delay in the meningitis group ranged from 44% in the cognitive domain 
to 60% in the gross motor skills. This again was higher compared to the range of 
26% in the receptive language to 47% in the fine motor skills at 6 months of age. 
In the neonatal sepsis group the rate of delay at 12 months of age was from 25% in 
the fine motor domain to 31% in the cognitive domain. This was higher than the 
rates at 6 months which ranged from 6% in the expressive language domain to 25% 
in the fine motor skills. The same trend was noted in the severe pneumonia group 
with the range of delay having increased from 0 (receptive language) to 24% (fine 
motor) at 6 months of age to 13% (fine motor) to 35% (gross motor) at 12 months 























































































4.4.3.2.1 Logistic regression univariate analysis on the association between 
severe neonatal infection and developmental delay at 12 months of age  
 
In the univariate logistic regression analysis for the risk of neurodevelopmental 
delay in the neonatal infection cases there was a statistically significant 
increased risk of delay of 3.1-fold ( p value 0.001), 6.8-fold (p value <0.0001) and 
3.4-fold (p value <0.0001) in gross motor, fine motor and cognitive skills 
respectively at 12 months of age compared to controls. There was however a risk 
reduction of 61% (p value 0.001) in the severe neonatal infection cases 
developing receptive language delay at 12 months of age compared to controls 
and this was statistically significant ( Table 4.9). There was also a risk reduction 
of 30% in expressive language delay but this was not statistically significant 
(p=0.143). There was however a difference in the risks reported at 6 months of 
age with gross motor 3.7- fold (P-value of 0.002) and fine motor- 4.1-fold (p 
value <0.0001) continuing to show a statistically increased risk at 12 months of 
age gross motor 3.1-fold ( p value 0.001),  and fine motor 6.8-fold (p value 
<0.0001), cognitive skills showing a statistically significant risk at 12 months of 
age 3.4-fold (p value <0.0001)   compared to a statistically non-significant 
increased risk at 6 months of age 1.6 fold (p value 0.18). There was a reverse on 
the risk of delay in receptive language skills with an improvement at 12 months 
of age from an increased risk of 3.9 fold (p value 0.01) at 6 months of age to a 




In the logistic regression analysis on the odds of delay at 12 months in the 
neonatal meningitis cases there was a statistically increased risk of delay in the 
gross motor domain of 8.5-fold (p value <0.0001) , fine motor of 17.4-fold (P 
value <0.0001) and cognitive skills of 5.6-fold (p value 0.002). However there 
were no statistically significant differences in the risk of delay in the expressive 
1.2-fold (95% CI 0.41-3.44) and receptive language 0.96(95% CI 0.33-2.78) 
domains of the neonatal meningitis cases compared to controls. This is in 
contrast to what was observed at 6 months of age with the meningitis cases 
having an increased risk of delay in all the developmental domains( Table 4.4 and 
4.6).    
In the univariate logistic regression analysis of the odds of developmental delay 
in the neonatal sepsis cases at 12 months of age there was a statistically 
significant  increased risk of delay in the fine motor domain of 6.6-fold (p value 
<0.0001)  and cognitive skills of 3.3-fold (p value 0.003). However there was a 
non-significant increase of delay in the gross motor domain of 2-fold (95% CI 
0.88-4.54) (Table 4.6).  On the other hand there was an improvement in the 
receptive language skills at 12 months of age  with a statistically significant risk 
reduction of 69% (p value 0.002) compared to an increased risk of 3.5-fold at 6 
months of age (p value 0.04) ( Table 4.4 and 4.6) 
In the logistic regression analysis of the odds of developmental delay at 12 
months of age there was a statistically significant 3 fold (p value 0.025) increased 
risk of delay in gross motor skills in infants that had an episode of severe 
pneumonia compared to controls. There was also an increased risk of 3 fold ( p 
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value 0.14) and 2.4fold (p value 0.1) in the acquisition of fine motor and 
cognitive skills but these were not statistically significant. On the other hand 
there was a risk reduction of 70% (p value 0.02) in receptive language delay at 12 





Table 4.6 Logistic regression univariate analysis on the association between severe neonatal infection and developmental delay at 
12 months of age  
*Logistic regression univariate analysis p value 

























































































































4.4.3.3 Neurodevelopmental outcomes for neonatal infection infants and control 
infants - a comparison of scaled BSID-III scores 
There was a difference in the scaled scores (chapter 2) between the control babies 
and the neonatal infection cases at both 6 months and 12 months of age (see Fig 
4.2 and 4.3). The control babies had statistically significant higher scores than the 
neonatal infection cases in all the domains. 
 
Fig 4.2 Scaled scores of neurodevelopmental outcomes at 6 months of age 









Controls Neonatal infection cases
Receptive language Cognitive
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Gross motor





Fig 4.3 Scaled scores of neurodevelopmental outcomes at 12 months of age 
comparing severe neonatal infection and control infants 
 
4.4.3.3.1 Neurodevelopmental outcomes for neonatal sepsis, meningitis, severe 
pneumonia infants and control infants- a comparison of scaled BSID-III scores 
In a subgroup analysis of the severe neonatal infection group; the control infants 
had statistically significant higher scaled scores in the gross motor, fine motor, 
expressive language and cognitive domains at 6 months of age compared to those 
who had neonatal sepsis. However, the control infants had statistically significant 
higher scores in all the neurocognitive domains than the meningitis cases (see Table 
4.9). On the other hand the control infants had statistically significant higher scaled 










Controls Neonatal infection cases
Receptive language Expressive language
Fine motor Gross motor
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Graphs of Neurodevelopmental outcomes at 12 months of age
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The severe pneumonia group had statistically significant lower scores in the 
cognitive domain when compared to the control babies (see Table 4.10). 
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Fig 4.5 Receptive language outcomes- BSID-III scaled scores 
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Fig 4.7 Fine motor outcomes- BSID-III scaled scores 
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Graphs of gross motor outcomes 
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4.4.3.4 Mortality Outcomes at 12 months of age. 
There were a total of 21 deaths at the end of the follow up period in the severe 
neonatal infection group and 14 in the control infants group. 
 In the survival analysis at age 12 months survival chances were higher in the control 
infants group compared to the severe neonatal infection group (See Fig 4.9). 
However in the cox regression model analysis for mortality, the hazards ratio for 
death in the severe neonatal infection group was 1.35 (95% CI 0.68-2.65; P=0.39). In 
the severe neonatal infection subgroup survival analysis, the highest risk of 
mortality was in the meningitis group 2.45-fold followed by the severe pneumonia 
group 1.66-fold (see Fig 4.10). The hazards ratios in the subgroups of severe 
neonatal infection namely; neonatal meningitis, neonatal sepsis and severe 






                           
 Fig 4.9 Survival analysis comparing severe neonatal infection cases and control 
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Fig 4.10 Survival analysis comparing subgroups of severe neonatal infection 




       Table4.7 Cox regression analysis on the risk of dying 
 
Parameter Hazards ratio(95% CI) P value 
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   4.5 Discussion 
This study has shown that severe neonatal infections are a risk factor for poor 
neurodevelopment at 1 year of age. The findings are in keeping with what has been 
observed in the developed world {Seale A.C, H. Blencowe et al (2013), Lawn J.E, H. Blencowe 
et al (2013), Blencowe H, T.Vos et al (2013), Seale A.C, M Mwaniki et al (2009), Gordon A.L, 
M. English et al (2005), Osrin D, S. Vergnano et al (2004)Heath P.T, N.K Nik Yusoff et al 
(2003)},  Bennet R, S.Berdahl et al (1989), }. However in this study the majority of the severe 
neonatal infection cases were born at term (85%) which is in sharp contrast to the 
predominantly preterm cases in the developed setting. In resource restrained settings there 
are several factors that impact on neurodevelopment in a child. The factors include HIV 
infection, low socio-economic status and maternal education {Waseen R., A. A. and Shah 
(2005)}. In this study the socio demographic profile and baseline characteristics of the 
severe neonatal infection and the control infants groups were similar except for HIV 
exposure status which unsurprisingly was higher in the infection group than the control 
infants group (36% compared to 15.5% respectively). The impact of HIV exposure on the 
long term outcome of severe neonatal infections has been described in chapter 5. The 
balance in the baseline characteristics between the 2 groups made it possible for us to 
associate the neurological outcome at 12 months of age in these infants to the episode of 
severe neonatal infection.  
In this study having had severe neonatal infection was associated with an up to 4-fold 
increased risk of developmental delay at 6 months of age and up to 6-fold at 12 months of 
age. However, in the sub-group analysis of the severe neonatal infection cases the highest 
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risk was from neonatal meningitis up to 17-fold at 12 months of age. It was surprising to 
note that neonatal sepsis cases (without overt meningitis) had an increased risk of 
developmental delay of up to 6 fold in the fine motor domain at 12 months of age. The 
findings in this study were similar from published reports that put the risk at 2-6-fold for 
neurodevelopmental delay{Shah D.K, L.W., Doyle et al (2008), Adams-Chapman I, B.J., Stoll 
et all (2006), Stoll B.J., N. Hansen et al (2002), Hack M.D, D. Wilson-Costello et al (2000), 
Stoll B.J, T. Gordon et al (1996)}.}. The majority of the studies were done in preterm or very 
low birth weight babies and as such one would expect a much higher risk of developmental 
delay in these groups of patients than term babies. In this study 86% of the neonatal sepsis 
cases were full term with birth weights of equal to or above 2.5 kg. It has been reported that 
inflammatory cytokines are associated with an increased risk of neurodevelopmental delay 
in preterm neonatal sepsis cases {Volpe J.J(2008), Shah D.K, L.W. Doyle et al (2008), Volpe J. 
J,(2003), Duncan J.R, M.L Cock (2002)} It is therefore important to try and explore possible 
mechanisms of developmental delay in these term babies with neonatal sepsis. It would be 
important to explore the role of inflammatory markers in these septic neonates’ brains and 
look at the immunology of these septic newborns. 
It is important to note that routinely young infants who have had an episode of neonatal 
sepsis (without overt meningitis) are not followed up in Malawi and the findings in this 
study underscore the importance of follow up in this group of infants. However looking at 
the burden of neonatal sepsis in Malawi it would be a challenge to follow up all the cases 
and as such identifying those septic infants who have a much higher risk of developmental 
delay would help in focusing on the type of infants who would benefit from follow up. In 
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chapter 5 we discuss the predictors of poor long term outcome in the severe neonatal 
infection cases.  
In this study it has been shown that 60% of the survivors of neonatal meningitis had 
complications at the age of 1 year. The rates of complications in this study are higher than 
figures reported elsewhere {Heath P.T, N.K., Nik Yusoff et al (2003), Stevens J.P., M. Eames 
et al (2003), Bedford H, J. Delouvois et al (2001), Holt D.E, Halket et al (2001), Delouvois J., T. 
Blackburn et al (2001)}. It is however important to note that in most of the reported studies 
on long term outcome of neonatal meningitis the participants were followed up for a 
duration longer than 1 year {Heath P.T, N.K., Nik Yusoff et al (2003), Stevens J.P., M., Eames 
et al (2003), Bedford H, J. Delouvois et al (2001), Holt D.E, Halket et al (2001), Delouvois J., T. 
Blackburn et al (2001)}. In this study the infants were followed up to the age of 1 year and 
this could have led to underestimation of complications arising from neonatal meningitis. It 
is also a known fact that most of the behavioural problems cannot be picked up in infancy 
the same is true with learning difficulties {Holt DE, S., Halket (2001)}. A longer period of 
follow up preferably up to the age of 6 years could have picked up most of the 
complications arising from neonatal meningitis. However it is important to note that even 
within this study the rate of neurodevelopmental delay was higher overall at 12 months 
than at 6 months of age which could be an indicator of higher rates of complications later 
on in life. 
The rates of other neurological sequelae were higher in the neonatal meningitis group with 
17.6% of the survivors having hydrocephalus, 7.3% blind, 13.2% had epilepsy and 33% with 
hearing loss.  The rate of hydrocephalus was lower in this study compared to other settings 
where 24% of neonatal meningitis cases will have hydrocephalus. However the rate of 
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hearing loss was similar in this study to what has been reported elsewhere i.e. 30% { }. The 
number of hydrocephalus cases reported in this study could have been lower due to 
logistical reasons. All the neonatal meningitis cases did not have follow up cranial 
ultrasound scans as explained in chapter 6. This could have led to some cases of 
hydrocephalus being missed.  
 
It is therefore important to strengthen the prevention, diagnosis; management and long 
term follow up of these infants. Group B streptococci were the commonest cause of 
neonatal meningitis {see Chapter 3). It has been shown in the developed world that better 
prenatal care can reduce the incidence of GBS infections in the neonate {Lawn J.E, H. 
Blencowe et al (2013), Ganatra H.A, Stoll B.J et al (2010), Vergnano S., M. Sharland et al 
(2005), Seale A.C, M., Mwaniki (2009) }. In Malawi the quality of prenatal care is poor 
{Malawi, New born Health analysis 2013} and there is need to improve the quality of 
prenatal care. It is important to introduce routine follow up of neonatal meningitis cases in 
developing countries such as Malawi where routine follow up of these cases is non-existent.  
Hearing screens also need to be introduced as part of the routine follow up of these 
patients. In this study all the hydrocephalus, blindness, epilepsy and hearing loss cases 
occurred in infants who had neonatal meningitis except for I infant in the control group who 
had hydrocephalus. 
In this study the severe pneumonia group had the lowest risk of developmental delay both 
at 6 months and 12 months at age. As indicated in the literature review set out in Chapter 1, 
there was paucity of data on the long term impact of neonatal severe pneumonia {Sazawal 
S, R. E Black et al (2003), Bang A.T, R.A Bang et al (1993) .  
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In this study it was also noted that the lowest scores were in the expressive and receptive 
language domains in both the severe neonatal infection and control infants groups. A study 
done in Malawian children by Cromwell et al  {Cromwell E., Q. Dube et al (2014)} 
demonstrated that population reference curves for the BSID-III, a neurodevelopmental tool 
developed for and commonly used in the USA, differed depending on the origin of the 
reference population. Reliance on US norm-based standardized scores can therefore result 
in misclassification of the neurological development of Malawian children, with the greatest 
potential for bias in the measurement of cognitive and language skills {Cromwell E., Q. Dube 
et al (2014)}. This finding could explain the low scores noted in the language domains but 
not in the motor and cognitive domains. 
In the survival analysis there was no overall statistical difference in mortality between the 
severe neonatal infection and control infants group at 1 year. The same was true for the 
neonatal meningitis, sepsis and severe pneumonia group. 
Limitations of the study 
 Mortality was not the primary outcome in this study and as such the sample size calculation 
was not based on mortality but on neurodevelopmental outcomes. One would need a much 
bigger sample size to better demonstrate differences in survival between the severe 
neonatal infection and control groups. The survival analysis results from this study should 
therefore be interpreted with caution. 
Participants were followed up to the age of 1 year and as discussed above other 
developmental challenges that become apparent in later life would have been seen. This 
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could lead to an under estimation of morbidity outcomes associated with severe neonatal 
infections. 
4.6 Conclusion 
In summary, the study found that severe neonatal infections were associated with a higher 
risk of neurodevelopmental delay. The risk was greatest in the neonatal meningitis group 
with up to 60% of the meningitis cases being delayed developmentally in at least one 
neurocognitive domain. The study has also shown an increased risk of neurodevelopmental 
delay in neonatal sepsis cases (without overt meningitis).   It is important therefore to 
introduce routine monitoring and follow up in all cases of severe neonatal infections. It is 
important to do neurodevelopmental screening assessments particularly in the first year of 
life in these young infants who have had severe neonatal infections even in the absence of 
meningitis. Some of the developmental delay can improve if picked up earlier and 
appropriate interventions made {Grantham-McGregor S, Y.B., Cheung et al (2007), Engle P.L, 











                          CHAPTER FIVE 
 
PREDICTORS OF POOR NEURODEVELOPMENTAL OUTCOMES IN 




Severe neonatal infections have been shown to have an increased risk of developmental 
delay in this study (chapter 4). This finding is in keeping with studies in other settings {Seale 
A.C, H. Blencowe et al (2013), Lawn J.E, H. Blencowe et al (2013), Blencowe H, T.Vos et al 
(2013), Gordon A.L, M. English et al (2005), Heath P.T, N.K Nik Yusoff et al (2003)},  Bennet 
R, S.Berdahl et al (1989)}. 
 However, most of the studies on the long term impact of neonatal sepsis on 
neurodevelopment have been done in premature and low birth weight babies in the 
developed setting {Shah D.K, L.W., Doyle et al (2008), Adams-Chapman I, B.J., Stoll et all 
(2006), Stoll B.J., N. Hansen et al (2002), Hack M.D, D. Wilson-Costello et al (2000), Stoll B.J, 
T. Gordon et al (1996)}. Prematurity on its own is a known risk factor for developmental 
delay {Alshaikh B., K. Yusuf et al (2013), Beaino G., B. Khoshnood et al (2010), Woodward 
L.J., H.G. Taylor (2003), Volpe J.J (2003), Hack M., D Wilson-Costello (2000) }. It has been 
shown that preterm babies who have severe neonatal infection have an even higher risk of 
developmental delay { Shah D.K, L.W., Doyle et al (2008), Adams-Chapman I, B.J., Stoll et all 
(2006), Stoll B.J., N. Hansen et al (2002), Hack M.D, D. Wilson-Costello et al (2000), Stoll B.J, 
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T. Gordon et al (1996)}. There is a paucity of data on the long term impact of either neonatal 
meningitis or sepsis (without overt meningitis) in term babies within the developing setting. 
In this study the majority of the cases (85%) were born at term (chapter 3) and up to 60% of 
neonatal meningitis cases and up to 31% of the neonatal sepsis cases without overt 
meningitis had developmental delay at 12 months of age (chapter 4). The prevalence of 
developmental delay was higher in the neonatal sepsis cases without overt meningitis than 
what was expected (chapter 2). It is important therefore to explore possible risk factors that 
could have led to such a high prevalence of developmental delay. 
This chapter therefore seeks to explore the risk factors associated with poor developmental 
outcomes in neonates with severe neonatal infection. 
5.2 Materials and methods 
As previously described, this study took place at Queen Elizabeth Central hospital and 
included all severe neonatal infection cases that were recruited in the prospective cohort 
arm (chapter 4). Developmental assessments were done at 6 and 12 months of age using 
the Bayley Scale of Infant Development III. The assessments were divided into 5 domains; 
gross motor, fine motor, cognitive, expressive language and receptive language.  
Univariate logistic regression analysis was done to identify risk factors associated with 
developmental delay in each of the domains at 12 months of age. All significant identified 
risk factors in the univariate analysis were evaluated for effect modifying and confounding 
and appropriate multivariate backward elimination models were constructed to evaluate 
the measure of association between exposure and outcome- being developmental delay in 
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each of the domains. All known clinical risk factors were also evaluated for even though they 
showed no significance in the univariate analysis. 
In this study three different models were used namely; 
I Including the Severe neonatal infection effect only using the infection indicator variables 
like positive blood or CSF culture and raised CRP 
ii Including the neonatal infection effect together with design factors namely  gestation age 
iii Adjusting for design factors as well as post design baseline factors like; HIV status, age at 
onset of disease and serum sodium results. 
5.3 Results 
A total of 102 neurocognitive assessments were done in the severe neonatal infection cases 
at 12 months of age. 
5.3.1 Gross motor outcomes at 12 months of age 
As shown in Table 5.1, in the univariate analysis of risk factors associated with gross motor 
delay at 12 months of age a significant CSF culture was associated with a 2.15-fold increased 
risk of gross motor delay (95% CI 1.02-4.55), hypothermia was associated with an 18-fold 
increase (95% CI 1.79-181) and HIV exposure was associated with a 3.79-fold increase (95% 
CI 1.39-10.37). A non-significant increased risk trend for gross motor delay was observed in 
infants with a significant growth in blood culture(2.1 fold [95% CI 1-4.43], infants who had 
anaemia (1.3-fold [95% CI 0.37-4.4], hyponatraemia (2.5-fold [95% CI 0.79-7.97], hypoxia 
(1.38-fold [95% CI 0.5-3.8], prematurity (2.5-fold[95% CI 0.75-8.36], convulsions (1.57-fold 
[95%CI 0.38-6.38] and early onset disease (1.3-fold [95%CI 0.41-4.13]). 
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On the other hand a non- significant risk reduction was observed with hypernatraemia 
(0.32[95% CI 0.04-2.86]), raised CRP (0.58[0.16-2.05]), and thrombocytopenia (0.24 [95% CI 
0.03-2.04]) (Table 5.1).  
Table 5.1 Univariate logistic regression analysis on factors associated with gross motor 
delay at 12 months of age 
Parameter 
 
OR(95% CI) *P value 
Positive blood culture 
 
2.1 (1.0-4.43) 0.050 
Positive CSF culture 
 
2.15 ( 1.02-4.55) 0.045 
HIV exposure 
 
3.79 (1.39-10.37) 0.009 
Anaemia 
 
1.3 (0.37-4.4) 0.700 
Hyponatraemia 
 
2.5 (0.79-7.97) 0.120 
Hypernatraemia 
 
0.32 (0.04-2.86) 0.310 
Hypoxia 
 












Early onset disease 
 
1.3(0.41-4.13) 0.650 
Convulsions  1.57(0.38-6.38) 0.530 









5.3.1.1 Multivariate analysis of risk factors for gross motor delay at 12 months of age 
An adjusted logistic model of the odds of gross motor delay at 12 months of age that 
included positive CSF culture, hypothermia,  positive blood culture, convulsions, prematurity  
and hyponatraemia was formulated as described in section 5.2 above.  
Table 5.2 Adjusted logistic model of the odds of gross motor delay at 12 months of age 
Parameter 
 
OR (95% CI) *P value 
Positive CSF culture 
 
2.7 (1.22-5.86) 0.014 
Positive blood culture 
 
2.3 (0.79-6.76) 0.130 
Hypothermia 
 
12.5 (1.13-140) 0.040 
Prematurity 
 
2.8 (0.7-11.7) 0.160 
Hyponatraemia 
 
2.3 (0.7-7.4) 0.170 
HIV exposed 
 
5.04 (1.49-17) 0.009 
Convulsions 1.17(0.16-8.52) 0.880 
*Adjusted logistic regression p value 
In all adjustments infants who had significant growth in their CSF had a 2.7-fold [95% CI 
1.22-5.86] increased risk of developmental delay in the gross motor domain (see table 5.2). 
However after adjustment for hypothermia, prematurity and hyponatremia, a significant 
blood culture growth was associated with a 2.3-fold [95% CI 0.79-6.76] increased risk of 
gross motor delay. Infants born from HIV infected mothers were found to have an increased 
risk of 5-fold [95% CI 1.49-17] in gross motor delay after adjusting for all the factors above 
(table 5.2). In all adjustments prematurity, convulsions and hyponatremia were associated 
with a non-significant risk of developmental delay of 2.8-fold [95% CI 0.7-11.7], 1.17-fold 




5.3.2 Risk factors for poor fine motor outcomes at 12 months of age 
In the univariate analysis, significant growth in blood or CSF culture was associated with an 
increased risk of fine motor delay at 12 months of age. A positive blood culture had a 3-fold 
risk [95% CI 1.38- 6.85] and positive CSF culture had a 2.67-fold risk [95% CI 1.24- 5.7]. A 
non-significant increased risk of fine motor delay was observed in HIV exposed infants of 
2.47 (95% CI 0.87-7), anaemia of 1.5 (95% CI 0.41-5.6), convulsions of 2.64-fold, 
hyponatraemia of 1.64 (95% CI 0.49-5.47), hypothermia of 1.8 (95% CI 0.33-9.89), 
prematurity of 1.33 (95% CI 0.36- 4.89) and early onset disease of 2.04 (95% CI 0.64-6.54) 
(Table 5.3). On the other hand as with gross motor delay hypernatraemia (0.43 [95% CI 0.05-
3.88]), fever 0.87[95% CI 0.28-2.72] and raised CRP (0.8 [95% CI 0.21-3.03]) were associated 















Table 5.3 Univariate logistic regression analysis on factors associated with fine motor 
delay at 12 months of age 
Parameter 
 
OR(95% CI) *P value 
Positive blood culture 
 
3.08(1.38-6.85) 0.006 



























Raised CRP 0.8(.21-3.03) 0.740 
 










5.3.2.1 Multivariate analysis of risk factors associated with fine motor delay 
The adjusted logistic model of the odds of fine motor delay at 12 months of age below 




In all adjustments a significant growth in either CSF or blood culture is associated with a 4.5-
fold [95% CI 1.48-13.8] and 3.7-fold [95% CI 1.27-10.76] increased risk respectively of fine 
motor delay at 12 months of age. However when adjusted for prematurity, hypothermia, 
positive CSF or blood culture growth and hyponatraemia, HIV exposure was associated a 
non-significant increased risk of 2.03 -fold (95%CI 0.56-7.32) in fine motor delay. 
 
Table 5.4 Adjusted logistic model of the odds of fine motor delay at 12 months of age 
Parameter 
 
OR (95% CI) *P value 
Positive CSF culture 
 
4.5 (1.48-13.8) 0.008 
Positive blood culture 
 
3.7 (1.27- 10.76) 0.020 
Hypothermia 
 
3.01 (0.35-26.12) 0.320 
Prematurity 
 
5.07 (0.6- 42.54) 0.140 
Hyponatraemia 
 
1.79 (0.41-7.8) 0.440 
HIV exposed 
 
2.03 (0.56-7.32) 0.280 
Convulsions 
 
3.2 (0.43-23.98) 0.260 
*Adjusted logistic regression p value 
5.3.3 Risk factors for poor neurocognitive outcomes at 12 months of age 
Even though in this study several factors had been shown to be associated with an increased 
risk of neurocognitive delay the only significant risk factor was being HIV exposed. Infants 
that were born from HIV infected mothers had a 2.7-fold increased risk of neurocognitive 
delay at 12 months of age (95% CI 1.05-6.86). Positive CSF culture (1.55[95% CI 0.78-3.05]),  
blood culture (1.44 [95% CI 0.71-2.92]), anaemia (1.58 [95% CI 0.46-5.38]), hyponatraemia 
(1.06 [95% CI 0.33-3.36], hypoxia (1.23 [ 95% CI 0.46-3.23]), hypothermia (1.36 [ 95% CI 
0.29-6.38]), convulsions (3.78[ 95% CI 0.98-14.7], prematurity (1.8[0.56-5.82]) and early 
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onset disease (1.48 [95% CI 0.51-4.3]) were all associated with a non-significant increased 
risk of neurocognitive delay (Table 5.5).However in keeping with the fine and gross motor 
domains hypernatraemia (0.55[95% CI 0.1-2.97]), fever (0.55[95% CI 0.1-2.97]) and raised 
CRP (0.43[95% CI 0.13- 1.4])  were all associated with a non-significant risk reduction on the 
odds of neurocognitive delay in these infants (Table 5.5). 
Table 5.5 Univariate logistic regression analysis on factors associated with neurocognitive 
delay at 12 months of age 
Parameter 
 
OR(95% CI) *P value 
Positive blood culture 
 
1.44(0.71-2.92) 0.310 












































5.3.3.1 Multivariate analysis of risk factors associated with neurocognitive delay 
A logistic regression model on the odds of neurocognitive delay at 1 year of age included 
hyponatraemia, HIV exposure, gestation, convulsions, positive CSF or blood culture and 
hypothermia. In the all adjustments HIV remained the only significant risk factor for 
neurocognitive delay at 12 months of age with a risk of 2.9-fold (95% CI 1.12-7.64) (Table 
5.8). However hyponatraemia (1.04 [ 95% CI 0.32-3.35] ), hypothermia (1.2[ 95% CI 0.2-
7.16]), prematurity (2.76 [ 95% CI 0.48-15.95] ) and positive CSF (1.63 [ 95% CI 0.75-3.53] )  
or blood culture (1.23 [95% CI 0.53-2.85] ) all continued to show an increased risk in all 
adjustments but it was non-significant (Table 5.8). 
 
Table 5.6 Adjusted logistic model of the odds of neurocognitive delay at 12 months of age 
Parameter 
 
OR (95% CI) *P value 
Positive CSF culture 
 
1.63 (0.75-3.53) 0.220 
Positive blood culture 
 
1.23 (0.53-2.85) 0.640 
Hypothermia 
 
1.2 (0.2-7.16) 0.840 
Prematurity 
 
2.76 (0.48-15.95) 0.260 
Hyponatraemia 
 
1.04 (0.32-3.35) 0.940 
HIV exposed 
 
2.92 (1.12-7.64) 0.030 
Convulsions 4.28 (0.53-34.4) 0.170 






5.3.4 Risk factors for poor expressive language outcomes at 12 months of age 
In the univariate analysis for risk factors associated with poor expressive language outcomes 
at 1 year of age there was no significant risk factor that was identified. However positive 
blood (1.18 [95% CI 0.56-2.46] ) or CSF culture (1.85 [95% CI 0.89-3.82] ), HIV exposure (1.5[( 
95% CI 0.56-4.05] ), convulsions (2.98 [ 95% CI 0.73-12.2]), anaemia (1.48[ 95% CI 0.43-5.11] 
), hyponatraemia (1.78[ 95% CI 0.56-5.6] ), hypoxia (1.47[ 95% CI 0.54-4.06]), hypothermia ( 
1.44 [ 95% CI 0.28-7.34]) and prematurity (1.97 [ 95% CI 0.59-6.61] ) were all associated with 
a non-significant increased risk of expressive language delay. On the other hand 
hypernatraemia (0.29 [95% CI 0.03-2.56] , fever ( 0.47[ 95% CI 0.28-7.34] ) 
thrombocytopenia (0.26 [95% CI 0.03-2.23] ) and raised CRP (0.27[0.07-1.03]) were all 













Table 5.7 Univariate logistic regression analysis on factors associated with expressive 
language delay at 12 months of age 
Parameter 
 
OR(95% CI) *P value 
Positive blood culture 
 
1.18(0.56-2.46) 0.660 






























Raised CRP 0.27(0.07-1.03) 0.063 
 
Early onset disease 
 
0.93(0.29-3.03) 0.910 
Convulsions 2.98 (0.73-12.2) 0.130 
*Univariate logistic regression p value 
 
 
5.3.4.1 Multivariate analysis of risk factors associated with expressive language delay 
The adjusted logistic regression model included the same factors as in the other 
developmental domains. 
In all adjustments there was no significant risk factor identified however positive CSF (3.37 
[95% CI 0.91-12.5]) or blood culture (1.53 [95% CI 0.61-3.84]) , prematurity (2.49[ 95% CI 
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0.37-16.87] ) , HIV exposure (1.04 [ 95% CI 0.35-3.1]) and hyponatraemia (1.69 [95% CI 0.52-
5.46] ) were associated with a non-significant increased risk of expressive language delay 
(Table 5.8) . Hypothermia on the other hand was associated with a 7% (0.93 [95% CI 0.14-
6.19] risk reduction for expressive language delay when adjusted for HIV exposure, positive 
blood or CSF culture, prematurity and hyponatraemia but this was not statistically 
significant (95% CI 0.14-6.19). 




OR (95% CI) *P value 
Positive CSF culture 
 
3.37(0.91-12.5) 0.070 
Positive blood culture 
 
1.53 (0.61-3.84) 0.360 
Hypothermia 
 
0.93 (0.14-6.19) 0.940 
Prematurity 
 
2.49 (0.37-16.87) 0.351 
Hyponatraemia 
 
1.69 (0.52-5.46) 0.384 
HIV exposed 
 




*Adjusted logistic regression p value 
 
5.3.5 Risk factors for poor receptive language outcomes at 12 months of age 
In the univariate analysis of risk factors associated with receptive language delay at 1 year of 
age positive CSF growth was associated with a statistically significant risk of 2.4 –fold (95% 
CI 1.13-5.1). A positive blood culture was associated with a 1.41- fold increased risk but this 
was not statistically significant (95% CI 0.68-2.93). Other factors that demonstrated an 
increased risk of delay though not statistically significant included; HIV exposure 1.87-fold 
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(95% CI 0.7-4.98), hyponatraemia 1.45 (95% CI 0.44-4.81), hypothermia 1.4-fold (95% CI 
0.28-6.98), convulsions 1.85-fold (95% CI 0.45-7.57) and prematurity 1.4-fold (95% CI 0.41-
4.79). Anaemia (0.39 [95% CI 0.08-1.92]), hypernatraemia (0.89 [95% CI.16-5.03] ), hypoxia 
(0.9 [ 95% CI 0.32-2.55]), fever (0.41 [ 95% CI 0.14-1.16]), thrombocytopenia (0.57 [95% CI 
0.11-3.03]), raised CRP (0.42 [95% CI 0.11-1.61]) were all associated with a non-significant 
risk reduction in receptive language delay (Table 5.9). 
Table 5.9 Univariate logistic regression analysis on factors associated with expressive 
language delay at 12 months of age 
Parameter 
 
OR(95% CI) *P value 
Positive blood culture 
 
1.41(0.68-2.93) 0.362 






























Raised CRP 0.42(0.11-1.61) 0.210 
 





1.85 (0.45-7.57) 0.536 




5.3.5.1 Multivariate analysis of risk factors associated with receptive language delay at 1 
year of age 
Positive CSF culture remained the only significant risk factor with a 2.82-fold risk of 
receptive language delay (95% CI 1.2-6.73) after being adjusted for hypothermia, 
prematurity, hyponatraemia and HIV exposure (Table 5.10). 




OR (95% CI) *P value 
Positive CSF culture 
 
2.82 (1.18-6.73) 0.021 
Positive blood culture 
 
1.92 (0.72-5.09) 0.198 
Hypothermia 
 
2.48 (0.23-26.47) 0.453 
Prematurity 
 
1.04 (0.17-6.3) 0.973 
Hyponatraemia 
 
1.58 (0.38-6.49) 0.531 
HIV exposed 
 




*Adjusted logistic regression p value 
 
5.3.6 Summary of findings 
Positive CSF culture, hypothermia and being HIV exposed were associated with an increased 
risk of gross motor delay at 1 year of age. Positive CSF or blood culture was associated with 
an increased risk of fine motor delay at 1 year of age. In the neurocognitive domain being 
HIV exposed was the only identifiable risk factor and a positive CSF culture was the sole 
significant risk factor in the receptive language domain. There was no significant risk factor 
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identified in the expressive language domain. Below is table 5.11 with a summary of all the 
significant findings from the multivariate analysis. 
 




Risk factor OR(95% CI) *P value 
Gross motor Positive CSF culture 
 
2.7(1.22-5.86) 0.014 
 Hypothermia  
 
12.5 (1.13- 140) 0.041 
 HIV exposed 
 
5.04(1.49-17) 0.009 
Fine motor Positive CSF culture 
 
4.5 (1.48-13.8) 0.008 
 Positive blood culture 
 
3.7 (1.27-10.76) 0.021 
Neurocognitive  HIV exposed 
 
2.92 (1.12-7.64) 0.031 
Receptive language Positive CSF culture 
 
2.82(1.18-6.73) 0.020 
Expressive language Nil   








In this study being born to an HIV infected mother was associated with an increased risk of 
gross motor and neurocognitive delay at 1 year of age.   HIV exposed non-infected children 
have been shown to have developmental delay in other poor settings whereas in the 
developed world they have been shown to have normal neurodevelopment {Afran L. M., 
Garcia Knight et al (2014), Le Doare K, R. Bland et al (2012), Chase C, J. Ware et al (2000), 
Levenson R.L jr. C.A., Mellins (1992) }. A number of factors could possibly lead to the 
increased risk of developmental delay in these HIV exposed un-infected infants. There is a 
possibility that the mothers could be unwell themselves either physically or mentally which 
may impact on their ability to care for and stimulate their infants {Le Doare K, R. Bland et al 
(2012)}. In this study mothers to the participants were not screened for depression and HIV 
disease staging was not done and impact from these factors could not be measured. There 
are added influences, such as poverty, early infant malnutrition and growth that combine to 
give a more complicated picture of developmental challenges in this environment {Le Doare 
K, R. Bland et al (2012), Seale A.C, M Mwaniki et al (2009), Osrin D, S. Vergnano et al (2004)}. 
The majority of the families in this study were poor (chapter 4). It is therefore not surprising 
that in this study being born to an HIV infected mother was independently associated with 
developmental delay. It is important to note that even if Malawi has made strides in PMTCT, 
there has been an increase in the rate of new HIV infections amongst adolescents {UNICEF 
Malawi report 2013}. It is also known that a significant proportion of pregnant women in 
Malawi are adolescents {Malawi DHS 2010}. This will likely have an impact on morbidity 
outcomes in infants as the number of HIV exposed infants is likely to increase. Efforts should 
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not just be directed at PMTCT but prevention of new infections in all age groups otherwise 
the gains from PMTCT might be diluted. 
 
Significant growth in blood culture was also independently associated with fine motor delay 
in the severe neonatal infection cases. This finding is in keeping with other studies in 
preterm and low birth weight infants with neonatal sepsis { Shah D.K, L.W., Doyle et al 
(2008), Adams-Chapman I, B.J., Stoll et all (2006), Stoll B.J., N. Hansen et al (2002), Hack 
M.D, D. Wilson-Costello et al (2000), Stoll B.J, T. Gordon et al (1996}. It has been postulated 
that in neonatal infection cases the presence of a bacteraemia is probably associated with a 
systemic inflammatory response resulting into cytokine and free radical activation. This 
would subsequently cause white matter damage eventually leading to developmental delay 
{ Volpe J.J(2008), Shah D.K, L.W. Doyle et al (2008), Volpe J. J,(2003), Duncan J.R, M.L Cock 
(2002)}.  Blood culture positivity rate has been reported to be low in neonatal sepsis {Seale 
A.C, M Mwaniki et al (2009), Osrin D, S. Vergnano et al (2004), Mishra U.K, S.E. Jacobs et al 
(2006) Claudio C., A Panero et al (2004),}. In this study the culture positivity rate was 11% 
(chapter 3).It is therefore important to try and explore affordable ways of increasing the 
yield from cultures as positive cultures are associated with poor developmental outcomes. 
The molecular diagnostics available in the developed settings can improve the yield but are 
too expensive for a developing setting like Malawi. 
 
Neonatal meningitis with a significant growth in CSF has also been shown to be 
independently associated with developmental delay in these participants. This again is in 
keeping with other studies { Heath P.T, N.K., Nik Yusoff et al (2003), Stevens J.P., M. Eames 
154 
 
et al (2003), Bedford H, J. Delouvois et al (2001), Holt D.E, Halket et al (2001), Delouvois J., T. 
Blackburn et al (2001)}. 
 
5.5 Limitations of the study 
The major challenge in this study was the small sample size of 102. It was challenging to do 
most of the sub group analysis as the numbers were further reduced. The small sample size 
could explain the wide confidence intervals observed in this study.  
In view of the high prevalence of developmental delay observed in this study further work is 




Positive blood culture, Neonatal meningitis with a positive CSF culture and being born to an 
HIV infected mother were predictors of poor developmental outcomes at 1 year of age in 
this study.   
Severe neonatal infection cases that are HIV exposed or have a positive blood or CSF culture 
need to be screened for developmental delay in the first year of life. The burden arising 
from these infections is large and therefore measures that are known to prevent neonatal 
infections should be undertaken so as to avoid the complications. There is need to invest in 
better antenatal, antepartum and postnatal care all of which have been shown to improve 
neonatal outcomes.  
HIV exposure as shown in other studies remains a risk of poor developmental outcomes in 
childhood. More needs to be done to try and reduce the prevalence of HIV in the general 






                          CHAPTER SIX 
 
6. A CASE SERIES OF MRI BRAIN FINDINGS IN NEONATAL SEPSIS 
AND MENINGITIS AT QECH, MALAWI. 
6.1 Introduction 
Although the overall numbers are relatively small when compared to meningitis in older 
children, the greatest risk of acquiring meningitis is in the neonatal period {Heath P.T, N.K., 
Nik Yusoff et al (2003), Stevens J.P., M. Eames et al (2003), Bedford H, J. Delouvois et al 
(2001), Holt D.E, Halket et al (2001), Delouvois J., T. Blackburn et al (2001)}. The effects of 
infection on the rapidly developing brain, which continually evolves in its susceptibility to 
damage, and in the context of a rapidly evolving immune system, lead to complex patterns 
of pathology that are different from those seen in an older child affected by a similar 
infectious agent {Wintermark P.(2011)}. In the previous chapters (chapter 3 and 4), it has 
been shown that the mortality associated with neonatal meningitis presenting to QECH is 
20% and amongst those that survive up to 60% are impaired at 1 year follow-up. Even in the 
developed setting, up to 50% of neonatal meningitis cases are known to have complications 
{Heath P.T, N.K., Nik Yusoff et al (2003)}.  
In older children in particular, neuroimaging has been used to identify and monitor 
structural focal lesions, hydrocephalus, subdural effusion, empyema and ventriculitis some 
of which require prompt neurosurgical intervention {Jarenko J.L A.S Moon (2010), Srinivasan 
L. and M.A Rutherford (2008), Maalouf E.F, P.J. Duggan (1999), Levene M.I, A Whitelow 
(1982)}. Differences have been reported in the imaging and pathologic appearances 
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amongst the various infectious agents causing meningitis in a neonate {Wintermark P. 
(2011), Jarenko J.L A.S Moon et al (2010)}. For example, neonatal meningitis due to 
Citrobacter koseri and Enterobacter sakazakii is associated with the development of brain 
abscesses {de Vries L.S., Verboon-Maciolek M.A et al (2006), Kline M.W (1988), Willis J., J.E., 
Robinson et al (1988), Graham D.R, J.D. Band et al (1981)}. Therefore to better understand 
the pathology associated with the high mortality and morbidity associated with meningitis 
in Malawi, the neuroimaging data available from this cohort was reviewed. 
 
Non-invasive trans-fontanelle ultrasonography is available at QECH but although able to 
provide information on ventricular size and presence of haemorrhage, ultrasonography is 
heavily operator-dependent and experience is needed to demonstrate the meningeal and 
parenchymal findings of bacterial meningitis {de Vries L.S., Verboon-Maciolek M.A (2006)}. 
Neonates in this cohort were not systematically scanned and the data was not recorded. 
Until recently, CT scans of the brain were available at QECH but although useful in detecting 
cerebral abscesses, cerebritis, effusions, hydrocephalus and encephalomalacia {Kanamalla 
U.S, R.A Ibarra et al (2000), Karampekios S, J.Hesselink et al (2005), Castillo M (2005), Harris 
T.M, Edwards M.K et al (1991)}, the quality of the images at QECH was poor and none of the 
cohort underwent CT imaging. Fortunately, as part of an ongoing collaborative severe 
malaria study between Blantyre Malaria Project (Michigan State University) and MLW, a MRI 
facility (permanent magnet-based Signa Ovation 0.35-T MR scanner, GE Healthcare, 
Waukesha, WI, USA) was established at QECH which is also available for routine clinical care. 
This is the only such facility in Malawi and one of the few MR scanners in the Region. Even in 
industrialised countries, neonates with meningitis are not routinely imaged. MRI is thought 
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to be superior to CT scans in that it can better detect leptomeningial enhancement and 
distension of the subarachnoid space with widening of the interhemispheric fissure {Jarenko 
J.L, A.S Moon (2010), Srinivasan L. and M.A Rutherford (2008), Karampekios S, J.Hesselink et 
al (2005), Castillo M (2005), Kanamalla U.S, R.A Ibarra et al (2000), Maalouf E.F, P.J. Duggan 
(1999), Levene M.I, A Whitelow (1982) }.  
This chapter therefore reports 5 cases of neonatal meningitis and 2 cases of neonatal sepsis 
enrolled in the study where MRI scans of the brain were performed as part of routine 
clinical care. 
6.2 Methodology 
The recruitment and outcome of this neonatal meningitis and sepsis cohort is described in 
chapter 2. Brain MRI was done in 5 cases of meningitis and 2 of sepsis as part of routine 
clinical care, where there were repeated seizures for at least 2 days so as to rule out 
complications of meningitis. The MRI scans were done on the 0.375T magnet using multiple 
planes and conventional T1 and T2 weighted images were included. Sagittal T1 FLAIR (fluid 
attenuated inversion recovery), axial T2 FRFSE, axial T2 FLAIR, axial DWI (diffusion weighted 
images) and coronal T2 FRFSE sequences were taken. The scans were re-reviewed 
retrospectively with a specialist neuroradiologist (Dr S Kampondeni). None of the MRIs were 
done with contrast enhancement (unavailable in the government sector). Additional scans 
as part of this research study were not possible for financial reasons. 
6.3 Case Reports 
There were 4 boys and 3 girls who had MRI scans of the brain (age range 6 to 56 days old). 




A 13 day old girl presented to the QECH with a day’s history of fever, irritability difficulties 
with breathing and poor feeding. She was born at term to an HIV negative mother at an 
urban health centre but had a low birth weight of 2.4kg. The delivery was uneventful. On 
arrival to QECH she was fully conscious and well perfused, had a sunken fontanelle, a pulse 
rate of 168 beats per minute, temperature of 36.6oC and respiratory rate of 64 cycles per 
minute. The peripheral white cell count was 1.6 X109/L (differential not done), haemoglobin 
of 10.4g/dl and platelets of 228 X109/L. She had normal serum electrolytes but the CRP was 
elevated to 58mg/L. Her CSF was xanthrochromic with a white cell count of 12/mm3 and 
protein of 2.58mg/dl. The CSF culture grew group B streptococcus which was sensitive to 
penicillin and ceftriaxone. There was no growth on the blood culture. She was treated with 
parenteral ceftriaxone.  She rapidly deteriorated over the next 24 hours with repeated 
generalised seizures lasting at least twenty minutes that spanned the first 2 days of 
admission. She required IV phenytoin infusions to control the seizures. EEG was done on day 
2 of admission at the MLW/ BMP Paediatric Research Ward facility that showed focal 
epileptiform activity on the left. An MRI brain was done on day 2 of admission and showed 
diffusion abnormality along the cerebral cortices sparing the right parietal region. There was 
diffuse swelling in the cerebral hemispheres (see fig 6.1). At the age of 1 year this girl had 
delayed cognitive and fine motor development and had bilateral hearing loss. She had no 
reported seizures at this age. 
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Fig 6.1 Axial and Sagittal Brain MRI images of a 13 day old girl with GBS meningitis showing 








A 6 day old HIV unexposed boy born at home at term with no complications during delivery 
presented to QECH with a day’s history of fever, poor feeding and irritability. He was 
lethargic on arrival, tachycardic (pulse rate of 180/min) and febrile (temperature of 40.5oC.). 
His respiratory rate was 44cycles /minute and had an oxygen saturation of 97% on room air. 
He had a generalised convulsion on arrival. He had a peripheral white cell count of 14.4 
X109/L, haemoglobin of 10.4g/dl and platelets of 199 X109/L. He had a raised CRP of 
127mg/dl. His CSF was hazy with a raised white cell count of 400/ mm3 of which 65% were 
polymorphs and 35% lymphocytes. CSF protein was 2.16mg/dl and CSF glucose 5.4mmol/dl. 
The blood glucose at the time of the lumbar puncture was 10.2mmols/dl. There was no 
significant growth from either the CSF and blood culture. She had repeated focal and 
generalized seizures on the ward that were difficult to control with parenteral phenytoin. An 
MRI brain was done on day 11 of admission which showed diffuse heterogeneous high T2 
signal and abnormal architecture of the cerebral hemispheres. There was high T2 signal in 




   
   
 
 Fig 6.2 Axial and Sagittal Brain MRI Images of a 6 day old boy with bacterial meningitis the 
arrows are showing abnormal architecture of the cerebral hemisphere. 
 
At the age of 1 year the boy had gross global developmental delay in all the domains, 






An 18 day old boy born at an urban health centre at term uneventful delivery to an HIV 
negative mother presented to QECH with poor feeding and difficulties with breathing for 4 
days. On arrival the infant was lethargic, floppy, hypothermic with a temperature of 350C, 
bradycardia (pulse rate of 74 beats per minute), hypoxic (oxygen saturation of 79% in room 
air) and was having apnoeas. He was noted to have lost 22% of his birth weight. He had a 
peripheral white cell count of 14.4 X109/L with 37% neutrophils, 59% lymphocytes and 3% 
monocytes. His platelet count was 75 X109/L. He was hypernatraemic with sodium of 179 
mmol/L, urea of 77.8 mmol/L, potassium of 5 mmol/L and chloride of 134 mmol/L. His CSF 
was clear with no cells and had normal protein and glucose, blood and CSF cultures were 
sterile. He was initially treated with high dose parenteral penicillin and gentamicin but was 
switched to parenteral ceftriaxone after 24 hours. This boy had repeated focal seizures over 
6 days. On day 6 of admission an MRI brain was done which showed prominent gyri and 
high T2 in the left temporal lobe suggesting ischemia (see Fig 6.3). 
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Fig 6.3 Axial and Sagittal Brain MRI images of an 18 day old boy with neonatal sepsis the arrows 
are showing left temporal lobe ischaemia- top axial images and prominent gyri in the sagittal 
images. 
 
At 1 year of age he had a left sided convergent squint and had mild delay in language and cognitive 
development. He had normal hearing at 1 year of age and was seizure free. 
Case 4 
A 36 day old girl born at term via caesarean section at QECH to an HIV negative mother 
presented from home with a 2 day history of fever, jaundice, difficulties in breathing and 
vomiting. She had generalised convulsions on the day of admission. She was unconscious on 
arrival and had epistaxis. She had a pulse rate of 144 beats per minute, respiratory rate of 
44 cycles per minute, temperature of 36.90C and oxygen saturation of 99%. She had a 
bulging fontanelle and was hypertonic. She had a hepatomegaly of 5 cm below the costal 
margin. She had a peripheral white cell count of 34.8 X109/L of which 79% were neutrophils, 
haemoglobin of 5.6g/dl and platelet count of 430 X109/L. She had a serum total bilirubin of 
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12.9 mg/dl. Her CSF had a white cell count of 10/mm3, protein of 1.43mg/dl and glucose of 
1.39mmols/l. The random blood sugar at the time of the lumbar puncture was 5.3mmol/l. 
The CSF and blood cultures were sterile. She had repeated generalized convulsions for 4 
days which were controlled with parenteral phenobarbitone and phenytoin. An MRI was 
done on day 20 of admission which showed a diffuse high T2 signal throughout the left 
cerebral hemisphere (Fig 6.4). There was an 11mm wide left occipital subdural effusion 
exerting mass effect on the occipital lobe. A smaller 6mm left cerebellar subdural effusion 
was also noted. There was mild communicating hydrocephalus. A porencephalic cyst was 
noted in the right parietal region connecting with the right trigone. There was high T2 and 
DWI signal in the right frontal lobe, suggesting infarction. She was treated with ceftriaxone 
for the presumed meningitis. She had gross global developmental delay at 6 months of age 
and bilateral hearing loss. There were no reported seizures at home.  She died at home at 8 
months of age of unknown cause. 
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Fig 6.4 Axial and Sagittal  Brain MRI images of a 36 day old girl with presumed meningitis 
showing multiple complications of meningitis- Right Anterior Cerebral Artery infarct, 





A 23 day old HIV non-exposed girl born at term at an urban health centre, HIV non-exposed 
presented to QECH with a day’s history of fever, difficulties in breathing and irritability. On 
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arrival she was hypoxic (oxygen saturation 88% on room air), unconscious, tachycardic 
(pulse rate of 193/minute), febrile with a temperature of 39.5 0C and had a bulging 
fontanelle. She had a peripheral white cell count of 4.9 X109/L with a predominance of 
lymphocytes 80.8%, haemoglobin was 14.2g/dl and the platelet count was 237 X109/L. Her 
electrolytes were normal.  The CSF and blood culture both grew Group B streptococcus. She 
was treated with parenteral ceftriaxone. She had recurrent generalised and focal seizures 
the first 6 days of admission and an MRI scan of the brain was done on day 5 of admission. 
The MRI scan showed diffuse cortical high T2 and high DWI signal in the right frontal lobe 
and both occipital lobes (see Fig 6.5). 
 
She was seen at 6 and 12 months of age and had normal development. Her hearing was 
normal and was seizure free. 
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Fig 6.5: Axial and Sagittal MRI brain images of a 23 day old girl with GBS meningitis arrows 
showing diffuse cortical high T2 signal in the right frontal and Occipital lobes 
  
Case 6 
A 56 days old boy HIV exposed born at term at an urban health centre presented to QECH 
with a 3 days history of cough and a day’s history of vomiting, irritability and difficulties in 
breathing. On arrival he was in shock with a prolonged capillary refill time (no.) and 
tachycardic (pulse rate of 196 beats/minute). He was tachypnoeic (respiratory rate of 82 
cycles/minute) but had normal oxygen saturations of 94% and had oral thrush. His 
peripheral white cell count was 22 X109/L which was 62% neutrophils, haemoglobin of 
7.7g/dl and platelet count of 227 X109/L. His urea and electrolytes were normal and she had 
a CRP count of 15.3 mg/dl. He had a negative HIV DNA PCR at 2 months of age. His CSF had 
no white cells and the protein was 0.88 mg/dl and glucose of 12.33mmol/l. A random blood 
sugar was not done at the time of the lumbar puncture. The CSF and blood cultures were 
sterile. He had repeated focal seizures for the first 6 days of admission. He was treated with 
parenteral benzyl penicillin and gentamicin and the seizures were controlled with parenteral 
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phenobarbitone and phenytoin. On day 7 of admission he had an MRI brain done which was 
normal (Fig 6.6). 
 
        
Fig 6.6 Normal axial and sagittal MRI Images of the brain of a 56 day old boy with neonatal sepsis 
 
He was seen at 6 and 12 months of age seizure free with normal development.  
Case 7 
A 33 day old boy born at term at an urban health centre from an HIV negative mother 
presented with a 2 days history of a fever and a day’s history of poor feeding and difficulties 
with breathing. She had focal seizures on the day of presentation. On arrival he was afebrile 
with a temperature of 37.20C, tachypnoeic (respiratory rate of 68cycles/minute), had a pulse 
rate of 171 beats per minute and had normal oxygen saturations of 92%.  He was hypotonic 
with a bulging fontanelle. His peripheral white cell count was 17.8 X109/L, haemoglobin of 
9.6g/dl and a platelet count of 910 X109/L. His urea and electrolytes were normal but he had 
a raised CRP of 215 mg/dl. The CSF consisted of pus and so a cell count could not be given, 
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however there was no growth from both blood and CSF culture. He had repeated focal 
seizures for the first 3 days of admission which were controlled with parenteral 
phenobarbitone and phenytoin. He remained in coma over the first 3 days of admission. He 
was treated with parenteral ceftriaxone for the meningitis.  He had an MRI scan of the brain 
on day 3 of admission which showed severe diffuse oedema of the cerebral hemispheres 
with loss of grey/white definition and total effacement of sulcal markings. The cerebellum 
was also diffusely swollen see Fig 6.7 below. 
                  











Table 6.1 Summary of MRI brain findings in neonates with meningitis and sepsis 
Age 
(days) 














Meningitis Abnormal cerebral 
architecture 



















and cerebral gliosis 





























This MRI brain case series describes the extent of complications caused by neonatal 
meningitis and sepsis. The abnormalities described in these series  included brain oedema, 
abnormal architecture of the cerebral hemispheres, ischaemia, subdural effusion, 
hydrocephalus, porencephalic cyst and infarction are in keeping with what has been 
reported in other studies { Jarenko J.L A.S Moon (2010), Srinivasan L. and M.A Rutherford 
(2008), Kanamalla U.S, R.A Ibarra et al (2000), Karampekios S, J.Hesselink et al (2005), 
Castillo M. (2005), Harris T.M, Edwards M.K et al (1991)Maalouf E.F, P.J. Duggan (1999), 
Levene M.I, A Whitelow (1982) }. 
 In this case series the infant that had temporal lobe ischaemia was a neonatal sepsis case 
without overt meningitis. We postulate that this 18 day old boy could have had the 
ischaemia as a result of venous thrombosis secondary to severe dehydration. He had lost 
22% of his birth weight and his urea was high on admission 77.8mmols/l. He also had high 
sodium of 179mmols/l which could have led to the seizures. There are no similar reported 
cases of neonatal sepsis without overt meningitis with similar findings in the literature. 
 
Because of the logistical challenges, all these infants did not have follow up MRI scans so as 
to ascertain whether the abnormalities had resolved.  
 
MRI scans are not without risk in children particularly from sedation. All the infants that had 
MRI scans in this series were critically ill with difficult to control seizures. These infants were 
on either phenytoin or phenobarbitone for seizure control and these anticonvulsants are 
known to cause respiratory depression {Wintermark P. (2011)}. The risk of hypoxia or even 
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apnoea was therefore high in these patients however the benefits of ruling out a potentially 
amenable surgical cause like a cerebral abscess was judged to outweigh the risk. These 
infants were being accompanied by a nurse and a medical officer who monitored their vital 
signs throughout the scanning period. 
It was clear from these few cases that were done that MRI has a potentially significant role 
in the understanding and management of neonatal meningitis. In 4 out of the 7 cases with 
persistent seizures their CSF parameters on admission were normal with negative cultures 
after 48 hours. Repeat CSF in all of them at 48 hours was sterile. However the MRI brain 
findings were strongly suggestive of brain pathology. 
Based on this small sample, a larger study is required to fully understand the pathological 
basis of the poor outcome that was observed 
 
6.5 Limitations 
We were not able to do MRI scans in all the participants who had the standard indications 
namely; poor clinical response after 48 hours of treatment, seizures and lack of CSF sterility 
after 48 hours of antibiotic administration due to lack of resources. Therefore this was a 
highly selected group. All the scans were not enhanced by contrast and they were done on 
different days of admission ranging from day 2 to day 20 of admission. This could have 
affected the type of abnormalities seen on the scans. Routine contrast- enhanced brain MRI 
is known to be the most sensitive modality particularly early on in the disease {Wintermark 
P. (2011), Srinivasan L. and M.A Rutherford (2008), de Vries L.S, M.A Verboon-Maciolek 
(2006)}. It has been shown that non-enhanced MRI studies performed in patients with 
uncomplicated meningitis may appear to be normal but enhanced studies in the same 
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patient can show abnormalities { Wintermark P. (2011), Srinivasan L. and M.A Rutherford 
(2008), de Vries L.S, M.A Verboon-Maciolek (2006)}. Most of the patients that had MRI scans 
done 86% (6 out of 7 participants) did show abnormalities on their scans. However there is a 
possibility that subtle abnormalities might have been missed in the non-enhanced films.  
The MRI scanner used on these participants was a 0.375 magnet whereas today, most 
centres of excellence are using 1.5-3 magnet size MRI scanners. The machine used in this 
study has a much smaller magnet than standard more modern machines and that could 
have affected the quality of the images. However, these machines require a level of 
servicing and consumable supply (liquid nitrogen) not available in Malawi. 
 
6.6 Conclusion 
This case series has demonstrated a wide range of complications that arise in neonatal 
meningitis and sepsis. The findings underscore the importance of MRI scan of the brain in 
the diagnosis and management of severe neonatal infections. MRI scans are however 
expensive and out of reach in most resource restrained settings and as such cheaper 












This thesis set out to examine the aetiology and outcome of neonatal sepsis in Malawi, a 
country where the neonatal mortality rate has remained static over the past two decades 
{Zimba, E., M.V Kinney et al. (2012). Neonatal sepsis has been reported as a cause of nearly 
30% of all neonatal deaths in Malawi {Liu L, H.L. Johnson et al. (2012)}. It has been shown 
from this thesis that group B streptococci and Streptococcus pneumoniae are important 
causes of neonatal sepsis and meningitis in Malawi (40% of all organisms grown in neonatal 
blood culture and 48% in CSF culture were group B streptococcus, 12% and 30% were S. 
pneumoniae respectively). This finding has further strengthened the evidence showing the 
importance of GBS as a cause of neonatal sepsis and meningitis in Malawi and probably in 
similar countries around sub-Saharan Africa. This thesis has also shown the poor long term 
outcome associated with neonatal sepsis and meningitis. Importantly, the data show that 
not only is neonatal meningitis associated with poor neurodevelopmental outcome but also 
neonatal sepsis without evidence of CNS inflammation on lumbar puncture also poses an 
increased risk of neurodevelopmental delay. 
The thesis literature review started by describing the global epidemiology of neonatal 
mortality with the developing setting contributing 99% of all neonatal deaths {Zupan, J and 
Aahman E., (2005) } and Sub-Saharan Africa contributing 30% of all global neonatal deaths 
{World Health report 2013}. The top 3 causes of neonatal mortality remain prematurity, 
birth asphyxia and neonatal sepsis {Lawn, J., A., Lee et al (2009)}. It was noted that the 
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distribution of the causes of neonatal deaths varied between countries, with infections 
causing most of the neonatal deaths in very high mortality settings like the Sub Saharan 
region { Lawn, J., A., Lee et al (2009), Lawn, J., S.,Cousens et al (2005)}. It was also noted that 
although there has been tremendous progress in the reduction of neonatal mortality in the 
developed setting since the 1970’s, there has been minimal progress in the developing 
setting { Lawn, J., A., Lee et al (2009), Rajaratnam, J., J.,Marcus  et al (2008), Lawn, J., 
S.,Cousens et al (2005)}. These improvements in neonatal mortality have been largely due to 
changes in obstetric care, maternal health, introduction of neonatology and better infant 
nutrition{ Lawn, J., S.,Cousens et al (2005), Child Health Research Project Special Report 
(1999) }. It is therefore imperative that all efforts should be made to try and accelerate the 
reduction of neonatal mortality in the developing setting. 
The literature review then described the aetiology of neonatal sepsis in both the developed 
and developing settings with GBS being the commonest cause of neonatal sepsis in the 
developed setting and based on  studies of varying quality, gram negative organisms being 
the commonest cause in the developing world{Zaidi A. K, D. Thaver et al (2009), Vergnano, 
S., P.T Heath et al (2005)}. It was postulated that the difference in bacterial aetiology was as 
a result of more unhygienic home deliveries in the developing setting that exposes the 
newborn to infections by gram negative organisms {Vergnano, S., P.T Heath et al (2005)}. 
This is in sharp contrast to the developed setting where almost all the deliveries are 
conducted by a skilled birth attendant in a hospital environment. The thesis also looked at 
the carriage of GBS by pregnant women in  both the developed and developing settings 
concluding that the carriage rates are similar between these 2 settings – up to 30%{ Gray 
K.J, G. Kafulafula et al (2011)}. It would be expected therefore that GBS should also be a 
176 
 
significant pathogen in developing countries. The fewer cases of GBS seen in the developing 
settings raises questions on the quality of data reported from these settings{ Vergnano, S., 
P.T Heath et al (2005)} as robust microbiology culture facilities are often lacking  . There has 
been a decline in the burden of GBS disease in many developed countries as a result of 
active screening of pregnant women and properly treating those known to carry GBS with 
antibiotics in labour{Schrag S.J and A Schuchat (2004)}. However screening of pregnant 
women for GBS is routinely not done in most developing countries. There are  prospects of a 
GBS vaccine given to pregnant women so as to prevent disease in the newborn {Clinical 
trials.gov}. The vaccine would further reduce the burden of neonatal GBS disease and would 
be easier to implement in a developing setting if the price was within reach for most 
countries. 
The  long term outcome of neonatal sepsis and meningitis in both the developed and 
developing settings was also reviewed. There has been a decline in mortality from neonatal 
meningitis  in the developed setting but the progress in the developing setting has been 
slow{Heath P.T, O.I Okike et al (2011), Puopolo K. M., L.C Madoff et al (2005), Heath P.T, 
N.K. Yusoff (2003)}. However the major challenge has been lack of progress on the burden 
of complications as a result of neonatal meningitis with up to 50% of the  survivors ending 
up with sequelae {de Louvois J,S. Halket et al (2007), Krebs VLJ, G.A.M Costa et al (2007), 
Stevens JP, M.Earmes et al (2003), Bedford H, J. de Louvois et al (2001) } . The thesis has 
gone further to review the reported long term outcome of neonatal sepsis particularly in 
preterm infants { Adams-Chapman I (2012), Schlapbach L. J., M. Aebischer (2011), Stoll B. J, 
Hansen N.I (2004) }. In these studies neonatal sepsis has been shown to increase the risk of 
neurological complications in surviving preterm babies. However, there is paucity of data on 
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long term neurological outcomes of neonatal sepsis in term babies from both the 
developing and developed settings. Understanding the neurological outcomes in neonatal 
sepsis cases can help in the acute management and follow-up of these cases. The potential 
long-term burden of these surving but affected children on socities is potentially 
considerable. 
7.1 Review of the methodologies employed  
To undertake a study of this nature, it is critically important that the appropriate clinical, 
developmental  and laboratory methods are employed to ensure that this approach can be 
duplicated in other settings and that the data generated is generalisable. In the 
development of the methods, there was a focus on three main areas: clinical definitions; 
laboratory analysis and neurodevlopment assessment. 
7.1.1 Clinical Methods 
In most developing settings the diagnosis of neonatal sepsis is mainly based on clinical signs 
and symptoms as laboratory confirmation for neonatal sepsis and meningitis are frequently 
unavailable. A clinical definition of neonatal sepsis was based on the WHO recommended 
criteria which lists 7 clinical signs as predictors of neonatal infection {The Young Infants 
Study group (2008)}. These include history of difficulty feeding, history of convulsions, 
movement only when stimulated, respiratory rate of 60 breaths per minute or more, severe 
chest in drawing and temperature of 37·5°C or more or below 35·5°C. Any neonate who 
presented with any of these signs was included in the study. Neonates who were also 
cyanosed, lethargic or shocked were also included in the study. Neonatal meningitis was 
defined based on positive laboratory findings on top of the clinical signs alluded to above. 
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These laboratory findings included a raised white cell count above 25 in the CSF, positive 
CSF gram stain and positive microbiological growth in the CSF culture {Squire E, B. Favara et 
al (1979)}.   
 
The clinical definition of neonatal sepsis that was used in this study has its own challenges. 
Most of the clinical signs outlined above are not restricted to infection but other conditions 
can present in a similar fashion in a neonate {Kliegman R.M, R.E Behrman et al (2011) }}. 
These conditions include complex congenital heart disease, inborn errors of metabolism, 
hypoxic ischaemic encephalopathy and non-accidental injury. This would lead to a 
misdiagnosis of neonatal sepsis which might compromise the interpretation of the results in 
this study. In this study all infants that had APGAR scores of less than 6 at five minutes after 
birth were excluded so as to avoid enrolling infants that could have had hypoxic ischaemic 
encephalopathy. As discussed in Chapter 3 the diagnosis of hypoxic ischaemic 
encephalopathy was purely clinical without any laboratory investigations. It is therefore 
possible that some neonates who were septic at birth could have been wrongly misclassified 
as hypoxic ischaemic encephalopathy cases. These would have presented as early onset 
neonatal sepsis and this could partly explain the low number of early onset neonatal sepsis 
(25%). Infants that had other signs strongly suggestive of complex congenital heart disease 
had echocardiography done and in this study 2 infants who had been recruited were found 
to have complex congenital heart disease. They were excluded in the analysis. It was 






7.1.2 Laboratory analysis 
7.1.2.1 Blood culture Analysis 
In this study blood specimens were cultured in BacT/ALERT PF plus (BIOMÉRIEUX, INC, 
Durham, N.C.USA) automated systems and bacterial identification was performed with 
standard bacteriological techniques {Murray B and Pfaller T (1999)}. Antimicrobial 
susceptibility testing was done by using the modified Kirby-Bauer disc diffusion method 
according to the Clinical and Laboratory Standards Institute/National Committee on Clinical 
Laboratory Standards (CLSI/NCCLS). The culture positivity rate for significant bacterial 
organisms in this study was 11% which is lower than the reported 20% in other studies 
{Claudio C, A. Panero et al (2004), Maiwald M (2004), Squire E., B. Favara et al (1979)}. The 
BacT/ALERT PF plus requires up to 4mls of blood to be added to the 30ml volume of culture 
media. Getting adequate volumes of blood from small babies is challenging and this could 
have affected the culture positivity rate in this study. It has been shown that increasing the 
volume of blood drawn for culture in young children improves the culture positivity rate 
{Sarkar S., I Bhagat et al (2006)}. The low yield from blood cultures in this study could have 
had an impact on the management of the severe neonatal infection cases as duration and 
type of  treatment is frequently guided by the aetiological organism.{Blackburn R.M, N.Q 
Verlander et al (2013), Van den Hoogen A, L.J. Gerards et al (2009)}. We found that nearly 
half of the gram negative organisms in this study were resistant to the standard first line 
treatment for severe neonatal infections in Malawi. If the organisms were not known in 
these infants they would have been put on the wrong choice of drugs .This in turn could 
have had an impact on both the short and long term outcome. In this study the impact of 
having had a significant positive growth in blood culture on neurodevelopmental outcome 
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at 12 months of age was analysed and the small number of organisms grown could have 
affected the analysis. 
 
The frequency of an aetiological diagnosis would have been increased if molecular 
diagnostics had been done in this study. PCR which does not require such large volume of 
specimen   has been shown to increase the yield from both blood and CSF cultures {Maiwald 
M (2004), Fowlie P.W and B Schmidt (1998)}. PCR could also have been used to detect viral 
aetiologies such as Herpes simplex enterovirus, coxsackie and adenovirus which, have been 
reported as important causes of neonatal sepsis elsewhere [Simonsen KA, A.L. Anderson-
Berry et al (2014)]. Viral molecular diagnostics work on samples stored from the study is 
planned.  
 
7.1.2.2 Cerebral Spinal Fluid Analysis 
In this study 330/412(80%) participants had their CSF analysed and 323/330 (98%) had their 
CSF cultured.  Significant findings from CSF analysis were defined by a raised white cell 
count of at least 25 cells/mm3, positive gram stain or positive CSF culture. Bacterial 
identification was performed with standard bacteriological techniques {Murray B and Pfaller 
T (1999)}. Antimicrobial susceptibility testing was done by using the modified Kirby-Bauer 
disc diffusion method according to the Clinical and Laboratory Standards Institute/National 
Committee on Clinical Laboratory Standards (CLSI/NCCLS). The normal white cell count in 
neonatal CSF ranges from below 20 cells to below 30 cells. In this study we chose to use the 
midway point between 20 and 30. In this study 8 out of the 86 cases (9.3%) of culture-
proven meningitis had a normal white cell count below 10 cells in their CSF. In other words 8 
out of the 33(24%) positive CSF culture cases had a normal CSF white cell count and if 
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cultures had not been done they would have been missed. In most developing settings CSF 
cultures are not available and at best, the diagnosis of neonatal meningitis is mainly clinical 
aided by a raised white cell count in the CSF. This study underscores the importance of CSF 
cultures in the diagnosis and management of neonatal meningitis. 
 
7.1.2.3 HIV testing 
HIV exposure status was determined through serological testing of the mothers for HIV 
infection using 2 rapid tests for HIV 1 and 2 namely; Determine and Unigold rapid tests 
(Abbot and Biotech laboratories). A third test SD Bioline HIV Ag-Ab combo was used as a tie 
breaker in cases of a discrepancy. 
All HIV exposed babies had HIV DNA PCR (Roche Amplicor) testing to ascertain on whether 
they had acquired the infection or not. HIV DNA PCR testing was done once during 
enrolment. It was therefore difficult to ascertain whether there had been any change in the 
HIV status of the participants during follow/up. Most of these HIV exposed infants were still 
being breastfed and as such they continued to be at risk of acquiring HIV from their mothers 
{Quintanilla K (1996)}. Therefore results from the impact of HIV should therefore be 
interpreted with this potential confounder in mind. 
7.1.3 Bayley assessment of neurodevelopment 
In this study neurodevelopmental assessments were done using the Bayley scales of infant 
development III (BSID-III; Bayley 2006). The BSID-III assesses developmental functioning in 
children aged between 1 month and 42 months. Several authors have raised concerns about 
the use of a psychometric tool in a population other than the one in which the tool was 
developed as the BSID-III was developed in the USA {Gladstone M., G. A. Lancaster (2010), 
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Nampijja M, B. Apule (2010), Hambleton R.K (1996), Poortinga Y.H (1995), Geisinger K.F., 
F.J.R. Van de Vijver (1994) }. In another study by Cromwell et al conducted in Malawi 
reliance on US norm-based standardized scores resulted in misclassification of the 
neurological development of Malawian children, with the greatest potential for bias in the 
measurement of cognitive and language skills {Cromwell E, Q. Dube et al (2014)}. However 
Cromwell et al were able to create the norm for the Bayley in Malawi which made it possible 
for us in this study to interpret the Bayley results. The other challenge with the Bayley-III is 
its full use in children with significant sensory impairments such as blindness, deafness and 
severe spinal cord injuries.  Standardized administration is difficult in these groups of 
children and as such other domains may not be tested {Kolobe T. (2010)}. In this study we 
were unable to fully administer Bayley in 32 participants. 
Mellissa Gladstone developed the Malawi Development Assessment tool (MDAT), a 
culturally relevant developmental assessment tool which showed good reliability, validity, 
and sensitivity for identification of children with neurodisabilities in rural Malawi 
{Gladstone, M., G.A. Lancaster et al. (2010)}. We were unable to use the MDAT in this study 
because the MDAT had not been validated for use in young infants in the urban setting at 
the time the study was commencing.  
7.2 Aetiology of neonatal sepsis and meningitis 
As in many developed countries, the commonest aetiological organism identified in this 
study was group B streptococcus (GBS). GBS is known to cause most of the neonatal 




7.2.1 Group B streptococcus 
In this study GBS comprised 17 out of 42 (40%) organisms grown in blood culture. This is 
higher than rates reported in previous studies in Malawi {Gray K. J., S.L. Bennett (2007), 
Milledge J, J. C Callis et al (2005)}.  In a retrospective study from 1996-2001 in Malawi GBS 
was reported to have contributed 17 % of all neonatal pathogens grown in blood culture 
{Milledge J, J. C Callis et al (2005)}. In 2004-2005 the rate had increased to 22% {Gray K. J., 
S.L. Bennett et al (2007)}. The increase in the rate of GBS is likely to be a reflection of the 
true burden of the disease in our community and is unlikely to be due to an ascertainment 
bias or enhanced surveillance. The carriage rates for GBS in pregnant women in Malawi 
range from 17 to 21% which is higher than the rates in the USA reported at 14% {Gray K.J., 
G.Kafulafula et al (2011)}. GBS comprised 48% of all organisms grown in CSF culture. It is 
worth noting that all except one of the GBS grown in both blood and CSF culture were in 
late onset disease. This is contrary to reports from the developed setting that have reported 
that 75% of GBS infection in the neonatal period will occur in the first week of life 
{Vergnano, S., P.T Heath et al (2005). Other studies in Malawi have reported that 45-50% of 
GBS infection occurs as early onset disease {Milledge J, J. C Callis et al (2005)}. The 
predominance of late onset disease observed in this study was therefore surprising. It is 
noteworthy that, regardless of the culture result, 76% of all severe neonatal infection cases 
were late onset. Given that this was a general trend, it is therefore possible that since 
mortality rates in early onset disease are reported to be as high as 50%  in this setting { 
Milledge J, J. C Callis et al (2005)},  a significant proportion of newborns with sepsis or 
meningitis, particularly those born at home,  did not reach a health-care facility. In a study 
done by Kakhobwe et al in Ntchisi district in Malawi on the knowledge, attitude and 
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treatment preferences for neonatal sepsis, 83% of the mothers preferred home treatment 
using  traditional medicine compared to treatment at a health facility {unpublished work}. It 
would therefore be important to try and understand the health seeking behaviour of the 
mothers within the catchment area of the current study. On the other hand this change in 
the balance between late onset and early onset disease could be a genuine change in the 
epidemiology of neonatal infections in Malawi. To further investigate this observation, a 
community-based study is currently underway in Blantyre.  
In developed countries, screening pregnant women for GBS and administration of 
prophylactic antibiotics in labour to those women at risk has led to a dramatic reduction of 
early onset GBS disease but has had less of an effect on late onset disease { Schrag S.J and A 
Schuchat (2004)}. In Malawi, screening pregnant women for GBS is not routinely done and it 
would be challenging given the laboratory facilities available. There are no immediate plans 
to introduce this measure by the Ministry of Health. Should the data in this study be correct 
that there is predominance of late onset disease, it would be unlikely for intrapartum 
antibiotics to result in much benefit. There are, however, phase II and III GBS vaccine trials 
in pregnant women being carried out currently {Clinical Trials.gov}. The Novartis sponsored 
phase II study has been looking at safety and immunogenicity of a Group B Streptococcus 
vaccine in non-pregnant and pregnant women 18-40 years of age In Malawi and South 
Africa. Preliminary results suggest that the vaccine is (ESPID 2014) generally well-tolerated 
and immunogenic but that vaccine induced antibody concentrations at delivery are higher 
among HIV negative mothers and their infants, than HIV positive mothers and their infants. 
The phase III studies have been looking at prevention of GBS colonization using single GBS 
vaccination. If the GBS vaccine is proven to work it may provide a potentially affordable 
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route to achieve reduction of GBS infection in Malawi. The major challenge however with 
new vaccines is the cost that is unreachable without outside donor funding such as the GAVI 
Alliance (http://www.gavialliance.org/).  
 
7.2.2 Staphylococcus aureus  
In this study, Staphylococcus aureus was the second commonest organism grown in blood 
culture 10/42(24%). In a number of studies conducted within sub-Saharan Africa S. aureus 
has been reported to be a predominant cause of neonatal sepsis {van den Hoogen A., L.J. 
Gerards et al (2009)}. It is also known to cause predominantly late onset disease and the 
findings in this study are in keeping with this literature (90% were late onset). 
S. aureus   is generally spread through human to human contact and therefore emphasis on 
infection control both at home and in the hospitals is vital in the prevention of infection. 
Hand hygiene is a simple infection control measure that has been proven to work but is not 
well adhered to in our settings {Nerby J.M., R.Gorwitz et al (2011), von Eiff .C, K.Beckeret al 
(2001),}.  
Biological control especially in health workers which are the main source in nosocomial 
infections might be a new possible way to control Staphylococcus aureus in body surfaces 
and this need to be explored further. It has been shown that colonization of body surfaces 
especially in the nose by Staphylococcus epidermidis- inhibitory strain JK16 impairs the 
establishment of Staphylococcus aureus {Iwase T., Y Uehara et al (2010), Otto M., Submuth 
R. et al (1999)} . It is understood that these 2 microorganisms have an amensalistic 
relationship which is an association between organisms of 2 different species in which one is 
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inhibited or destroyed and the other is unaffected.  This could help prevent infection in the 
few cases that were possibly exposed to S. aureus whilst still in hospital. 
7.2.3 Streptococcus pneumoniae 
In this study, Streptococcus pneumoniae was the second commonest aetiological agent in 
CSF cultures 10/33 (30%). S. pneumoniae rarely causes neonatal infections in the developed 
setting but has been shown to be a common cause of infections in several resource-poor 
settings {Osrin D, S. Vergnano et al (2004), Downie L., Duke T et al (2012)}. In Malawi and 
elsewhere in sub-Saharan Africa, children carry S. pneumoniae in their nasopharynx from a 
very early age, probably acquired from their siblings {Marchisio P, S. Esposito et al (2011), 
Sanae Dashti A., Abdinia et al (2012)}.  Exposure at this early stage could easily lead to an 
invasive infection. In addition, it has been shown that pneumococcal carriage amongst HIV 
infected adults is high {Janoff E.N, J, O’brien J et al (1993)}}. In this study, out of the 366 
young infants with severe infections, where HIV exposure status was determined, 131(36%) 
were HIV exposed. Therefore, these infants were being looked after by adults who were 
more likely to be carrying S. pneumoniae and therefore at risk of acquiring the 
pneumococcus from their parents as well as their siblings.  
Since November 2011, Malawi introduced the 13 valent pneumococcal vaccine {Ministry of 
Health, EPI programme}and it is hoped that as the cohort of children who have received the 
vaccine increases, herd immunity will build up and pneumococcal infections in neonates will 
go down. Preliminary MLW surveillance data for invasive pneumococcal disease suggests 
that vaccine-serotype disease is decreasing in children but is too early to predict the impact 
on neonates {Bar Zeev N., D. Everett et al ISPPD (2014)}. A study by French et al in HIV 
infected adults in Malawi showed that vaccination with the pneumococcal conjugate 
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vaccine resulted in a reduction of invasive pneumococcal disease in these adults {French N., 
S.B Gordon et al (2010), Hammitt L.L., Bruden D.L et al (2006) }. It is therefore important to 
evaluate the potential impact of offering pneumococcal vaccination to all HIV infected 
adults as a way of reducing pneumococcal infections in neonates.  
7.2.4 Gram negative organisms 
Gram negative organisms comprised 17% of all organisms grown in blood culture and 22% 
of all organisms grown in CSF culture. In an earlier retrospective study conducted in Malawi 
gram negative organisms comprised 32% of all significant organisms grown in neonatal 
sepsis cases {Milledge J., J.C.J Callis (2005)}. In this current study the gram negative 
organisms were resistant to penicillin, erythromycin, ampicillin and chloramphenicol. Fifty 
percent of the gram negative organisms were resistant to ceftriaxone, gentamicin and 
ciprofloxacillin. The multidrug resistance observed in this study is in keeping with findings 
from other studies {Blackburn R.M, N.Q Verlander et al (2013), Mehar V., D Yadav et al 
(2013), Vergnano S., M. Sharland et al (2005)}. Enterobacter cloacae were only sensitive to 
amikacin, a drug that is not generally available in Malawi and that has unproven penetration 
into the CSF. The multidrug resistance exhibited by these gram negative bacteria is worrying 
in Malawi whose standard antibiotic treatment for severe neonatal infection is parenteral 
benzyl penicillin and gentamicin. This regimen would not adequately treat the gram 
negative organisms. Ceftriaxone is the drug of choice for patients who fail on the second line 
but again it is worrying that up to 50% of these gram negatives exhibit high resistance to 
ceftriaxone-. This leaves these vulnerable neonates few alternatives as amikacin is not freely 
available in Malawi. It is therefore not surprising that mortality rates in those young infants 
that had grown gram negative organisms were high at around 51%. 
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7.2.5 Coagulase negative staphylococci 
In this study 85/366 (23%) of the participants grew coagulase negative Staphylococcus in 
their blood cultures. Coagulase negative Staphylococcus has been increasingly seen as a 
cause of nosocomial or late-onset neonatal infections especially in premature infants in 
neonatal intensive care settings. It is mostly seen in preterm low birth weight infants who 
have indwelling catheters. Coagulase negative Staphylococcus has several intrinsic 
properties that allow it to readily adhere to the plastic mediums found in intravascular 
catheters and intraventricular shunts. The adherence creates a capsule between the 
microbe and catheter, preventing C3 deposition and phagocytosis thereby making coagulase 
negative Staphylococcus more difficult to treat {Anderson-Berry A.L, T. Rosenkrantz et al 
(2014), Healy C.M, Baker C.J et al (2013)}. Coagulase negative Staphylococcus is ubiquitous 
as part of the normal skin flora and as such has been reported as a contaminant of blood 
and CSF cultures.  
It is was a challenge to establish the significance of coagulase negative Staphylococcus 
growth in this study however none of the cases were nursed in a NICU nor had intravenous 
catheters or intraventricular shunts. We excluded infants that were at least 32 weeks of 
gestation and the majority of the cases (85%) were term, normal birth weight babies. We 
further looked at a number of factors that could possibly indicate a higher chance of a 
disease rather than colonisation with coagulase negative Staphylococci and compared with 
cases that had grown other significant organisms. Most of the CRP values of the coagulase 
negative Staphylococci infants were normal (80% vs 25% for coagulase negative 
Staphylococci vs. other significant organisms respectively).The white cell counts for these 
cases were largely normal (85%). We however did not do colony counts for the coagulase 
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negative Staphylococci which have been shown to help in the differentiation between true 
infection and a contaminated specimen {Anderson-Berry A.L, T. Rosenkrantz et al (2014)}. 
On balance we therefore concluded based on the clinical setting, the gestation of these 
infants and some of the laboratory parameters that the coagulase negative Staphylococcus 
grown in blood culture in this study was as a result of contamination.  
 In Malawi routine blood or CSF cultures are not done except at QECH where this study was 
carried out. Considering the important role that gram negative organisms play in neonatal 
infections, it is important for Malawi to strengthen its microbiological laboratory testing so 
as to better manage neonatal infection cases and monitor sensitivity patterns of the 
aetiological agents. 
 
7.3 In hospital mortality outcome of severe neonatal infections 
In this study the in hospital mortality rate was 11% in all the neonatal infection cases 
(Chapter 3). An earlier study by MIlledge et al conducted in Malawi reported a much higher 
neonatal sepsis case fatality rate of 48% [Milledge J., J.C.J Calis et al (2005)]. A number of 
factors could have contributed to the discrepancy. Firstly, the majority of the research 
participants (90%) were admitted on a jointly run department of Paediatrics/ MLW/ 
Blantyre Malaria Project research ward at QECH which is better equipped both with human 
resource and supplies. Secondly, the majority of the cases (76%) in this study were late 
onset whereas in the earlier studies at least 50% of the cases were early onset. Mortality is 
known to be higher in early onset disease than late onset {Klinger G., I Levy et al (2009)}. 
Earlier presentation could also have helped reduce mortality in this study with up to 60% of 
190 
 
the cases having presented within the first 24 hours of the symptoms developing. The 
majority of the cases in this study were born at term (85%). It is known that mortality from 
neonatal sepsis is higher in preterm babies that those born at term. We found that, as in 
keeping with other studies, term gestation was associated with a significant risk reduction of 
88% (p=0.005) in mortality {81, 82, 83 and 84}.  
 
In this study in the univariate logistic regression analysis; thrombocytopenia, hypothermia, 
hypernatraemia, hypoxia and a significant growth in either blood or CSF culture were 
associated with a significantly increased risk of in hospital mortality. All these factors have 
been shown to be predictors of poor outcome in severe neonatal infections in other settings 
{Wasen R., A.A Fraga JM, R.C. Gracia (1998)}). However in all adjustments hypoxia, 
significant blood or CSF culture and hypernatraemia independently increased the risk of in 
hospital mortality.  
It was surprising to note that 141/330 (43%) of the severe neonatal infection cases had 
abnormal serum sodium levels on admission, 67/141 (48%) were hypernatremic. The rates 
of hypernatraemia were higher in neonatal sepsis cases without overt meningitis and these 
babies also had high serum urea levels which could reflect a high frequency of dehydration. 
The rates of hyponatraemia were higher in the neonatal meningitis and severe pneumonia 
group, which could be as a result of syndrome of inappropriate ADH secretion and is in 
keeping with what has been reported elsewhere {Wasen R., A.A Fraga JM, R.C. Gracia 
(1998)}. In many resource constrained settings, electrolytes are not routinely available even 
for severe neonatal infection cases. The high rate of electrolyte imbalance observed in this 
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study and the subsequent impact on mortality would justify routine monitoring so as to 
better manage these cases. 
7.4 Long Term impact of Severe Neonatal infections 
7.4.1 Mortality at 1 year of age 
It was surprising to note that the post neonatal mortality rate at 1 year of age was 4.5% 
amongst the controls. The post neonatal mortality rates for Malawi are currently estimated 
at 22/1,000 live births (2.2%) {Zimba, E., M.V Kinney et al. (2012), Liu L, H.L. Johnson et al. 
(2012)} and the higher rates observed in this study are worrying. Several factors have been 
known to increase the risk of childhood mortality and these include; poverty, malnutrition, 
infections, maternal education and urbanization. All the participants enrolled in the 
prospective cohort study were from Blantyre urban but nearly half of their families were 
living on less than one US dollar per day. The majority of the mothers (90%) were 
unemployed and only 42% of them had some secondary level education. Even though these 
families were residing in Blantyre urban, 93% of them were using pit latrines. All these 
complex factors would have further increased the risk of dying in infancy regardless of them 
not having had an episode of severe neonatal infection. 
Overall in this study the post neonatal mortality rate at 1 year of age was higher in the 
severe neonatal infection group than the controls (6.6% vs 4.5%). The difference between 
the 2 groups was however not statistically significant. This study was not powered to look at 
differences in mortality and a bigger sample size will be required to better describe the 
impact of severe neonatal infections on mortality. 
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In this study HIV status showed no impact on mortality or morbidity in children who have 
recovered from neonatal infection at 1 year of age. This is contrary to findings from other 
resource restrained settings where mortality has been shown to be higher in infants born 
from HIV infected mothers. These results should again be interpreted with caution as the 
study was not adequately powered to look at the impact of HIV.  
 
7.4.2 Neurodevelopmental outcomes at 1 year of age 
In this study it was surprising to note that the rate of neurodevelopmental delay was up to 
15% in the controls. It was much higher than the 8% that was postulated at the beginning of 
the study (see chapter 2). There are several factors that have been known to impact 
neurodevelopment in children namely nutritional status, low socio-economic status, 
congenital anomalies, brain insults, infections, HIV, neglect, maternal education and mental 
status {Amouzou A. and  Hill K (2004)}. In Malawi, one of the poorest countries in the world, 
the rates of stunting which is a marker of chronic malnutrition are very high (thought to be 
50%)  {UNICEF 2012}. Both cases and controls came from poor families (chapter 4) and this 
could have compounded the effects of malnutrition. The mental status of the mothers was 
not analysed and therefore its impact on this cohort cannot be analysed. It is also difficult to 
rule out any brain insult from other causes ranging from intrauterine infections to 
environmental causes {Mwaniki M.K, M. Atieno et al (2012)}.More research is required to 
better understand the risk factors associated with the considerable burden of 
developmental delay observed in the general Malawian paediatric population so as to 
develop better prevention and management strategies. 
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It was found that the rates of neurodevelopmental delay occurred in up to 35% of severe 
neonatal infection cases and again this was much higher than what was postulated at the 
beginning of the study. The rates of delay were much higher in the meningitis group (60%) 
compared to the neonatal sepsis (31%) and severe pneumonia groups (35%). It was 
surprising to note that neonatal sepsis without overt meningitis was associated with a 
higher risk of developmental delay at 1 year of age of up to 6-fold in the fine motor domain. 
Most studies have reported an increased risk of neurodevelopmental delay in preterm, low 
birth weight infants with neonatal sepsis. In this study as pointed out earlier the majority of 
the cases were infants born at term and as such one would not have expected such a high 
magnitude of developmental delay {Alshaikh B., W. Yee et al (2014), Alshaikh B., K Yusuf 
2013, Chapman I.A (2012)}. There is paucity of data on the long term outcome of neonatal 
sepsis (without overt meningitis) in term babies in both the developed and developing 
settings. This study has shown the high risk of developmental delay associated with 
neonatal sepsis. In preterm babies with neonatal sepsis inflammatory cytokines have been 
postulated to cause white matter damage thereby leading to neurodevelopmental delay 
{Divyen K, D.K. Shah et al (2008)}. The brain of preterm babies is more vulnerable to insults 
than term babies and as such further studies are required to explore the possible 
mechanisms leading to delay in these infants with neonatal sepsis.  
7.4.3 Neonatal meningitis 
60% of Infants who had neonatal meningitis had complications at 1 year of age and this is 
higher than the 50% reported in other studies {Stevens J.P, M.Eames et al (2003), P.T Heath, 
N.K.,Nik (2003)}. The complications included visual loss, hydrocephalus, epilepsy and 
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hearing loss. The presence of other factors like poverty as outlined in section 7.2.4.2 would 
have further increased the risk of sequelae arising from neonatal meningitis.  
7.4.4 Predictors of poor neurodevelopmental outcomes at 1 year of age 
Positive growth in either blood or CSF culture was independently associated with an 
increased risk of developmental delay (chapter 5). This finding is in keeping with other 
reports {Wasen R., A.A Fraga JM, R.C. Gracia (1998)}. Inflammatory cytokines have been 
known to be associated with poor neurodevelopmental outcomes in preterm infants with 
neonatal sepsis. We postulate that the presence of bacteria in the blood stream or CSF 
could increase the surge cytokines produced thereby causing a greater insult to the rapidly 
growing brain. Being born to a HIV infected mother was independently associated with an 
increased risk of developmental delay. Studies have shown that HIV exposed non-infected 
infants have a high risk of developmental delay in resource restrained settings but those 
from the developed setting have normal development. Several factors have been shown to 
contribute towards such an increased risk in the resource restrained setting namely; poor 
maternal health leading to poor bonding and lack of stimulation of the infants, malnutrition 
and poverty { Amouzou A. and  Hill K (2004)} 
7.5 Limitations and gaps in the study  
The severe infection cases were recruited from QECH a referral facility and therefore could 
have missed cases that went to a private hospital (very few inpatient beds) or  went to other 
facilities and were treated as an outpatient or went to traditional healers or dies in the 
community (there are no other government paediatric inpatient facilities in Blantyre). In one 
study in a rural setting in Ntchisi, Malawi, 83% of the mothers had opted to seek help from 
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traditional healers first before visiting a health facility with their sick neonate {Kakhobwe T 
et al (thesis -2010)}. Although not formally quantified the degree of bias in this urban setting 
is thought to be small. A community based study is currently planned in Blantyre to 
determine what would better tackle this problem. 
Neonatal sepsis is predominately a clinical diagnosis supported by positive microbiology if 
available. As such there is the possibility patients were included with non-infectious causes 
of sepsis {Kliegman R.M, R.E Behrman et al (2011)} } including metabolic causes such as 
inborn errors of metabolism. This could affect interpretation of the data as not all the 
neonatal sepsis cases would have been truly septic. However in a setting like Malawi it is 
difficult to rule out some of these non-infectious causes due to diagnostic challenges. In 
addition some infants ascribed to the neonatal sepsis group could have had meningitis but it 
would seem unlikely that this would have sufficed to affect the observations of poor 
outcome in this group. Some infants presenting with sepsis or meningitis soon after birth 
may have been mis-labelled as birth asphyxia and therefore excluded, however, it is unlikely 
that this represents a significant bias. 
Changes in clinical practice during the course of the study could have impacted on the 
results and generalizability. However, the Department of Paediatrics at QECH uses standard 
protocols that did not change during the course of the study. In particular, changes in 
clinical practice resulting from the “FEAST Trial” {Maitland K, D.M Gibb et al (2011)} 
occurred after the cross-sectional component of the study was completed. Similarly, the 
overall rate of HIV infection was low in the infant cohort and very few mothers were 
receiving full ART as part of option B+ {Ministry of Health, Malawi (2011)}. 
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As discussed previously, the culture positivity rate for the study was low at 11% and the 
yield could have been improved if molecular diagnostics were used. Multiplex PCR has been 
shown to increase the yield for viruses and bacteria in samples. The low yield could have 
affected some of the analysis on aetiological organisms as the numbers were small. This is 
being address in a molecular diagnostic study currently underway. 
In this study the participants were followed up to the age of 1 year. Some developmental 
delay issues become apparent as the child gets older and particularly as they reach school 
going years {Alshaikh B, K. Yusuf et al (2013). Behavioural problems are more likely to 
manifest in the school going years. Due to the short duration of follow up this study could 
have missed some of these developmental problems. It was also clear from the study that 
the rates of developmental delay had increased by age 12 months (Chapter 4). This again 
reinforces the fact that longer duration of follow up was likely to pick up more cases of 
developmental delay. A longer duration of follow up would also have allowed us to better 
describe the progress amongst the participants particularly those who had delay. It would 
have been desirable to be in a position to describe as to how many of them improved or 
retrogressed overtime. 
The long term follow up only included infants residing within the urban setting and would 
raise a question on generalizability. However it was noted that the socio-demographic 
profile of the participants was similar to the rural setting in Malawi. It can be said therefore 
that the participants though leaving in an urban setting had the same levels of poverty and 
living standards as most rural settings in Malawi {Malawi DHS 2010}. The study results can 




7.6 Future work 
We found that 15% of the control children had developmental delay at 1 year of age and 
this is almost double that which was postulated. There should be underlying factors leading 
to such a high rate of developmental delay. We hypothesize that early insults to the brain 
whether in utero or very early on in infancy coupled with malnutrition and poor socio 
economic status could be the causative factors of developmental delay in Malawian 
children. We would propose intervention studies tackling these factors and measuring their 
effectiveness on neurodevelopment. Interventions could include provision of cash transfers 
to these poor families or nutritional supplementation to infants born in these poor families. 
UNICEF is currently partnering the Malawi government on early childhood development and 
would find results from such studies useful.  
There was an increased risk of developmental delay in the neonatal sepsis cases (without 
overt meningitis) of up to 6-fold in the fine motor domain. Most of the studies have looked 
at neurodevelopmental outcomes in preterm or low birth weight babies with neonatal 
sepsis. We propose to undertake further studies exploring the factors that cause 
developmental delay in term babies with neonatal sepsis in a resource poor setting. We 
would want to understand the role of both blood and CNS cytokines in causing 
developmental delay in these settings. Understanding the role of cytokines can help in the 
development of treatment therapies that can potentially block the effects of the cytokines 
{Shah D.K, L.W, Doyle et al (2008)}. 
To better understand the aetiology and burden of neonatal infections in Malawi a 
community based study is currently underway. We are prospectively following up pregnant 
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women and their babies for the first month of life to see who amongst them would develop 
neonatal infection and the risk factors associated. 
7.7 Conclusion 
 Group B streptococcus is a significant cause of severe neonatal infections in Malawi. 
Screening pregnant women for GBS and treating the mothers carrying GBS has been proven 
to reduce early onset GBS disease in neonates and is not so effective in preventing late 
onset disease. In this study most of the GBS was late onset and as such screening which 
logistically would be very challenging in Malawi would not be appropriate. However a GBS 
vaccine though still in being evaluated in clinical trials would be the most appropriate.  
The background rates of developmental delay amongst Malawian children are high and all 
efforts should be made to better understand factors involved and interventions that can 
help reduce it. 
Significant growth in either CSF or blood culture have been shown as predictors of poor 
developmental outcomes in Malawi. Microbiology plays an important role in the diagnosis 
and management of these neonates both in the acute and long term. Malawi’s health 
system needs to improve on the availability of microbiology services in its hospitals so as to 
better manage severe neonatal infection cases and prevent complications. 
Neonatal sepsis is associated with poor developmental outcomes at 1 year of age in Malawi. 
There is need to better understand the mechanism of delay in this group of patients. Most 
of the participants recruited in this study were term babies with normal birth weights and 
according to my knowledge this is the first large prospective study looking at the long term 
outcome of severe neonatal infections in infants in a resource restrained setting. 
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University of Malawi, College of Medicine and Malawi-Liverpool-Wellcome trust 
Parental Permission for a Minor Child to participate in the Aetiology and Outcome of 
Neonatal Sepsis and Meningitis in Malawi Research Study 
 
Consent form version date: September 29, 2009 
 
 
Title of Study: Aetiology and Outcome of Neonatal Sepsis in Malawi. 
 
 
Principal Investigator: Queen Dube 
                                     College of Medicine 
                                     Department of Paediatrics 
Email address    : qdube@mlw.medcol.mw 
Co-Investigators: Rob Heyderman, Mac Malewa, Liz Molyneux 
 
Funding Source: Malawi-Liverpool Wellcome trust 
 
Study Contact Telephone number: 0888940014 or 01876444 
Study contact email: qdube@mlw.medcol.mw 
 
 
General Things you and your child should know about research studies 
 
You are being asked to allow your child to take part in a research study. Research studies are 
designed to obtain new knowledge that may help other people in the future. 
 
Enrolling your child in this study is voluntary. You may refuse to give permission or you may 
withdraw your child at any time and for any reason. Your child does not have to be in this 
research study in order to receive treatment. If you choose not to enroll your child in this study, 
your child can still receive care and treatment. 
 
Details about this study are discussed below. It is important that you understand this 
information so that you can make an informed choice about your child being in this research 
2 
 
study. You will be given a copy of this form. You should ask the researchers, or staff members 
who may assist them, any questions you have about this study at any time. 
 
Purpose of this study 
The purpose of this study is to describe the complications that may arise in babies that have 
had a serious infection requiring admission in the first 2 months of their lives. We will look at 
how the infection affects how the child learns how to move, learn and speak as they grow up. 
We will also check whether the infection affects the child’s hearing. 
We expect to have 470 children in this study and we will compare a group of children who have 
had the infection and a group who have not. And that the comparison will focus on the first 
year of life. 
 
 
How long will your child’s part in this study last? 
Your child is expected to be in the study up until the age of one year. Your child will be asked to 
come to the clinic 4 times during the duration of the study. This will be at 3months, 6 months, 9 
months and 12 months of age. 
The study visit evaluation will take one hour at the maximum. 
 
What will happen if your child takes part in the study? 
You will be asked to answer general questions about the child’s family’s living condition, and 
about the health of your child, your partner and yourself. 
Your child will be examined by a team of nurses and doctors to determine how your child has 
developed in moving, learning and speech since birth. This will not hurt the child as most of 
these are observations. 
The study nurse will also test your child for hearing and this does not hurt. 
We will also check your child for HIV infection at beginning of the study. At each follow up visit 
your child will be fully examined. There is no specific intervention in this study (no new drugs). 





Possible Benefits from being in the study. 
The benefits of your child from being in the study will be that they will be closely followed up 
and if any problems are detected will be referred to an appropriate institution for early 
intervention and treatment.  
The nurse will also give you information at each visit on age appropriate ways that you can 
interact and play with your child to stimulate their development. 
Your child will have a chance of being tested for HIV and therefore benefit from early referral 
for treatment if they are HIV infected. 
The knowledge gained from this study will teach us how to better follow-up babies with an 
initial episode of severe infection and the services that they need. 
 
Possible Risks from being in the study 
There are minimal risks for your child to participate in this study. 
 
Protection of your child’s privacy 
All information about your child including the name and date of birth will remain confidential. 
This means that only researchers will know the information about your child and they will keep 
it a secret. Your child’s name will not be included in any report about this study. 
 
What if you want to stop before your child’s part in the study is complete? 
Your child can stop participating in this study at any time without penalty. If you choose to 
withdraw your child from this study, you and your child can still receive care at this hospital. 
Information collected on your child before you decide to stop your child’s participation will still 
be used in this study 
 
Cost of involvement in the study 
It will not cost anything to be in the study. 
 
What if you have questions about this study? 
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If you have any questions during the course of the study you can contact the researchers listed 




I have read the information provided above. I have asked all the questions I have at this time. I 





Name of Research Subject (child) 
 
 
………………………………………………………               ………………………….. 





Name of Parent 
 
 
……………………………………………………..                …………………………… 










                                                                                                              Neonatal Sepsis 
Project ID number:  |___|___|___|___| 
         Date of visit (dd/mm/yy):  |__|__| / |__|__| / |__|__| 





Administered to: All Children at all Visits 
 
 
CLINICAL HISTORY:  
 
Visit Type:           Enrollment   6 months Visit   
  1Month Visit   9 Months Visit  
  3Months Visit    12 Months Visit  
Since the birth disharge or last study visit, has your child had any of the following for 
which you did not go to any health care worker (nurse, doctor, etc.)? 
  
Symptom Yes No If yes, specify when, severity , diagnosis made 
1. Skin problems    1a. 
2. Cough    2a. 
3. Oral Thrush    3a. 
4. Ear Infection    4a. 
5. Conjunctivitis    5a. 
6. Fever    6a. 
7. Vomiting    7a. 
8. Measles    8a. 
9. Meningitis    9a. 
10. Malaria    10a. 
11. Diarrhea    11a. 
12. Other    12a. 
Note – If child has experienced a severe adverse event, follow appropriate reporting procedures 
 
13. Has your child visited a clinic, other than the study clinic, since birth / the last visit?   
 Yes   No 
If Yes,  13a. Date (dd/mm/yy):  |__|__| / |__|__| / |__|__| 
13b. Reason___________________________________________ 
13c. Date  (dd/mm/yy):  |__|__| / |__|__| / |__|__| 
13d. Reason___________________________________________ 
14. Has your child been hospitalized since birth / the last visit?   Yes   No 
If Yes, 14a. Date (dd/mm/yy):  |__|__|/ |__|__| / |__|__| 14b. Duration:  |___|___| days  
14c. Reason___________________________________________ 
14d. Date (dd/mm/yy):  |__|__| / |__|__| / |__|__| 14e. Duration:  |___|___| days  
14f. Reason___________________________________________ 
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         Date of visit (dd/mm/yy):  |__|__| / |__|__| / |__|__| 
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15. Has your child received a blood transfusion since birth/ the last visit?  Yes  No 
 
If Yes,   15a. Reason_____________________________________________________ 
 
 15b. Date (dd/mm/yy):  |__|__| / |__|__| / |__|__| 
 
 
16. What type of feeding does your child usually receive? 
 
  (1) Breast milk only; no solid foods, no liquids (no water) (exclusive breastfeeding) 
  (2) Breast milk plus water (mixed feeding) 
  (3) Breast milk plus water and/or other liquid and solid food (mixed feeding) 
  (4) Formula only 
  (5) Liquid and solid foods only  





17.  Temperature: |___|___| . |___| 
o 
C 18.  Weight: |___|___| . |___| kg 
   
19.  Height or length: |___|___|___|. |___| cm 20.   Head circumf.|___|___|. |___|  cm 
        19a.  Height (1)     Length (0) 
 








If ‘ABNORMAL’  
a. Findings 
22. General   22a. 
23. Skin   23a. 
24. Mouth   24a. 
25. ENT   25a. 
26. Neck   26a. 
27. Cardiovascular   27a. 
28. Lungs   28a. 
29. Abdomen   29a. 
30. Extremities   30a. 
32. Genitourinary   32a. 
33. Lymph nodes   33a. 
34. Other findings/notes: 
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Vision   Looks at person for a few seconds     
   Follows across midline   
   Grabs red colored cube   
Not done     
Nystagmus  Absent         
   Eyes beat to the right    
   Eyes beat to the left    
   Eyes beat in both directions   
Eyes beat up and down   
Not done     
Eye movements Eye movement full   Left  Right  
    If no:  Eye fails to abduct Left  Right  
Eye fails to adduct Left  Right  
Not done     
Facial paralysis Eyes closed equally    
   If not: eye closed less   Left  Right  
   Mouth angle symmetric   
    If not: angle deviates to  Left  Right  
Not done     
 
CEREBELLAR 
Tremor  Absent      
   Present     
Not done     
TONUS 
Elbow extension Normal    Left  Right  
   Rigid / spastic    Left  Right  
   Hypotonia    Left  Right  
Not done     
 
Knee extension Normal    Left  Right  
   Rigid / spastic    Left  Right  
   Hypotonia    Left  Right  
Not done     
REFLEXES 
Upgoing toe  Absent     Left  Right  
   Present    Left  Right  
Not done     
 
Ankle clonus  Absent     Left  Right  
   Transient (< 5 beats)   Left  Right  
   Sustained (≥ 5 beats)   Left  Right  
   Spontaneous    Left  Right  
Not done     
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Biceps reflex  No reflex    Left  Right  
   Muscle contraction only  Left  Right  
   Limb displacement   Left  Right  
   Clonus     Left  Right  
Not done     
Patellar relex  No reflex    Left  Right  
   Muscle contraction only  Left  Right  
   Limb displacement   Left  Right  
   Clonus     Left  Right  
Not done     
Neurologic findings:  Normal  Abnormal 
 
                                                                                                              Neonatal Sepsis 
Project ID number:  |___|___|___|___| 
         Date of visit (dd/mm/yy):  |__|__| / |__|__| / |__|__| 
 Page 5 of 5 
 
 Signature ______________ Date __/___/______ 
 
                              PAEDIATRIC ADMISSION SHEET            Hosp No: 
                                                                                                                     
 
Name ............................   Age .........  Date of Birth ............   Date of Admission ............... 
 Weight ............kg          %Weight for Age..............                                                                   
    
HISTORY  Fever                   Y / N               How long for .......... 
   Convulsions        Y / N   How long for .......... 
              Pallor/Jaundice     Y / N                     How long for .......... 
                                   Vomiting         Y / N   How long for .......... 
                                   Diarrhoea               Y / N                    How long for .......... 
   Cough          Y / N   How long for .......... 
   Rash          Y / N    How long for .......... 
   Difficulty breathing  Y / N                    How long for ..........      
   Eating / Sucking      Y / N   If N           How long for ..........  
                                   Oedema                  Y / N                   How long for ...                                                                                                                                                                                                                 
                                   Other (Please specify)                       .......................................................   
                                  
Any previous admissions? Y / N  (Please give details)   Diagnosis. and Dates ............................. ........ 
................................................................................................................................................ 
HIV-test done?  Y / N  If Y: Date  Result:  R / NR ON ARV’s?  Y / N  
Mother tested Y/N/NK   CoT prophylaxis?                 ARTs?             
FAMILY HISTORY Any history of TB contact  Y / N, Epilepsy  Y / N, Diabetes Y / N,  Allergy Y / N               
Other   Y /N (detail please).............................................................................................................................................................. 
 
   Mother well  Y / N    (details please)............................................................  
   Father  well Y / N    (details please)............................................................  
   Parents separated   Y / N     when? ...............................................    
   Number of Siblings                   Alive ............. Died ..............  . 
   Siblings Well    Y / N       (details including age) .............................................................  
...................................................................................................................................................................................................... 
 
Birth History  ................................……………    Vaccinations ..............................……… 
Previous blood transfusion Y / N  when...............        Previous drugs in last 2 weeks ......................................  
Other.............................................................................. 
               under 
               -fives 
                                                           chart 
                                  
EXAMINATION 
Nutritional status   good / fair / poor                             
Blantyre Coma Score (BCS)= 
Pallor        0      +        ++       +++  
Jaundice     0       +         ++         +++ 
Oedema   0      +        ++       +++        
Rash      0      +        ++       +++                
Neck stiffness         Y / N   Hepatomegaly   Y / N ......cm   
Oral thrush/ sores   Y / N                    Splenomegaly    Y / N ..... cm 
Lymphadenopathy  Y / N                    Cardiac signs      Y / N     
Respiratory signs    Y / N                    Ear signs             Y / N 
Finger Clubbing      Y / N                    Neurological signs Y / N 
please draw your findings    Any other masses  Y / N  where..........      
 
        right       left 
 
            
                    
                                                                                                                                                  0 
                                                                                                                   
                                                                                                                      
 
                                                                                                                                              
         Diagnosis……………………………… 
 
NEONATAL INFECTION STUDY 
Date of admission………………Name…………………………………Study number……… 
 
Date of Birth:          Age in days:    Sex F/M 
 
Place of delivery:  Home TBA HC Hospital Other (please specifiy)…………………. 
 
Type of birth:  FTND  Breech   Forceps  LSCS (if so give reason for CS)……………….. 
 
Preterm/ Full term Singleton/Twin 
 
Mother HIV  Pos/neg/Unknown  Infant received  PMTCT?  Y/N 
 
Birth weight     gms   Immunisations  Pentavalent  1 2 Polio 0. 1. 2     BCG 
 
 
Mother well Y/N   if no what is the problem…………………………………………………….. 
Father well Y/N   if no what s the problem…………………………………………………….. 
Siblings well  Y/N if no what is the problem……………………………………………………. 
How many siblings?.. Alive  ............  Died       ............................ 
 
 
History of present complaint: 
Fever?   Y/N If yes for how long……………………. 
Convulsions?  Y/N If yes for how long…………………….  If yes   focal or generalised 
Irritable   y/n If yes for how long……………………. 
Cough?   Y/N If yes for how long……………………. 
Bulging fontanelle? Y/N If yes for how long……………………. 
Stiff neck/body?  Y/N If yes for how long……………………. 
Diarrhoea  Y/N If yes for how long……………………. 
Vomiting  Y/N If yes for how long…………………… 
Sucking?  Y/N If yes for how long……………………. 
Difficulty breathing? Y/N If yes for how long……………………. 
Passing urine?  Y/N If yes for how long……………………. 
Pallor?   Y/N If yes for how long…………………… 
Jaundiced  Y/N If yes for how long……………………. 
Rash   Y/N If yes for how long……………………. 
Oedema  Y/N If yes for how long……………………. 
 
Other   Y/N Please say what and for how long…………………………………… 
 
Received any medications before arrival at hospital Y/N  if yes describe ……………………………. For how long……... 
                        When…………. 
           
EXAMINATION 
 
Admission weight  Admission length:  head circumference:  Temp  ….R/A 
 
Well nourished/fair/poor   Bilirubin level………………………………. 
BCS…… 
Seizures  Y/N Focal / General?   Cap refill time…………sec 
 
Pale    + ++ +++ 
Jaundices   + ++ +++ 
Rash (Purpuric Y/N) + ++ +++ 
Oedema  + ++ +++ 
Oral thrush  + ++ +++ 
Nappy rash  + ++ +++ 
Gen LNs  Y/N + ++ +++ 
 
Chest signs  Y/N …………………………………………  RR /min SaO2………………. 
 
H sounds Normal Y/N ………………………………………………..PR     /min 
 
Umbilicus   Clean/dirty/septic 
Nasal discharge  Y/N    Tests done  LP, BC, FBC, ELISA. MP. PCV. BSugar. U and E 
Ears infected  Y/N      (please circle if done)   
Liver size……………….. cm  








   
